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Abstract 
Lung cancer is the most commonly diagnosed cancer worldwide. 87% of cases are classified 
as non-small cell lung cancer (NSCLC). Neurofibromin-1 (NF1) is a tumour suppressor gene 
which limits RAS mediated signal transduction within the MAPK pathway. Up-regulation of 
this pathway leads to uncontrolled cellular proliferation. Somatic mutations in NF1 are 
reported in 8-12% of NSCLC patients. It was hypothesised that NF1 variants have a functional 
consequence on the activation of the MAPK pathway. 
86 NSCLC patients were recruited and consent obtained to access their archived formalin 
fixed paraffin embedded tumour tissue. Next generation sequencing (NGS) was used to 
screen the patients for NF1 variants. Copy number changes of NF1 were investigated using 
digital droplet PCR. Finally, the NanoString nCounter was utilised to measure mRNA gene 
expression signatures which relate directly to MAPK and PI3K/AKT/mTOR activation in order 
to determine whether the NF1 variants observed were functionally relevant.  
This study confirmed the prevalence of NF1 variants in NSCLC previously reported. Of the 25 
NF1 variants identified 15 were novel with no previous reports in the literature or in 
databases. Analysis via the NanoString nCounter determined NF1 mRNA transcript 2 to be the 
predominantly expressed transcript in NSCLC. In accordance with previous reports it was 
shown that the MEK gene expression signatures was able to predict KRAS variants and 
therefore MAPK activation. Expanding on this using data from Pan-Lung TGCA the MEK 
signatures were shown to also predict EGFR and BRAF driver variants. Finally, we 
demonstrated that NF1 variants with loss of function of the GAP domain causes upregulation 
of the PI3K/AKT/mTOR pathway, while cases with co–occurring NF1 and RASA1 variants result 
in up regulation of the MAPK pathway. We also identified a third of NF1 loss of function cases 
which had an increased MEK signature score, which suggests unknown co-drivers are required 
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1.1 Non-Small Cell Lung Cancer 
1.1.1 Incidence 
In 2018 there were an estimated 1.8 million new cases of lung cancer, making it the most 
commonly diagnosed cancer worldwide (Bray et al., 2018). In the UK alone 46,388 new 
cases were reported in 2015, of which 87% were classified as non-small cell lung cancer 
(NSCLC) (CRUK, 2018). Lung cancer has a poor prognosis, with a 5 year survival rate of less 
than 10%. This is largely due to late stage diagnosis, with 68% of cases being diagnosed at 
stage III and IV (CRUK, 2018). At this late stage, curative measures such as surgical 
intervention and radical radiotherapy are not possible. Patients have a median age of 70 
years. In most cases the lung cancer is associated with cigarette smoking and these 
patients may have co-morbidities related to smoking, such as cardiovascular and 
cerebrovascular disease (Rojewski et al., 2016). These factors may make delivery of any 
treatments more difficult. Whilst the number of treatments has increased over the last 
decade with the emergence of targeted therapeutics, such as tyrosine kinase inhibitors 
and immunotherapies, the prognosis statistics still remain poor.  Such facts illustrate that 
there is an unmet need to improve early diagnostic techniques and further identify the 
molecular mechanisms that underlie NSCLC, in order to identify better therapeutic and 
clinical management options. 
1.1.2 Genetic Traits  
Genomic anomalies are the defining trait of many cancers. Genomic mutations in key loci 
give a cell a new modus operandi, redefining the cell’s purpose and function. Such genomic 
aberrations are often the hallmarks of cancer (Hanahan and Weinberg, 2011). These 
aberrations can vary from a single nucleotide variant to gains and losses of whole 
chromosomes. The genetic aberrations we observe, and the genes affected in 
carcinogenesis can be broadly characterised into terms such as driver or passenger 
mutations and oncogenes or tumour suppressor genes (TSG). Driver mutations give the 
cell a distinct growth advantage over surrounding cells and tissue and are positively 
selected during clonal expansion. Passenger mutations do not have any functional 
relevance, but can be passed down the tumour’s evolutionary lineage (Michael et al., 
2009). Oncogenes are affected by mutations that result in an increase or constitutive 
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activation of intracellular signalling pathways, enabling unregulated proliferation. 
Conversely TSG generally protect against growth signals and provide oncogenic protection, 
such that inactivation can lead to loss of regulation of critical pathways. 
1.1.3 Risk Factors  
The main risk factor in the acquisition of somatic mutations leading to the development of 
lung cancer is cigarette smoking. This is reported to account for 85% of cases in the UK 
(Parkin, 2011). Differential mutational distribution is observed between current/former 
smokers and never smokers. Current/former smokers have a higher chance of Kirsten rat 
sarcoma viral oncogene homolog (KRAS) mutations relative to never smokers (41% vs. 5%). 
Conversely, never smokers have a higher chance of epidermal growth factor receptor 
(EGFR) mutations relative to current/former smokers (38% vs. 14%) (Paik et al., 2012). 
Occupational carcinogenic risk factors include; overexposure to arsenic, asbestos, 
cadmium and related compounds, and diesel engine exhaust (Brown et al., 2012). 
Inherited germline mutations are less common in NSCLC, but aberrations in the TSG 
retinoblastoma and tumour protein 53 (TP53) have been linked to an increase in tumour 
susceptibility (Hwang et al., 2003, Kleinerman et al., 2000). Epidemiology is also an 
influencing factor, with EGFR activating mutations being more prevalent in the female 
gender and those of East Asian ethnicity (Fukuoka et al., 2003, Miller et al., 2004). 
1.1.4 Histological Subtypes of NSCLC 
Histologically NSCLC has been traditionally divided into three subtypes; large cell lung 
cancer, squamous cell carcinoma (SQCC), and adenocarcinoma (ADC), with the latter two 
being the most prevalent (Pao and Chmielecki, 2010). Over the last two decades, 
molecular-based analysis has started to identify key genetic changes observed across and 
within these subtypes. This has led to cancer being further characterised based on 
common genetic variants. Such variants can help inform prognosis and predict sensitivity 




1.1.5 Genetic Landscape 
Genetic instability is a key hallmark of cancer. Next generation sequencing (NGS) has 
enabled the whole exome sequencing (WES) of ADC and SQCC. This has given us an in situ 
snapshot of the many genomic characteristics that define these histological subtypes, 
shown in Table 1.1. Large cell lung cancer still remains to be characterised in this way, but 
published WES data exists for over 660 ADC cases and 484 SQCC cases (Campbell et al., 
2016). This data has exposed the differences and similarities in the aberrant genomic 
landscapes. ADC and SQCC contain high mutation burdens, 8.87 per Mb and 8.1 per Mb 
respectively. Even with knowledge of the genomic aberrations it is still challenging to 
subdivide these into driver or passenger events, with many cases as yet having no 
recognised driver variants. 
1.1.6 NSCLC Candidate Driver Genes and Tumour Suppressor Genes 
ADC has been shown to be driven by somatic mutations in the mitogen-activated protein 
kinase (MAPK) signalling pathway. Collisson et al. (2014) highlighted known driver 
mutations in 62% of tumours analysed. This included mutations in the following; KRAS 
(32%), EGFR (11%), and v-Raf murine sarcoma viral oncogene homolog B (BRAF) (7%), 
consistent with previous ADC WES studies (Imielinski et al., 2012, Ding et al., 2008). Mutual 
exclusivity between EGFR and KRAS drivers was observed in all ADC WES studies. 
Conversely in SQCC, WES data highlighted fewer abnormalities; KRAS (<1%), EGFR (<2%), 
and BRAF (<2%) in these driver mutations (Hammerman et al., 2012). 
One recurrent characteristic seen in SQCC was a copy number increase of a region of 
chromosome 3 (3q25-26). Copy numbers increases are commonly <5, but have been 
reported up to 21 copies (Yamamoto et al., 2008). This is reflected in the amplification 
levels of sry-related HGM-box gene 2 (SOX2) and phosphoinositide 3-kinase (PI3K) catalytic 
subunit PIK3CA, both found within this locus. PIK3CA amplification was observed in 38% of 
SQCC cases, but rarely in ADC (Yamamoto et al., 2008). Non-synonymous PIK3CA driver 
substitutions p.Glu454Lys and p.His1047Arg are observed in both ADC and SQCC, but make 
up less than 2% and 4% of cases respectively (Yamamoto et al., 2008, Scheffler et al., 2015, 
Collisson et al., 2014, Ding et al., 2008, Imielinski et al., 2012, Hammerman et al., 2012). 
Fibroblast growth factor receptor 1 (FGFR1) amplification is another commonly observed 
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event in SQCC. FGFR1 is a candidate driver of SQCC and observed in 17-22% of cases 
(Hammerman et al., 2012, Moch et al., 2010). Discoidin domain-containing receptor 2 
(DDR2) is also a rare but a reported candidate driver of SQCC, with non-synonymous 
substitutions observed in 1-4% of cases (Hammerman et al., 2011, Hammerman et al., 
2012). 
Despite their differences in candidate oncogenic drivers, ADC and SQCC do have parallels. 
Both are subject to homozygous deletion of the cyclin-dependent kinase inhibitor 2A 
(CDKN2A) locus. However, SQCC is also prone to epigenetic silencing of CDKN2A via 
methylation (Hammerman et al., 2012, Collisson et al., 2014). Both subtypes demonstrate 
a high frequency of mutations in the TSG TP53. This is a key characteristic in many cancers 
and has been extensively studied. TP53 functions include; cell cycle inhibition, inducing 
senescence, inducing apoptosis, and activation of DNA repair mechanisms in response to 
DNA damage and hyper-proliferative signalling from RAS activation (Kathryn et al., 2014). 
Another frequently mutated TSG in both subtypes, which has been less well examined, but 
again is observed in many different types of cancers is neurofibromin-1 (NF1) 





Table 1.1. Frequency of somatic variants and copy number variation in lung 

















KRAS 12p12.1 33 6 1 2 
EGFR 7p11.2 14 7 4 7 
BRAF 7q34 10 3 4 1 1 
RAB25 1q22 -- 13 -- 2 
NF1 17q11.2 12 1 11 1 
ALK:EML4 t(2p23.1)(2p21) 1 -- -- -- 
PIK3CA 3q26.32 7 2 16 38 
PTEN 10q23.31 1 2 8 3 
MTOR 1p36.22 5 1 1 7 -- 
RICTOR 5p13.1 5 10 2 8 
TP53 17p13.1 47 1 94 -- 
FGFR1 8p11.23 1 3 2 2 17 
DDR2 1q23.3 3 11 1 2 
SOX2 3q26.33 <1 4 <1 43 
CDKN2A 9p21.3 4 20 17 27 
STK11 19p13.3 18 1 2 -- 
Genetic based division of the two most common histological subtypes of NSCLC. Blue (loss of copy 







1.2.1 NF1 Prevalence in cancer 
The prevalence of NF1 variants in multiple cancers is now becoming widely acknowledged. 
This is due to the increase of genomic profiling studies utilising NGS, WES, and large scale 
collaborations such as the Cancer Genome Atlas (TCGA). NF1 is described as one of the 
many genes which functions in RASopathy and thereby regulates the RAS family of proteins 
and subsequently MAPK signalling (Ratner and Miller, 2015). Anderson et al. (1993) first 
described a NF1 homozygote deletion in a melanoma cell line, and proposed its role as a 
tumour suppressor gene which functions in progression and development of malignant 
melanoma (Andersen et al., 1993b). Melanoma has a high overall mutation burden of 14.4 
per Mb and NF1 variants are observed in 13% of all cases (Hodis et al., 2012).  Reports in 
epithelial ovarian and breast cancers have shown NF1 variants to be observed in 14.5% 
and 5% of all cases respectively (Perou, 2012, Ross et al., 2013). This is not an extensive list 
and most cancers which have been subjected to genomic profiling have been shown to 
carry NF1 variants at various degrees of prevalence (Gao et al., 2013, Cerami et al., 2012). 
Several studies have also investigated mRNA editing of NF1 in cancer. Marrero and 
colleagues demonstrated NF1 mRNA transcript 1 to be predominant in breast cancer, with 
surrounding normal tissue predominantly expressing NF1 transcript 2 (Marrero et al., 
2012).  Marrero proposed the shift from NF1 transcript 2 to transcript 1 could be a 
significant event in the development of sporadic breast cancers. Similar results have also 
been observed in ovarian cancer, with cell lines expressing an 11 fold increase in NF1 
transcript 1 compared to transcript 2 (Iyengar et al., 1999). Iyengar and colleagues 
suggested the expression of transcript 2 was related to a decreased cellular growth rate of 






1.2.2 NF1 Prevalence in NSCLC 
NSCLC genomic profiling studies show 8-12% of patients display somatic NF1 mutations. 
Over half of these mutations result in a reading frame shift, a non-synonymous non-sense 
variant, or a splice site mutation which results in protein inactivation. The remainder have 
non-synonymous mis-sense mutations. As with TP53 there is a clear lack of NF1 mutation 
hotspots observed in NSCLC cases, shown in Figure 1.1 (Campbell et al., 2016). It is also 
important to note that NF1 and KRAS mutations in ADC display a significant tendency of 
mutual exclusivity (p = 0.006), whilst NF1 and EGFR display a tendency of mutual 
exclusivity, it is not deemed statically significant (p = 0.084) (Imielinski et al., 2012).  
 
 
Figure 1.1. NF1 somatic mutations observed in lung adenocarcinoma and squamous cell cancer patients. 
Green pins (mis-sense mutation), black pins (truncating mutations). NF1 variants reported in Pan-Lung TCGA 
(Campbell et al., 2016). Figure generated via Cbioportal.org (Cerami et al., 2012, Gao et al., 2013). 
 
1.2.3 Evolutionary Occurrence and Risk Factors of NF1 Mutations in NSCLC 
Data from Collisson et al. (2014) and Imielinski et al. (2012) demonstrated that somatic 
NF1 mutations occur early in the evolution of ADC. Both studies showed a bias towards 
patients with a stage I or II diagnosis, 76% and 69% respectively. In addition 85% of the 
reported NF1 mutations from these studies were seen in these early stages of the disease. 
Data from these two studies also revealed 89% of NF1 mutations were observed in patients 
with a smoking history, the remainder (11%) had unknown smoking status, but no non-
smokers were reported. Another striking correlation in ADC is that NF1 mutations are 
found in 25% of oncogene-negative tumours, compared to just 2% of oncogene-positive 




NF1 is most commonly known for its role in the autosomal dominant disease 
Neurofibromatosis type 1 (MIM: 162200), otherwise known as von Recklinghausen’s 
disease. The disease is reported to affect an average of 1 in 3000 individuals (Friedman, 
1999). Neurofibromatosis is commonly diagnosed in early childhood based on clinical 
manifestations. These include; café-au-lait spots (flat light brown spots on the skin), lisch 
nodules (small lumps on the iris of the eye), neurofibromas (soft bumps under the skin), 
plexiform neurofibroma, axillary or inguinal freckling, characteristic skeletal abnormalities 
(pseudarthrosis, hypoplasia of sphenoid wing, severe kyphoscoliosis), and optic glioma 
(tumour of the optic nerve) (Tonsgard, 2006). 
The disease is the result of mutations in the NF1 gene leading to functional inactivation of 
the protein. These mutations leave the individual with increased susceptibility to the 
development of benign and malignant tumours of the peripheral nerve sheaf. NF1 
mutations in these cases, as with NSCLC lack any significant hotspots and are distributed 
throughout the coding region (Mattocks et al., 2004, Brinckmann et al., 2007). Whilst 
germline mutations are passed onto offspring, they have no direct correlation with the 
clinical phenotype. Family members with identical mutations can demonstrate very 
different clinical characteristics (Easton et al., 1993). This suggests the phenotypic 
characteristics are owing to further pathogenic mechanisms, which remain to be fully 
elucidated. Loss of function of one NF1 allele displays haplosufficient characteristics, but 
the disease still has 100% penetrance (Riccardi and Lewis, 1988). Loss of heterozygosity 
(LoH) is therefore required for disease penetrance, following Knudsen’s two-hit hypothesis 
paradigm (Rasmussen et al., 2000). LoH is suspected to originate in Schwann cells, which 
then increase paracrine growth signals, resulting in haploinsufficiency of the surrounding 
cell types, in particular mast cells (Yang et al., 2008). However, genetic aberrations in 
addition to bi-allelic inactivation of NF1 are thought to be involved in the transition of 
tumours from benign to malignant, including; polycomb repressive complex 2 subunit 




1.2.5 NF1 Structure 
The gene encoding NF1 and its cDNA sequence was first identified in 1990 (Cawthon et al., 
1990). NF1 (17q11.2) spans approximately 350 kb and is comprised of 58 exons which yield 
a 12 kb mRNA transcript (Cawthon et al., 1990, Apolline et al., 2015). The transcript is 
subject to mRNA editing resulting in multiple protein isoforms, the three most common 
being; isoforms I-III (Cawthon et al., 1991, Suzuki et al., 1992, Andersen et al., 1993a). NF1 
isoform I (transcript variant 2, NM_000267.3) is the result of the exclusion of exon 31 
(commonly named exon 23a using legacy nomenclature) and results in a 2818 amino acid 
protein. Isoform II (transcript variant 1, NM_001042492.2) is the result of the insertion of 
exon 31, thus resulting in a 2839 amino acid protein. The splicing of NF1 pre-mRNA is 
orchestrated by three different families of RNA binding proteins. This includes CUG-BP and 
ETR-3 like factors (CELF) and Hu proteins, both of which promote the exclusion of exon 31 
(Barron et al., 2010). TIA-1/TIAR proteins promote the inclusion of exon 31 by 
competitively binding to the same downstream sequence as the Hu proteins (Barron and 
Lou, 2012). Finally, isoform III (transcript variant 3, NM_001128147.2) is truncated and 
terminated at exon 15, resulting in a 593 amino acid protein (Mukhopadhyay et al., 2002). 
Intriguingly, NF1’s largest intron 36 spans >60kb and has three genes encoded in the 
antisense strand. These genes are oligodendrocyte-myelin glycoprotein and two ecotropic 
viral integration sites which are transcribed in the opposite direction to NF1 (Cawthon et 
al., 1991, Viskochil et al., 1991). 
The resulting NF1 is a large multiple domain protein which is expressed ubiquitously 
(Philpott et al 2017). Although NF1 is expressed ubiquitously the different isoforms are 
largely observed in different tissues. Isoform I is more commonly expressed in neurons of 
the central nervous system, whilst isoform II is found in most other tissues (Hinman et al., 
2014). The exclusion of exon 31, which is located in the guanosine-triphosphatase (GTPase) 
activating proteins (GAP) domain, has been shown to have 10 fold increase in RAS 
regulatory activity compared to isoform I (Hinman et al., 2014, Suzuki et al., 1992). Isoform 
III is largely observed in cases of neurofibromatosis and lacks any GAP related domain 
(Mukhopadhyay et al., 2002). 
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The encoded NF1 protein has an approximate size of 250kDa and contains two well 
characterised domains. The most extensively studied GAP domain shares highly conserved 
sequences with GTPase activating proteins such as p129 GAP (Welti et al., 2011). The GAP 
domain makes up 8% of NF1 and spans amino acid 1235-1452, which translates to exons 
27-33 based on NF1 mRNA transcript 1, shown in Figure 1.2. The second is the Sec14 and 
pleckstrin homology (SEC14-PH) domain. The SEC14-PH domain spans amino acids 1580 -
1837 which translates to exons 36 to 38 based on NF1 mRNA transcript 1 
(www.uniprot.org/uniprot/P21359). The RAS-GAP and the SEC14-PH are the only regions 
of NF1 to have their crystal structures resolved via xray diffraction (D'Angelo et al., 2006, 
Ahmadian et al., 2003). 
 




1.3 NF1 Functions as a Tumour Suppressor Gene 
1.3.1 RAS Independent Mechanisms  
NF1 functions as a TSG in RAS-dependent and RAS-independent manners. RAS-
independent mechanisms include NF1 stimulation of adenylyl cyclase activity, leading to 
an increase of cyclic adenosine mono phosphate (cAMP) (Brown et al., 2010, Anastasaki 
and Gutmann, 2014). Brown and colleagues demonstrated that retinal ganglion neurons 
with NF1 heterozygous loss of function suffered from decreased growth and increased 
apoptosis. This was restored by increasing cAMP levels, but not by inhibiting the 
downstream signalling pathways activated by RAS, including PI3K/AKT/mTOR and the 
MAPK pathway (Brown et al., 2010).  
Further RAS-independent functions of NF1 have been related to the currently undefined 
region spanning amino acids 1-1163. Starinsky-Elbaz and colleagues demonstrated this by 
transfecting the giloblastoma cell line U87, which does not express NF1, and mouse 
embryonic fibroblasts which express very low levels of NF1 with the region of NF1 spanning 
the amino acids 1-1163 (Starinsky-Elbaz et al., 2009). It was shown that NF1 1-1163 
inhibited cell migration of both cell lines. The authors went on to confirmed this by 
measuring an increase in cell adhesion genes (Starinsky-Elbaz et al., 2009). Starinsky-Elbaz 
and colleagues proposed that the NF1 1-1163 domain acts as a negative regulator of the 
Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin pathway, via an unknown mechanism (Starinsky-
Elbaz et al., 2009).  
NF1 has also been identified as a negative regulator of the Rho/ROCK/LIMK2/cofilin 
signalling pathway which functions in cytoskeleton dynamics. Ozawa and colleagues 
demonstrated NF1 depletion increased activation of the Rho-ROCK-LIMK2 pathway. This 
resulted in an invasive phenotype in both HeLa and HT1080 cells (Ozawa et al., 2005). More 
recent data has shed further light on this process; Vallée and colleagues observed protein-
protein interactions using a yeast two-hybrid system between the SEC14-PH domain of 
NF1 and LIM domain kinase 2 (LIMK2). The authors used a HEK-293 transfected cell line 
and corroborated these findings demonstrating that the SEC14-PH domain interacts with 
the KIN and PDZ/SP domains of LIMK2 (Vallée et al., 2012). The authors proposed the 
SEC14-PH domain inhibits the Rho/ROCK/LIMK2/cofilin pathway through inhibition of 
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LIMK2 phosphorylation by Rho-associated protein kinase (ROCK). This demonstrates NF1 
can influence cytoskeleton remodelling in a RAS independent manner. 
1.3.2 RAS Dependent Mechanism  
The RAS-dependent pathway is the most documented NF1 mechanism and is enabled 
through the NF1 GAP domain (Ahmadian et al., 2003). The RAS family of signalling proteins 
includes three cell membrane bound GTPases homologs; KRAS, Harvey RAS (HRAS), and 
neuroblastoma RAS (NRAS) (Castellano and Downward, 2011). The NF1 GAP domain exerts 
its tumour suppressor ability over RAS via the hydrolysis of RAS-guanine triphosphate 
(GTP) to its inactive RAS-guanine diphosphate (GDP) state (Xu et al., 1990). This 
inactivation is the result of a conformational change of the switch I and II regions of RAS, 
facilitated by the hydrolysis process of removing the phosphate group (Ahmadian et al., 
2003). Driver mutations seen in the RAS family diminish its GTPase activity, no longer 
allowing GAP proteins such as NF1 to catalyse the hydrolysis of GTP to GDP  (Ahmadian et 
al., 1999). This locks the protein in its active conformational state, leaving it free to activate 




1.4 MAPK Signalling Pathway 
1.4.1 Ligand dependent activation of the MAPK pathway 
The RAS family have numerous upstream activators; one of the most comprehensively 
studied in relation to NSCLC is EGFR. EGFR (also known as HER1 and ErbB) is a 
transmembrane tyrosine kinase (TK) signalling protein belonging to the HER family 
(Cadranel et al., 2013).  Other members of this family include; HER2, HER3, and HER4. The 
extracellular domain of EGFR, HER3, and HER4 share an affinity for a number of 
extracellular ligands (Hartman et al., 2013). During ligand dependent activation, EGFR 
extracellular domains undergo a conformational change that allows a dimerisation with 
EGFR, HER2, HER3, or HER4 (Dawson et al., 2005). Dimer formation results in the 
autophosphorylation of the intracellular TK domain facilitated by adenosine triphosphate 
(ATP) (Hartman et al., 2013). In its phosphorylated state, the EGFR dimer forms a complex 
with downstream signalling proteins including, growth factor receptor-bound protein 2 
(GRB2) and the guanine exchange factor son of sevenless homolog 1 (SOS1) (Zarich et al., 
2006). SOS1 then catalyses RAS-GDP to its RAS-GTP active state, shown in Figure 1.3. 
Well studied effectors of the RAS family include RAF and PI3K (Gupta et al., 2007, Vojtek 
et al., 1993). Activation of these signalling proteins results in a downstream signalling 
cascade of the MAPK and PI3K/AKT/mTOR signalling pathways. The activation of these 
pathways if not negatively regulated downstream can ultimately lead to cell proliferation, 
cell migration, and cell survival (Siegelin and Borczuk, 2014). In vitro models demonstrate 
loss of NF1 predominantly drive tumourigenisis through activation of the MAPK pathway 




1.4.2 The MAPK Cascade 
The MAPK cascade is a three tier protein signalling network which transfers messages from 
the membrane bound cytoplasmic RAS family across the cytoplasm to within the nucleus. 
The RAF family is the first tier of the cascade and has three isoforms Raf-1/c-Raf, B-Raf, 
and A-Raf, all encoded by different genes. All share three conserved regions (CR1-3). CR1 
is located in the N-terminal and includes the RAS binding domain (Matallanas et al., 2011) 
CR3 is found at the C-terminal and is home to the mitogen-activated protein kinase Kinase 
1/2 (MEK1/2) serine/threonine kinase activation sites. All RAF proteins have a narrow 
range of substrates including MEK1/2, the second tier of the MAPK cascade. MEK1/2 are 
dual specificity tyrosine/threonine protein kinases, as with the RAF family MEK1/2 has a 
narrow range of substrates which includes extracellular-signal-regulated kinases (ERK)1/2, 
the third tier of the MAPK pathway (Roskoski, 2012). Unlike BRAF and MEK1/2, ERK has a 
wide range of substrates and is able to translocate from the cytoplasm to the nucleus. The 
subsequent phosphorylation of the threonine and tyrosine residues of ERK1/2 ultimately 
leads to activation of pro-survival transcription factors such as ELK-1 and CREB and 
deactivation of apoptotic transcription factor FOXO3 (Mebratu and Tesfaigzi, 2009). 
ERK1/2 activation also initiates the transcription of target genes involved in negative 
feedback of the MAPK pathway including the dual specificity phosphatases (DUSP) 4 and 6 




Figure 1.3. Ligand dependent activation of the MAPK pathway. Ligand binding of EGFR extracellular 
domains (ED) causes dimerisation with EGFR, HER2, HER3, or HER4. EGFR ligands include epidermal 
growth factor (EGF), transforming growth factor α (TGF α), and amphiregulin. Autophosphorylation is a 
result of ATP binding to the tyrosine kinase domain (TK) and donating a phosphate group. This is the same 
domain that TKI bind to, thereby inhibiting phosphorylation. The EGFR dimer illustrated forming a complex 
with GBR2 and SOS1, which converts RAS into its active GTP bound state. RAS-GTP then starts a signalling 
cascade through the MAPK pathway (p represents the signalling protein in its active phosphorylated 
state). NF1 is a negative regulator of RAS and catalyses the reaction of RAS-GTP to its inactive RAS-GDP 






1.5 NF1 Pseudogenes 
Pseudogenes are abundant throughout the genome and originate from a gene or partial 
gene duplication that has taken place throughout evolution (Tutar, 2012). It is calculated 
there are 14112 pseudogenes scattered about the human genome (Pei et al., 2012). 
Pseudogenes, as their name suggests demonstrate a high level of homology with the gene 
from which they originated. Luijten and colleagues reported 7 NF1 pseudogenes (NF1P) 
present on multiple chromosomes including; 2, 12, 14, 15, 18, 21, and 22 (Luijten et al., 
2000, Luijten et al., 2001). NF1P1 is shown in Figure 1.4. Their investigation suggested the 
NF1P on chromosome 2 was the first to arise and all NF1P to be located in the 
pericentromeric regions of the chromosomes. 
 
 





1.6 Selective Therapeutics for NSCLC 
1.6.1 ADC Targeted Therapeutics 
Knowledge of the genetic characteristics of NSCLC has led to a paradigm shift in the 
treatment of patients displaying key genetic drivers. This has enabled the use of selective 
therapeutics that target key activating driver mutations. However, there are a greater 
number of identified driver mutations such as KRAS that do not currently offer any 
therapeutic advantage, and are linked to a poor prognosis. 
In ADC three driver mutations are currently used as predictive biomarkers for the use of 
selective therapeutics. These include; EGFR in frame exon 19 deletions (19 del) and the 
Leu858Arg substitution in exon 21, both located in the TK domain (Lynch et al., 2004, Pao 
et al., 2004). The third is the anaplastic lymphoma kinase (ALK) and echinoderm 
microtubule-associated protein like 4 (EML4) fusion protein (Cadranel et al., 2013, 
Katayama et al., 2011). 
Tyrosine kinase inhibitors (TKI) that target these oncogenic mutations have been 
developed and approved by the National Institute of Health and Care Excellence (NICE) 
(NICE, 2014). The TKIs Gefitinib, Erlotinib, Afatinib and Crizotinib have demonstrated 
significant increase in progression free survival compared to systemic chemotherapy for 
EGFR and ALK-EML4 positive cases (Haaland et al., 2014, Maemondo et al., 2010, Rosell et 
al., 2012). 
Clinical trials using KRAS as a predictive biomarker for the potential MEK inhibitor 
(selumetinib) and docetaxel in combination have been investigated in the SELECT-1 trial 
(NCT00890825, 2018). SELECT-1 initially yielded significant progression free survival 
compared to docetaxel mono therapy in phase two trials. Patients with metastatic or 
locally advanced NSCLC demonstrated a medium progression-free survival of 5.3 months 
(95% confidence interval (CI), 4.6-6.4) in the combination group, compared to and 2.1 
months (95% CI 1.4-3.7) in the docetaxel group The difference between groups was 3.2 
months with a progression hazard ratio (HR) of 0.58 (80% CI, 0.42-0.79), p = 0.014 (Janne 
et al., 2013). However, the phase three trial demonstrated no significant difference 
between the docetaxel vs. docetaxel and selumetinib arms (NCT01933932, 2018). The 
Medium progression free survival observed for the selumetinib in combination with 
19 
 
docetaxel arm was 3.9 months (interquartile range (IQR), 1.5-5.9) compared to the 2.8 
months (IQR, 1.4-5.5) in the docetaxel arm. The difference observed was, 1.1 months with 
a HR of 0.93 (95% CI, 0.77-1.12), p = 0.44 (Janne et al., 2017). 
1.6.2 SQCC Targeted Therapeutics 
Unfortunately, SQCC currently has no approved targeted therapies. There have been 
preclinical and early phase trials investigating the potential of targeted therapeutics in 
SQCC. A phase two trial investigating the multi target kinase inhibitor Dasatinib in patients 
with DDR2 and BRAF variants was terminated due to low accrual and lack of efficacy 
(NCT01514864, 2015). The Lung-MAP trial is currently investigating the use of the FGFR 
tyrosine kinase inhibitor AZD4547 as a second line therapy in patients with stage 4 SQCC 
with FGFR1 amplification (NCT02965378, 2017). 
1.6.3 Future NSCLC Targeted Therapeutics 
Future advancements for potential targeted treatments for both ADC and SQCC are being 
investigated in the National Lung Matrix Trial (NCT02664935, 2018). The Matrix trial is a 
collaboration between Cancer Research UK, Experimental Cancer Medicine Centre 
Network, AstraZeneca, Pfizer, and Mirati Therapeutics Inc. The trial is currently recruiting 
for phase II and is investigating 10 potential therapies by stratifying NSCLC patients based 




1.7 Emergence of NF1 Loss as a Resistance Mechanisms to Targeted 
Inhibitors 
Loss of NF1 and the presence of NF1 variants have also been linked to resistance in 
targeted therapies. Several studies have now demonstrated that loss of NF1 is enough to 
cause resistance to targeted inhibitors in NSCLC and melanoma (Whittaker et al., 2013, 
Beauchamp et al., 2014, Maertens et al., 2013b, de Bruin et al., 2014a). 
de Bruin and colleagues demonstrated that NF1 knockdown caused resistance to Erlotinib 
in a sensitive in vitro ADC model by increasing active RAS-GTP; this potentially led to MAPK 
and PI3K/AKT/mTOR activation (de Bruin et al., 2014a). The authors then demonstrated 
that transfection of the NF1-GAP domain in the model re-established Erlotinib sensitivity 
by diminishing ERK phosphorylation but not AKT phosphorylation. Additionally, 
constitutively active AKT and MEK were transfected into ADC PC9 cells. The MEK 
transfected cells demonstrated an increase in resistance to Erlotinib, whereas AKT only 
moderately increased cell survival compared to controls (de Bruin et al., 2014a). To further 
confirm MAPK as the dominant driving pathway, a combination of Erlotinib and the MEK 
inhibitor Selumetinib resulted in complete loss of ERK phosphorylation in the NF1 
knockdown model (de Bruin et al., 2014a).  
Similarly, in melanoma Whittaker and colleagues used PLX4720, a selective BRAFV600F 
inhibitor in a resistant cell line with NF1 knockdown and demonstrated that this in 
combination with Selumetinib re-sensitised the cells. The authors also noted a direct 
correlation between ERK phosphorylation and cell proliferation. These findings are also 
supported by Maertens and colleagues using a melanoma mouse BRAF/NF1 model 
(Maertens et al., 2013b). The authors demonstrated that PLX4720 alone did not reduce 
ERK phosphorylation. However, the MEK inhibitor PD0325901 abolished ERK 
phosphorylation and caused tumour regression in vivo (Maertens et al., 2013b). These 
models suggest that NF1 exerts its tumour suppressor abilities in a RAS dependent manner, 
functioning primarily through inhibition of the MAPK pathway. 
de Bruin and colleagues established that NF1 loss was enough to confer EGFR TKI 
resistance. In order to address whether NF1 loss occurs in response to exposure to EGFR 
TKI, the authors used an in vivo EGFR mouse model, subjected to prolonged exposure to 
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Erlotinib (de Bruin et al., 2014a). The authors reported reduced translation of NF1 mRNA 
in 10 out of 18 Erlotinib resistant tumours. Notably the remaining 8 all showed other 
resistance mechanisms, including a EGFR Thr790Met gatekeeper mutations and 
hepatocyte Growth Factor Receptor (MET) amplification (de Bruin et al., 2014a). NF1 
mRNA expression was investigated in a cohort of 34 patients with unknown EGFR status, 
high NF1 mRNA expression was associated with a statistically significant increased medium 
survival time, shown in Figure 1.5 (de Bruin et al., 2014a). 
 
 
Figure 1.5. Kaplan–Meier plot post EGFR TKI therapy. 34 Patients divided into two groups based on NF1 
mRNA expression (NF1 high and NF1 low), median NF1 mRNA expression cut off point was used to define 
the groups. EGFR status of the tumours is unknown. Figure adapted from de Bruin et al (2014a). 
 
NF1 has been identified as a resistance mechanism to the DDR2 inhibitor Dasatinib in SQCC 
(Beauchamp et al., 2014). The authors used a Dasatinib sensitive SQCC cell line and 
subjected it to prolonged exposure to Dasatinib until resistance developed. The cell line 
exome was then sequenced, identifying an NF1 splice site mutation 1392 G>A. This 
mutation was directly linked to reduced protein expression. NF1 was knocked down in the 
parental cell line which confirmed protein loss does confer resistance to Dasatinib 
(Beauchamp et al., 2014). A comparison of phosphorylation of AKT, MEK, and ERK between 
resistant and parental cell lines revealed ERK phosphorylation was maintained in the 
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resistant cell line but not AKT and MEK (Beauchamp et al., 2014). Beauchamp and 
colleagues also investigated a Dasatinib sensitive alpha type platelet-derived growth factor 
receptor amplification dependent cell line. Again NF1 knockdown resulted in increased 
Dasatinib resistance (Beauchamp et al., 2014). 
Genomic profiling studies have revealed NF1 somatic mutations are present in both ADC 
and SQCC in 8-12% of cases (Ding et al., 2008, Collisson et al., 2014, Hammerman et al., 
2012, Campbell et al., 2016). In ADC NF1 mutations are more prevalent in oncogene 
negative tumours and are mutually exclusive to KRAS drivers (Campbell et al., 2016). In 
vitro models of NSCLC and melanoma have both shown that loss of NF1 drives the increase 
of growth signalling through the MAPK pathway (de Bruin et al., 2014a, Maertens et al., 
2013a, Whittaker et al., 2013), whilst Beauchamp and colleagues demonstrated that a 
somatic mutation of NF1 is enough to confer resistance to Dasatinib, through 
haploinsufficient mechanisms, in SQCC. However, the full consequences of the spectrum 
of mutations observed in NSCLC need to be addressed to determine their functional 




1.8 Hypothesis and Study Aims 
It was hypothesised that NF1 variants have a functional consequence on the activation of 
the MAPK pathway. NF1 variants are commonly observed in the NSCLC population and in-
vitro models have demonstrated that NF1 loss is enough to drive the MAPK pathway. The 
current study sets out to determine the functional consequences that these NF1 variants 
have on clinical cases. 
 To address this hypothesis we set out the following study aims. 
1. Recruit 100 NSCLC patients via Weston Park Hospital (WPH) Cancer Clinical Trials 
Centre. 
2. Screen the patients archive tumour tissue for genetic NF1 variants and NF1 copy 
number changes using a combination of next generation sequencing and digital 
droplet PCR. 
3. Measure MAPK activation in the archive tumour tissue using mRNA gene 
expression signatures and relate this back to the NF1 variants, known MAPK 











All materials were stored according to manufacturers’ instructions unless otherwise 
stated  
2.1.1 Nucleic Acid Extraction 
2.1.1.1 Qiagen QIAamp FFPE Tissue Kit and Deparaffinization Solution 
 Qiagen QIAamp FFPE Tissue Kit, Catalogue number: 56404 
o QIAamp MinElute® Columns and Collection Tubes 
o Tissue lysis buffer (Buffer ATL) 
o Lysis buffer (Buffer AL) 
o Wash buffers (Buffers AW1 and AW2 concentrate) 
o Elution Buffer (Buffer ATE) 
o Proteinase K 
 Deparaffinization Solution Catalogue number: 19093 
2.1.1.2 Covaris truXTRAC FFPE DNA kit 
 Covaris truXTRAC FFPE DNA kit, Catalogue number: 520161 
o MicroTUBE Screw-Cap FFPE 
o Purification columns and collection tubes 
o Tissue lysis buffer (SDS Buffer) 
o Binding buffer (B1 Buffer) 
o Wash buffers (BW and B5 Buffer) 
o Elution Buffer (PE Buffer) 
o Proteinase K 
2.1.1.3 Qiagen EZ1 DNA Tissue Kit and Protocol Card 
 EZ1 DNA Tissue Card, Catalogue number: 9015588 
 Qiagen EZ1 DNA Tissue Kit, Catalogue number: 953034 
o Reagent Cartridge 
o Disposable Tip Holders  
o Disposable Filter-Tips  
o Sample Tubes (2 ml)  
o Elution Tubes (1.5 ml)  
o Proteinase K  
o Buffer AVE 
2.1.1.4 Chemagen (Chemagic) 360 
 Chemagic DNA Blood kit, 2ml, Catalogue number: CMG-1097 
o Magnetic Beads 
o Lysis Buffer 1 
o Binding Buffer 2 
o Wash Buffer 3 
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o Wash Buffer 4 
o Wash Buffer 5 
o Wash Buffer 6 
o Elution Buffer 7 
o Protease 
2.1.1.5 Qiagen Rneasy FFPE Tissue Kit 
 RNeasy FFPE Kit, Catalogue number: 73504 
o RNeasy Mini spin column 
o Lysis buffer (Buffer RBC) 
o Digestion buffer (Buffer PKD) 
o Proteinase K 
o RNase-Free DNase I (lyophilized) 
o RNase-Free Water 
o Dnase Booster Buffer 
o Wash Buffer (Buffer RPE) 
o Rnase Free Water 
 
2.1.2 DNA Quantification & Quality Control 
2.1.2.1 ThermoFisher Scientific: Qubit assay kits 
 Qubit dsDNA BR Assay Kit, Catalogue number: Q32850 
o Qubit® dsDNA BR Reagent 
o Qubit® dsDNA BR Buffer 
o Qubit® dsDNA BR Standard #1 (100 pg/µL) 
o Qubit® dsDNA BR Standard #2 (1000 ng/µL) 
 
 Qubit dsDNA HS Assay Kit, Catalogue number: Q32851 
o Qubit® dsDNA HS Reagent 
o Qubit® dsDNA HS Buffer 
o Qubit® dsDNA HS Standard #1 (10 pg/µL) 
o Qubit® dsDNA HS Standard #2 (100 ng/µL) 
 
 Qubit RNA HS Assay Kit, Catalogue number: Q33210 
o Qubit® RNA HS Reagent 
o Qubit® RNA HS Buffer 
o Qubit® RNA HS Standard #1 (250 pg/µL) 




2.1.2.2 Quantitative PCR 
 Qiagen, QuantiTect Probe PCR Kit, Catalogue number: 204343 
o QuantiTect Probe PCR Master Mix 
o RNase-Free Water 
o ThermoFisher, Hs01694011_s1 TaqMan® Gene Expression Assay, Catalogue 
number: 4331182, Ferratin heavy polypeptide chain (FTH1) probe and primers 
 
2.1.2.3 Agilent TapeStation 2200 
 All ScreenTape assays kits 
o D1000 ScreenTape Assay, Catalogue number: G2991-90030 
o High Sensitivity D1000 ScreenTape Assay, Catalogue number: G2991-90130 
o Genomic DNA ScreenTape Assay, Catalogue number: G5067-5365 
o RNA ScreenTape Assay, Catalogue number: G2964-90022 
o High Sensitivity RNA ScreenTape, Catalogue number: G2964-90121 
 
2.1.3 Sanger Sequencing 
 OneTaq® Quick-Load® 2X Master Mix with Standard Buffer, Catalogue number: 
M0486S, New England Biolabs 
 Oligo primers, Catalogue number: VC00021, Sigma Aldridge 
 BigDye™ Terminator v1.1 Cycle Sequencing Kit, Catalogue number: 4337449, 
ThermoFisher 
 96% Ethanol, Catalogue number: 20 823.327, VWR 
 Better Buffer, Catalogue number: 3BB1, Microzone Ltd 
 Illustra ExoProStar 1-Step, Catalogue number: 11941411 




2.1.4 NGS Library Preparation 
General Reagents  
 Agencourt AMPure XP Kit, Catalogue number: A63882, Beckman Coulter 
 Dynabeads MyOne Streptavidin T1, Catalogue number: 65602, Thermo Fisher 
Scientific 
 96% Ethanol, Catalogue number: 20 823.327, VWR 
 Nuclease-free Water (not DEPC-treated) Catalogue number: AM9930, Ambion 
 
Agilent’s SureSelect XT Low Input Target Enrichment System for Illumina Paired-End 
Multiplexed Sequencing Library 
 SureSelect XT Low input Reagent Kit, index 1-96, Catalogue number: G9707A 
o SureSelect XT HS Index Primers A01 through H12 
 
 SureSelect XT Low input Reagent Kit, index 97-192, Catalogue number: G9708A 
o SureSelect XT HS Index Primers A01 through H12 
 
 Hereditary Cancer v3.2 Design ID 3014041 
o Custom biotinylated 120 nt RNA probe set  
 
 Agilent XT Low input Library Preparation Kit for ILM (pre-PCR) 
o Ligation Buffer 
o T4 DNA Ligase 
o End Repair-A Tailing Buffer 
o End Repair-A Tailing Enzyme Mix 
o Herculase II Fusion DNA Polymerase 
o 5× Herculase II Reaction Buffer 
o 100 mM dNTP Mix 
o Forward Primer 
o Adaptor Oligo Mix 
 
 Agilent XT Low input Target Enrichment Kit ILM Hyb Module box 1 (post-PCR) 
o SureSelect Binding Buffer 
o SureSelect Wash Buffer 1 
o SureSelect Wash Buffer 2 
o SureSelect XT HS and XT Low Input Blocker Mix 
 
 Agilent XT Low input Target Enrichment Kit ILM Hyb Module box 2 (post-PCR) 
o SureSelect RNase Block 
o SureSelect Fast Hybridization Buffer 
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o Herculase II Fusion DNA Polymerase (red cap) 
o 5× Herculase II Reaction Buffer 
o 100 mM dNTP Mix 
o SureSelect Post-Capture Primer MixNGS Illumina Paired End Sequencing  
 
 HiSeq Rapid SBS Kit v2 (200 cycles), Catalogue number: FC-402-4021 
 HiSeq PE Rapid Cluster Kit v2, Catalogue number: PE-402-4002 
 PhiX Control v3, Catalogue number: FC-110-3001 
 Qiagen Buffer EB, Catalogue number: 19086 
 2N NaOH 
 TWEEN® 20 Catalogue number: P2287 
2.1.5 Bio-Rad Digital Droplet PCR 
 ddPCR NF1 copy number assay, Catalogue number: 10031240 
 ddPCR RPP30 copy number assay, Catalogue number: 10031243 
 ddPCR Supermix for probes (No DUTP), Catalogue number: 1863023 
 DG8 Cartridges, Catalogue number: 1864008 
 DG8 Gaskets, Catalogue number: 1863009 
 Droplet Generation Oil for Probes, Catalogue number: 1863005 
 Oligo primers, Catalogue number: VC00021, Sigma Aldridge 
2.1.6 NanoString nCounter 
 NanoString custom design XT formulation CodeSet, design ID: Sel-Yale_2 
o Reporter CodeSet 
o Capture CodeSet 
 nCounter Standard Master Kit, Catalogue number: NAA-AKIT-192 
o nCounter Cartridge 
o nCounter Prep Plates 
o nCounter Prep Pack, Catalogue number: 
 Racked tips and foil piercers 
 12-tube strips 
 Tip Sheaths 
 12-strip tube caps 
 Cartridge well seals 
 Hybridization buffer 




2.1.7 Patient Samples 
86 patients were recruited directly in this study (NF1 in NSCLC) based on the eligibility 
criteria described in section 2.2.1.2. 40 samples were also accessed from the ReSoLuCENT 
trial which had the same acceptance criteria as this study, as described in section 2.2.1.2. 
56/86 samples from this study (NF1 in NSCLC) passed initial pre-analytical acceptance 
criteria as described in section 4.2, all of which were surgical specimens. 34/40 samples 
from the ReSoLuCENT trial passed initial pre-analytical acceptance criteria, however a 
further 4 failed at initial library preparation stage. The remaining 30 ReSoLuCENT samples 
included in analysis were all biopsies, 17 from metastatic sites and 13 from primary sites. 





2.2.1 Recruitment of Patients to the Neurofibromin-1 in Non-Small Cell Lung 
Cancer Study 
2.2.1.1 Ethics Statement  
The initial aim for the academic study ‘Identifying functionally important aberrations in 
neurofibromin-1 in non-small cell lung cancer’ was to recruit 100 patients with NSCLC from 
WPH for genetic analysis. 
Local approval and peer review for the project was granted by Weston Park Hospital 
Clinical Trials Executive in February 2015. The project was approved by Sheffield Teaching 
Hospitals (STH) Research and Development department (STH18741) after reviewing the 
project protocol (Appendix 1), patient information sheet (Appendix 2), patient consent 
form (Appendix 3) and the Integrated Research Application System form. Final ethical 
approval came from Yorkshire and Humber Regional Ethics Committee (YHREC) 
(15/YH/0102) (Appendix 4) and was granted in June 2015. The project summary was 
published on the Health Research Authority website 
(http://www.hra.nhs.uk/news/research-summaries/nf1-in-nsclc). 
2.2.1.2 Patient Recruitment 
NSCLC patients were pre-screened for potential eligibility to the study prior to being 
approached at WPH lung cancer clinics. 
Principal patient eligibility criteria included: 
• Pathological (histological) confirmation of non-small cell lung cancers with 
ADC or SQCC subtypes. 
• Archived tissue available at STH 
• Willingness to have a blood test 
• Able to give written informed consent 
Once potential patients were identified, details were passed on to the clinical staff directly 
involved with the patient’s care. The patient’s Consultant or Registrar made the final 
decision regarding whether the patient would be approached or not. Patients who were 
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approached were given the patient information sheet and the STH ‘Donation of body tissue 
samples for research’ leaflet and allowed to ask questions regarding the study. Patients 
who decided to participate gave written consent for a one off blood sample to be taken, 
access to their archived tumour tissue, and for members of the research team to access 
their non-identifiable patient information. 
2.2.1.3 ReSoLuCENT Patient Samples 
To mitigate for low patient accruement and patient samples with insufficient tumour 
tissue we applied to access ‘Resource for the Study of Lung Cancer Epidemiology in North 
Trent’ (ReSoLuCENT) patient samples and non-identifiable patient information 
(STH13872), YHREC (05/MRE07/72). This application was successful and any shortfall was 
made up using these samples. A substantial amendment was submitted to YHREC updating 
the project protocol for inclusion of these samples. 
2.2.1.4 Processing and Storage of NSCLC Blood Samples 
Blood samples were collected from the consented patients by a trained phlebotomist, 
either on the day of consent or on their subsequent visit to WPH lung cancer clinic. Up to 
50 ml of whole blood was collected for each patient in 9 ml EDTA vacutainers. After the 
blood draw samples were stored on ice or at 2-8°C for a maximum of 2 hours before 
processing. One 9 ml EDTA vacutainer was decanted into 2 ml aliquots and stored at -20°C. 
The remaining 9ml EDTA vacutainers were subjected to a 2 cycle centrifuging step to 
isolate the plasma for potential circulating free DNA analysis. The first centrifugation step 
was at 800g for 10 minutes at 4°C.  The separated plasma was transferred to a new tube 
and further centrifuged at 1600g for a further 10 minutes at 4°C. The resulting plasma was 
transferred into 1.5 ml aliquots and stored at -80°C.  
2.2.1.5 FFPET Samples 
All patient surgical resected samples or bronchoscopies were undertaken at STH between 
2008-2017. These were processed into formalin fixed paraffin embedded tissue (FFPET) 
within the hospitals histology department. ReSoLuCENT samples were processed in 
hospitals throughout the UK from 2004–2013. All FFPET samples had slides created; these 
were stained by routine haematoxylin and eosin (H+E). The slides were examined by a 
trained pathologist for total cellularity of the section, the proportion of nuclei that are 
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tumour as opposed to normal, stroma, and inflammatory cells, and to determine if necrosis 
was present. Professor Simon Cross outlined the regions of tumour on the slides of study 
samples for guidance when macro dissecting.  
 
2.2.2 Nucleic acid extraction from FFPET samples 
2.2.2.1 Qiagen QIAamp FFPE Tissue Kit 
Qiagen’s QIAamp DNA FFPE Tissue Kit (QIAamp) and Qiagen’s Deparaffinization Solution is 
a DNA extraction method recommended by Illumina and Agilent for downstream NGS of 
FFPET. 
The original QIAamp protocol has had several steps added to optimise the process for 
downstream NGS. Qiagen’s deparaffinization solution was included to remove paraffin. An 
overnight incubation at 56°C was included to improve proteinase K digestion of proteins. 
The 90°C incubation, which is used to remove protein / DNA covalent crosslinks, was 
reduced to 80°C to reduce the amount of double stranded DNA (dsDNA) from 
denaturation. All reagents were prepared and stored according to the manufacturers’ 
instructions and all centrifuge steps were completed at room temperature. 
4-6 x 10 µm sections were added to a 1.5 ml microfuge tube. 320 µl of deparaffinization 
solution was added and vortexed vigorously for 10 seconds, then centrifuged at 1000 g for 
2 seconds. This was incubated at 56°C for 3 minutes then allowed to cool to room 
temperature (15–25°C). 180 μl buffer ATL was added and mixed by vortexing. This was 
centrifuged for 1 min at 11,000 g before adding 40 μl of proteinase K to the lower clear 
phase and mixed gently by pipetting up and down. It was then incubated at 56°C overnight, 
then transferred to an 80°C incubator for 1 hour and centrifuged at 1000 g for 2 seconds. 
The lysate (clear lower phase) was transferred to a new 1.5 ml microfuge tube and 200 μl 
of AL buffer was added followed by 200 μl of 96-100% ethanol which was then vortexed 
vigorously. The lysate was then transferred to a QIAamp MinElute column and centrifuged 
at 6000 g for 1 minute. The flow through was discarded and 500 μl of AW1 Buffer added 
before being centrifuged at 6000 g for 1 minute.  The flow through was discarded and 500 
μl of AW2 Buffer added before being centrifuged at 6000 g for 1 minute. The flow through 
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was discarded and the column was centrifuged at 20,000 g for 3 minutes. The QIAamp 
MinElute column was transferred to a new 1.5 ml microfuge tube, 50 μl of ATE buffer was 
added to the column and incubated at room temperature for 5 minutes.  Finally this was 
centrifuged at 20,000 g for 1 minute to elute DNA. 
2.2.2.2 Covaris truXTRAC FFPE DNA kit 
The Covaris truXTRAC FFPE DNA kit (truXTRAC) is a new extraction method released in 
2014. The actual column based extraction is similar to the QIAamp method, however, the 
initial deparaffinization step is replaced by a focused ultrasonication to remove the 
paraffin. All reagents were prepared and stored according to the manufacturers’ 
instructions and all centrifuge steps were completed at room temperature.  
4 x 10 µm sections were put into a Covaris microTUBE Screw-Cap and 100 μl of tissue SDS 
Buffer added. The Covaris microTUBE was put onto the mounting plate for the Covaris 
E220 and run using the parameters shown in Table 2.1 
 
Table 2.1. Covaris E220 setting for removing the paraffin from the fixed tissue. 
Setting FFPE DNA 
Duty Factor 10% 
Peak Incident Power (PIP) 175 
Cycles per Burst 200 
Treatment Time 300 seconds 
Bath Temperature 20°C 
 
Post focused ultrasonication, 20 μl of Proteinase K solution was added to each microTUBE. 
The Covaris E220 was then rerun using the above setting, with the exception that the time 
was reduced to 10 seconds. The microTUBE Screw-Caps were incubated overnight at 56°C, 
then transferred to an 80°C incubator for 1 hour and centrifuged at 1000 g for 2 seconds. 
Following this the lysate was transferred to a 1.5 ml tube and 140 μl of buffer B1 was added 
and vortexed thoroughly. 160 μl of 96-100% ethanol was then added and again vortexed 
thoroughly and centrifuged at 10,000 g for 2 minutes. The liquid layer was transferred to 
a purification column, avoiding the paraffin base white layer at the top. The purification 
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column was then centrifuged at 11,000 g for 1 minute. The flow through was discarded, 
500 μl of buffer BW was added to the column and centrifuged at 11,000 g for 1 minute. 
The flow through was again discarded, 500 μl of buffer B5 added and centrifuged at 11,000 
g for 1 minute. The flow through was then discarded and the tube centrifuge at 11,000 g 
for 1 minute. The purification column was transferred to a new 1.5 ml microfuge tube, and 
50 μl of buffer BE, pre-warmed to 70°C, added and incubated at room temperature for 3 
minutes.  This was then centrifuged at 11,000 g for 1 minute to elute DNA. The first eluate 
was reloaded to the top of the column, incubated for 3 min at room temperature and re-
centrifuged at 11,000 g for 1 minute. 
2.2.2.3 Qiagen EZ1 DNA Tissue Kit 
Qiagen EZ1 DNA Tissue Kit (EZ1) was used for FFPET DNA extraction at Sheffield Diagnostics 
Genetic Services (SDGS) based at Sheffield Children’s Hospital (SCH). It is a largely 
automated protocol run on the Qiagen’s BioRobot EZ1. Unlike the QIAamp and the 
truXTRAC, which use silica anionic column based technology, the EZ1 uses silica-coated 
magnetic particles which bind to the DNA and are washed in subsequent steps.  
4 x 10 µm sections were suspended in 180 μl of Qiagen’s ATL in a 1.5 ml tube. 20 μl of 
proteinase K was added to the tube before being vortexed vigorously. This was then 
incubated overnight at 56°C, on a shaking incubator at 300 rpm. It was then transferred to 
a 90°C incubator for 1 hour. The BioRobot EZ1 rack place was set up with elution tubes in 
row 1, tips and tip-holders in row 2, and the EZ1 reagent cartridges. After the 90°C 
incubation the lysate was transferred to sample tubes in row 4 of the eEZ1 rack. The EZ1 
DNA Tissue Kit protocol card was inserted into the BioRobot EZ1 along with the EZ1 rack. 
Elution volume was set to 50 μl and the protocol started.  
2.2.2.4 DNA Extraction from Whole Blood Samples 
Extraction of DNA from 1-2 ml of whole blood was performed using the automated 
Chemagic 360 (PerkinElmer) in the medium volume configuration using the Chemagic DNA 
Blood Kit. The extraction was carried out in two stages. The first stage involved mixing and 
lysing of the cells in the blood to release the DNA using lysis buffer 1. In the second stage, 
the DNA was bound to the magnetic beads using binding buffer 2.  The beads were then 
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washed several times in wash buffers 3-6. Finally the DNA was eluted from the beads in 
300 µL of TE buffer. 
2.2.2.5 Qiagen RNeasy FFPE Tissue Kit 
Whilst NGS requires high quality DNA to generate sequence, the Nanostring nCounter used 
for the gene expression analysis is very tolerant to FFPET derived RNA. All FFPET samples 
were sectioned at 10 µM and mounted on uncharged slides. Based on tumour content 
where possible, RNA was extracted from a minimum surface area of least 50 mm2. For 
smaller samples this required dissecting tissue from up to 8 slides.  
All reagents were prepared and stored according to the manufacturers’ instructions and 
all centrifuge steps were completed at room temperature.  
160 μl of deparaffinization solution was added to a 1.5ml tube. Tumour material 
(previously outlined by a Pathologist) was macro- dissected from the slide with a scalpel 
and added to the tube. This was vortexed vigorously for 10 s, then centrifuged at 1000 g 
for 2 seconds, before being incubated at 56°C for 3 min and allowed to cool to room 
temperature. 150 µl of Buffer PKD was added and mixed by vortexing. This was then 
centrifuged for 1 min at 11,000 g. 10 μl of proteinase K was added to the lower clear phase 
and mixed gently by pipetting up and down. This was incubated at 56°C overnight, then 
transferred to a 80°C incubator for 15 minutes. The lysate (clear lower phase) was 
transferred to a new 1.5 ml microfuge tube and incubated on ice for 3 minutes. This was 
then centrifuged for 15 min at 20,000g, before transferring the supernatant without 
disturbing the pellet to a new tube. 16 µl of DNase Booster Buffer was added followed by 
10 µl of DNase I. This was mixed by inverting twice and centrifuged very briefly, to collect 
residual liquid, and then incubated at room temperature for 15 minutes. 320 µl of Buffer 
RBC was added and mixed thoroughly by pipetting. 720 µl of ethanol (100%) was added to 
the sample, and mixed well by pipetting. 700 µl of the sample was transferred to a RNeasy 
MinElute spin column and centrifuged for 15 seconds, discarding the flow-through. The 
remainder of the sample (~515 µl) was added to the RNeasy MinElute spin column and 
centrifuged for 15 seconds. The flow-through was discarded and 500 μl of Buffer RPE 
added before being centrifuged at 8000 g for 15 seconds.  The flow-through was discarded 
and 500 μl of Buffer RPE added before been centrifuged at 8000g for 15 seconds. The flow-
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through was discarded and the column was centrifuged at full speed with the lid open for 
5 minutes. The RNeasy MinElute spin column was transferred to a new 1.5 ml tube. 15 µl 
of RNase-free water was directly added to the spin column membrane and centrifuged for 
1 min at full speed to elute the RNA. 
 
2.2.3 DNA Quantification  
2.2.3.1 UV spectrophotometry DNA Quantification   
Initial DNA quantification and contamination was assessed using the NanoDrop 8000 
(Thermofisher Scientific). The NanoDrop uses UV spectrophotometry to measure 
absorbance of light at specific wavelengths with in the UV range (<400 nm) when analysing 
nucleic acids.  Nucleic acid absorbs light at 260 nm and aromatic amino acids from proteins 
absorbs light at 280 nm.  
The ratio of absorbance at these wavelengths can be used to assess DNA purity. 
Absorbance (A) at 260 nm / 280 nm (A 260 / A 280) is used for protein contamination and 
generally a ratio of 1.8 – 2.0 suggests acceptable levels of protein contamination.   
UV spectrophotometry was used to calculate the quantity of nucleic acid using the Beer-
Lambert equation: 
A = ϵ C ℓ 
A is absorbance at the specific wavelength, ϵ = molar extinction coefficient (50 ng-cm / μl 
for dsDNA), C is concentration (ng/μl), and ℓ is the light pathway (cm). The NanoDrop 8000 
has a detection range for dsDNA of 2.5 – 3750 ng/μl. 
The NanoDrop pedestal was wiped with lint-free tissue prior to being blanked with 2 μl of 
nuclease free water. A known DNA concentration standard was then used to check the 
NanoDrop calibration. 2 μl of eluted DNA from the extractions was then added to the 
instrument for analysis. 
2.2.3.2 Qubit DNA Quantification  
DNA concentration was further quantified by the Qubit 2.0 Fluorometer. This is 
recommended by Agilent Technologies for DNA quantification for downstream analysis 
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using NGS. The Qubit 2.0 uses target-specific fluorescence and only emits light when 
specifically bound to dsDNA. The resulting concentration is more accurate than the 
NanoDrop as only dsDNA is detected. The Qubit 2.0 has a detection range of 2–1000 ng 
using the Qubit dsDNA BR Assay Kit and 0.2–100 ng using the Qubit dsDNA HS Assay Kit. 
As per Qubit dsDNA assay kit instructions 1 μl of Qubit dsDNA reagent was added to 199 
of Qubit dsDNA buffer creating a 1:200 Qubit working solution / per sample. For the two 
standards used in the assay, 10 μl of standard is added to 190 μl of Qubit working solution 
in Qubit assay tubes. 1-10 μl of sample is added to 190-199 μl of Qubit working solution in 
Qubit assay tubes resulting in 200 μl. These were vortexed for 3 seconds then incubated 
at room temperature for 2 minutes. The samples were then measured against the known 
standards providing the concentration. 
2.2.3.3 qPCR DNA Quantification 
To optimise for NGS downstream analysis we required a method of measuring the amount 
of DNA which is unaffected by chemical modifications and degradation introduced by the 
FFPET process. Sah at al., (2013) and Choudhary at al., (2014) previously described an 
absolute quantitative qPCR method to determine the volume of functional DNA (DNA that 
is amplifiable) (Sah et al., 2013, Choudhary et al., 2014). This method of quantification was 
used as a pre sequencing quality control check. The genomic copy number is directly 
related to the sequencing read depth. When a sequence depth of >300 X is required, at 
least 300 genomic copies starting material, not considering loss during library preparation, 
is needed. 
Ferritin heavy polypeptide 1 (FTH1) gene was used as the target for the qPCR assay. A 
Thermofisher Scientific TaqMan assay with both primers located in a single exon of FTH1 
was used to amplify a 180 base pair (bp) region of the gene. FTH1 was used as only 0.3% 
of SQCC and ADC cases have reported amplification or deletion of this gene and 0.4 % of 
cases have single nucleotide aberration mutations (Campbell et al., 2016). 
High quality genomic DNA (gDNA) was extracted from 2 ml of whole blood via ChemGen 
Mid. This was then quantified using the Qubit 2.0. A four-fold dilution series was created 
ranging from 50 ng to 0.2ng (15150 to 59 haploid copies) and used as standards. 
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The standards were analysed on Applied Biosystems real-time PCR 7500 instrument. 
Cycling parameters were 50°C x 2 mins, 95°C x 15 mins, (95°C x 15 sec, 60°C x 1 min) x 40 
cycles. Mastermix for the qPCR reaction shown in Table 2.2. 
Table 2.2. FTH1 qPCR reagent volumes 
Reagent Volume (μl)  
QuantiTect Master mix (2X) 12.5 
FTH1 probe and primers (20X) 1.25 
Molecular H20 6.25 
DNA  5 
Total reaction volume 25 
 
DNA standards (50 ng to 0.2 ng) were run in technical replicates of 3 shown in Figure 2.1. 
For the standards to be considered reproducible and accurate the 3 technical replicates 
had to fall within 0.5 Ct of each other (Standard deviation (SD) < 0.289). To demonstrate 
the amplification observed in the standards was efficient, thereby ensuring the DNA 
standards were of high quality, a standard curve was generated using the Log10 of standard 
concentration vs. cycle threshold (Ct). Efficiency should be between 95 – 105%. The 
gradient of the curve was used to calculate efficiency using the following calculation: 





Figure 2.1. Absolute qPCR Standard curve plot. Standards produced from high molecular weight 
DNA ranging from 200 ng to 0.2 ng (60600 – 59 haploid copies) shown in green. All the standards 
were run in triplicate and have a < 0.5 Ct between replicates. R2 = 0.0998, Slope= -3.312, 
Efficiency = 100.4%.  
 
FFPET extracted DNA was initially quantified using the Qubit 2.0 BR kit. The DNA was then 
re-quantified via qPCR running three technical replicates against the standard curve. In 
cases of very poor DNA yield only one replicate was run. The amount of amplifiable FFPET 
derived DNA was calculated using the following linear regression equation:  
y = a + bx 





A quantitative functional index (QFI) score was calculated as a percentage of amplifiable 
DNA as follows: 
qPCR quantification (ng/µl) 
x 100 = QFI (%) 
Qubit quantification (ng/µl) 
 
2.2.3.4 Agilent TapeStation 2200 
The Agilent TapeStation 2200 bioanalyser enables fast high throughput analysis of DNA 
and RNA using a ScreenTape based electrophoresis system. Data generated can be viewed 
in a standard pseudo-gel format or electropherogram.  Agilent ScreenTape comes in 
various formats dependent on requirements (Table 2.3). 
 
Table 2.3. Agilent TapeStation ScreenTape 
ScreenTape Fragment Size (bp) Concentration Range 
D1000 30 - 1000 0.1 – 50 ng/µl 
High sensitivity D1000 30 - 1000 75 – 1000 pg/µl 
Genomic DNA 200 to > 60,000 10-100 ng/µl 
High Sensitivity RNA 100 - 6000 500–10,000 pg/µL 
 
Manufacturers’ instructions were followed for loading the instrument. For DNA the 
relevant loading buffer was loaded into a 96 well fully skirted plate followed by DNA, RNA, 
or the ladder (Table 2.4). The 96 well plate was vortexed at 2000 RPM for 1 minute 
followed by a brief centrifuge. Barcoded ScreenTape, tips, and the 96 well plate were 
inserted into the TapeStation 2200 for analysis. For RNA analysis the same steps were used 
with an additional 72°C, 3 minutes incubation, followed by 2 minutes on ice, and a final 





Table 2.4. Agilent TapeStation loading volumes 
ScreenTape Loading Buffer (μl) DNA / RNA / Ladder (μl) 
D1000 3 1 
High sensitivity D1000 2 2 
Genomic DNA 10 1 
High Sensitivity RNA 1 2 
 
2.2.4 Next Generation Sequencing 
2.2.4.1 Designing Custom Next Generation Sequencing Probes 
In order to enrich the regions of interest during NGS, a custom Agilent SureSelect 
hybridisation probe set was designed. Hybridisation probes are biotinylated RNA 
nucleotide sequences complementary to the regions of interest.  The probes are incubated 
with fragmented gDNA, which are then used to pull down and enrich the areas of interest.  
Hybridisation probes were designed for NF1, EGFR exons 19 - 21, BRAF exon 11, and KRAS 
exon 2-3. However, Agilent recommends custom probe sets should be a minimum of 200 
kbp to limit off target sequencing. Therefore a 47 gene panel was designed as described in 
the following paragraph, consisting of 11537 probes (275 kbp) which were to be used at 
SCH for their new diagnostic hereditary cancer testing panel (Table 2.5). The panel included 




Table 2.5. Agilent SureSelect custom design cancer panel 
Sheffield Children’s Hospital, Genetics Department, Hereditary Cancer Panel 
ATM PTEN MSH6 MITF SDHAF2 
BAP1 RAD51C (FANCO) MUTYH SDHB SDHC 
BRCA1 RAD51D  PMS2 TSC1 SDHD 
BRCA2 STK11 SMAD4 TSC2 TMEM127 
BRIP1 TP53 POLD1 VHL KRAS 
CDH1 APC POLE WT1 BRAF 
CHEK2 BMPR1A FH MAX EGFR 
NBN EPCAM FLCN (BHD) NF1 
 
PALB2 (FANCN) MLH1 HNF1A PRKAR1A 
 
PPM1D MSH2 MET RET 
 
Genes included in Agilent’s SureSelect custom targeted sequencing for a hereditary cancer panel. 
Agilent Design ID: 3014041 
 
All relevant mRNA transcripts were acquired from the National Center for Biotechnology 
Information (NCBI) (www.ncbi.nlm.nih.gov) using the reference sequence accession 
numbers. NCBI gene accession numbers were added to Agilent’s SureDesign earray 
(https://earray.chem.agilent.com/suredesign/) as targets using coding exons and no 
flanking bases as the region of interest parameters.  A BED file was downloaded at the first 
review step. The BED file contains genomic coordinates for the start and end of each exon 
for a given target gene. For genes with multiple transcripts, the BED files were merged into 
one to ensure all possible exons of different transcripts were included. This was done using 
Galaxy.org BEDTools, MergeBED algorithm (https://usegalaxy.org/). The resulting BED 
files, including all exons of all transcripts were transferred to a custom excel file, which 
added ±25 bp of intronic region to the coordinates. These coordinates were then uploaded 






 Density = 5X (The amount of overlapping probes are 5 X deep in a staggered tile 
manner) 
 Masking = Moderately Stringent (Masking hides repetitive regions so probes are 
not designed in these regions) 
 Boosting = Max performance (Probes with a higher GC content are replicated by a 
higher factor) 
Once the probe set was designed the resulting BED file was downloaded. This annotates 
the target regions, missed regions, and covered regions. Any regions that were missed due 
to the level of masking in the algorithm were re-submitted with less stringent masking 




Figure 2.2. Broad Institute’s Integrated Genomic Viewer. Agilent’s probes covering exons 10 
and 11 ± 25 bp of intronic region of NF1. Probes are designed to 5X in a tiled manner offset by 
20 bp. 
 
The sequences from the resulting probes from the resubmitted missed regions were then 
requested from Agilent. Each individual probe sequence was then cross referenced with 
human reference genome (GRCh37/hg19) using the University of California Santa Cruz 
(UCSC) gnome browser alignment tool BLAT (https://genome.ucsc.edu/). Agilent’s 
hybridisation probes, which had a QSIZE score of >40 and mapped to other regions of the 
genome were discarded. QSIZE indicates the number of matching base pairs between the 
sequences uploaded and reference genome. 
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2.2.4.2 Agilent’s XT low input kit Library Preparation 
FFPET derived gDNA was used with Agilent’s XT low input kit to create NGS libraries 
following the manufacturers’ protocol. Agilent’s XT low input kit enables library 
preparation using between 10–200 ng of starting gDNA. The protocol was optimised using 
Agilent’s DNA integrity number (DIN) and the QFI score summarised in 2.1.2.  
Briefly, the gDNA is fragmented to ~200 bp in size and adaptors ligated to the end of the 
fragments. During the pre-hyb PCR indexes are added during the amplification process 
alongside P7 and P5 adaptors (complementary to the flow cell). The hybridisation step 
enriches for the regions of interest followed by a post-hyb PCR resulting in the sequencing 
libraries (Figure 2.3) 
 
 
Figure 2.3. Illumina paired end library preparation 
  
Quantity and quality of genomic DNA samples 
FFPET derived DNA for sample analysis was quantified using the NanoDrop and Qubit and 
analysed for integrity using the TapeStation’s DIN (2.1.2). The samples were also quantified 
using qPCR. 
Starting amounts of DNA were adapted from Agilent’s recommendations considering both 
the DIN score and qPCR quantification shown in Table 2.6. Samples were diluted in 50 µl 









DIN > 8 DIN < 8 
DNA input for 
Library 
Preparation 
10 ng to 200 ng DNA, quantified 
by Qubit Assay 
10 ng to 200 ng of amplifiable 
DNA, 
based on qPCR quantification 
Low Input DNA input modifications based on DNA Integrity Number (DIN) score and qPCR 
quantification 
 
Shear gDNA to 200 bp 
50 µl of H2O containing up to 200 ng of gDNA was transferred to a 130 µl Covaris 
microTUBE and briefly centrifuged. These were sheared on a Covaris E220 instrument 
using the settings shown in Table 2.7. 
 
Table 2.7. Covaris E220 setting for shearing of gDNA 
Setting FFPE DNA 
Duty Factor 10% 
Peak Incident Power (PIP) 175 
Cycles per Burst 200 
Treatment Time 240 seconds 
Bath Temperature 2° to 8°C 





Repair and dA-Tail the DNA ends 
A master mix was prepared for End Repair/dA-Tailing of the sheared gDNA samples.  The 
master mix was prepared according to Table 2.8. It was mixed by pipetting and briefly 
centrifuged. This was stored on ice till required. 
 
Table 2.8. Preparation of repair/dA-Tail master mix 
Reagent  Volume for 1 reaction Volume for 8 reactions  
End Repair-A Tailing Buffer 16 µl 144 µl 
End Repair-A Tailing Enzyme 
Mix 
4 µl 36 µl 
Total 20 µl 180 µl 
 
20 µl of the End Repair/dA-Tailing master mix was added to each sample well containing 
50 µl sheared DNA and mixed via pipetting in a 96 well PCR plate. The plate was sealed and 
briefly centrifuged. The samples were then incubated on a thermocycler using the 
following cycling parameters: 20°C for 15 minutes, 72°C for 15 minutes, and 4°C hold. The 
96 well plate was then transferred to ice. 
Ligate the adaptors 
A ligation mastermix was prepared according to Table 2.9, mixed by pipetting, and briefly 
centrifuged. The ligation mastermix was incubated at room temperature for 30-45 minutes 
before use. 
 
Table 2.9. Preparation of ligation master mix 
Reagent  Volume for 1 reaction Volume for 8 reactions  
Ligation Buffer 23 µl 207 µl 
T4 DNA Ligase  2 µl 18 µl 
Total 25 µl 225 µl 
 
25 µl of the ligation mastermix was added to the 70 ul of sample in the PCR plate and mixed 
by pipetting, followed by a brief centrifuge. 5 µl of Adaptor Oligo Mix was then added to 
each sample and was mixed by pipetting. The plate was sealed, followed by a brief 
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centrifuge. The samples were then incubated on a thermocycler using the following cycling 
parameters: 20°C for 30 minutes, and 4°C hold step. 
Purify the sample using AMPure XP beads 
The samples were then purified to remove all enzymes and substrates from d/A-tailing and 
adaptor ligation using AMPure XP beads. 80 μl of homogeneous AMPure XP beads (kept at 
room temperature for at least 30 minutes prior to use) was added to each DNA sample 
and mixed by pipetting. This was then incubated for 5 minutes at room temperature. The 
96 well plate was then added to a magnetic separation device until the solution was clear 
(approximately 5 to 10 minutes). Whilst still on the magnet the solution was aspirated 
without disturbing the pelleted beads. Keeping the plate on the magnet, 200 μl of freshly-
prepared 70% ethanol was added to each sample well and incubated for 1 minute before 
aspirating the ethanol. Another 200 μl of 70% ethanol was added and incubated for 1 
minute before being aspirated. The PCR plate was then left on the magnet for 5-10 minutes 
to allow any residual ethanol to dry off. The exact time was determined by the first crack 
appearing in any of the pellets. 35 µl of nuclease-free water was added to each sample 
well, the plate was sealed, vortexed, followed by a very brief centrifuge. The PCR plate was 
incubated at room temperature for 2 minutes. The 96 well plate was then added to the 
magnetic stand and left for approximately 5 minutes until the solution was clear. The 
supernatant containing the fragmented adapter ligated DNA was carefully transferred to 
a new 96 well plate ensuring not to disturb the beads.  This was kept on ice until the next 
step. 
Amplify the adaptor-ligated library 
The samples were then amplified using the adaptor sequences ligated to the DNA 
fragments in the previous steps. This was accomplished using one universal primer and 
one indexed primer which is unique to each sample. Indexes shown in Appendix 5. 
A pre-capture master mix was prepared as described in Table 2.10, this was vortexed 





Table 2.10. Preparation of pre-capture PCR master mix 
Reagent Volume for 1 
reaction 
Volume for 8 reactions 
5× Herculase II Reaction Buffer 10 µl 90 µl 
100 mM dNTP Mix 0.5 µl 4.5 µl 
Forward Primer 2 µl 18 µl 
Herculase II Fusion DNA 
Polymerase 
1 µl 9 µl 
Total 13.5 µl 121.5 µl 
 
13.5 µl of the PCR master mix prepared in Table 2.10 was added to each of the purified 
DNA library sample. 2 µl of the appropriate SureSelect XT Low Input Index Primer to was 
then added to each reaction. The plate was sealed, vortexed at high speed for 5 seconds 
followed by a brief centrifuge. The plate was then added to a thermocycler using the 
parameters shown in Table 2.11. The number of PCR cycles used is dependent on the 
starting amount of DNA shown in Table 2.12. 
 
Table 2.11. Pre-Capture PCR Thermocycler parameters 
Segment Number of cycles Temperature Time 
1 1 98°C 2 minutes 
2 11 - 14 
98°C 30 seconds 
60°C 30 seconds 
72°C 1 minute 
3 1 72°C 5 minute 
4 1 4°C Hold 
 
 
Table 2.12. Pre-capture PCR cycle number recommendations 
Quantity of Input FFPET DNA Cycles 
100 to 200 ng* 11 cycles 
50 ng* 12 cycles 
10 ng* 14 cycles 
* qPCR-determined quantity of amplifiable DNA 
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Purify the amplified captured libraries using AMPure XP beads 
Following the pre-capture PCR the plate was briefly centrifuged before a second AMPure 
XP bead clean-up was undertaken. This followed the same protocol as previously described 
on page 47, with the exceptions: 
 50 µl of AMPure XP bead was added to the post-PCR samples in the 96 well plate 
 15 µl nuclease- free water was added to each sample well after the beads were 
dried 
 15 µl of indexed library was transferred to a new 96 well plate 
Assess quality and quantity pre-hybridisation 
To assess the quantity and quality for the resulting indexed DNA libraries, the individual 
samples were analysed on Agilent’s TapeStation 2200 using a DNA D1000 ScreenTape 
using the protocol described in section 2.2.3.4.  The individual sample should demonstrate 




Figure 2.4. Tapestation D1000 electropherogram of pre-hybridisation library. Average peak 





Hybridization and Capture  
The prepared indexed libraries were then hybridized to a target-specific probe set 
designed in section 2.2.4.1. Up to 1000 ng of the DNA libraries were added to a new 96 
well plate in a volume of 12 µl. 5 µl of low input blocker mix was added, the plate sealed 
and vortexed at high speed for 5 seconds, followed by a quick centrifuge. The plate was 
then added to a thermocycler. Run parameters are shown in Table 2.13. The thermocycler 
was paused at the 3rd segment to enable additional reagents to be added. 
 
Table 2.13. Thermocycler program for hybridization with required pause 
Segment Number of cycles Temperature Time 
1 1 95°C 5 minutes 
2 1 65°C 10 minutes 
3 1 65°C 1 minute (pause cycler here) 
4 60 
98°C 1 minute 
 3 seconds 
5 1 65°C Hold 
 
A 25% solution of RNase Block was prepared according to Table 2.14, this was vortexed, 
briefly centrifuged and kept on ice until required. 
 
Table 2.14. Preparation of RNase block solution 
Reagent  Volume for 1 reaction Volume for 8 reactions  
SureSelect RNase Block 0.5 µl 4.5 µl 
Nuclease-free water 1.5 µl 13.5 µl 





A capture library hybridization mix was then prepared according to Table 2.15, vortexed 
at 1600 rpm for 5 second and centrifuged at 1000 g for 2 seconds. 
Table 2.15. Preparation of capture library hybridization mix 
Reagent 
Volume for 1 
reaction 
Volume for 8 
reactions 
25% RNase Block solution 2 µl 18 µl 
Capture Library probe set 2 µl 18 µl 
SureSelect Fast Hybridization Buffer 6 µl 54 µl 
Nuclease-free water 3 µl 27 µl 
Total 13 µl 18 µl 
 
The thermocycler containing the DNA libraries and low input blocker mix was paused at 
segment 3 as described in Table 2.13. 13 µl of the capture library hybridization mix 
prepared in Table 2.15 was added to the samples.  This was mixed by pipetting and re-
sealed. The 96 well plate was removed from the thermocycler and centrifuged at 1000 g 
for 2 seconds before returning it and resuming the programme. 
Prepare streptavidin-coated magnetic beads 
The Dynabeads MyOne Streptavidin T1 magnetic beads were vigorously re-suspended 
using a vortex mixer. 50 µl per sample of the re-suspended beads was added to a new 96 
well plate. 
Wash the streptavidin beads:  
200 µl of SureSelect binding buffer was added to 50 µl of the re-suspended beads, this was 
mixed by pipetting. The 96 well plate was added to a magnetic separator device. After 5 
minutes or when the solution was clear the supernatant was aspirated and discarded. The 
plate was removed from the magnet and the pellet re-suspended in 200 µl of SureSelect 
binding buffer. 
Washing the streptavidin beads was repeated another 2 times, resulting in three total 
washes. After the final wash the streptavidin beads were left re-suspended in 200 µl of 
SureSelect binding buffer. 
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Capture the hybridized DNA using streptavidin-coated beads 
When the thermocycler had completed the hybridization protocol the samples were 
transferred immediately to the 96 well PCR plate containing the washed streptavidin 
beads. These were mixed by pipetting then resealed. The plate was then mixed at 1600 
rpm for 30 minutes at room temperature.  
In a fresh 96 well plate 200 µl of wash buffer 2 was added to 6 wells per sample. The 96 
well plate was sealed and incubated at 70°C on a thermocycler.  
After the DNA libraries and streptavidin beads had finished the 30 minute 1600 rpm room 
temperature incubation, the plate was placed on a magnetic separator. When the solution 
was clear, the supernatant was aspirated and discarded. The plate was then removed from 
the magnet and the pellets re-suspended in wash buffer 1 and mixed by pipetting. The 
plate was then placed on the magnetic separator. When the solution was clear, the 
supernatant was aspirated and discarded. 
Wash buffer 2: 
The 96 well plate was removed from the magnetic separator and the pellets re-suspended 
in wash buffer 2, pre-warmed to 70°C. These were mixed by pipetting, the plate resealed, 
and incubated at 70°C for five minutes. The plate was then placed on a magnetic separator 
for 1 minute, or until the solution was clear. The supernatant was then aspirated and 
discarded. 
The wash buffer 2 washes were repeated 5 more times, resulting in six total washes. After 
the final wash the beads were re-suspended in 25µl of nuclease-free water and mixed by 





Amplify the captured libraries 
A post capture PCR master mix was prepared as described in Table 2.16. 
Table 2.16. Preparation of post-capture PCR reaction mix 
Reagent Volume for 1 reaction Volume for 8 reactions 
Nuclease-free water 12.5 µl 112.5 µl 
5× Herculase II Reaction Buffer 10 µl 90 µl 
Herculase II Fusion DNA Polymerase 1 µl 9 µl 
100 mM dNTP Mix 0.5 µl 4.5 µl 
SureSelect Post-Capture Primer Mix 1 µl 9 µl 
Total 25 µl 225 µl 
 
25 µl of the post capture PCR master mix prepared in Table 2.16 was added to the 25 µl of 
bead-bound target-enriched DNA. This was mixed carefully by pipetting. The 96 well plate 
was placed on a thermocycler using the run parameters shown in Table 2.17. 
 
Table 2.17. Post-capture PCR thermocycler program 
Segment Number of cycles Temperature Time 
1 1 98°C 2 minutes 
2 12 
98°C 30 seconds 
60°C 30 seconds 
72°C 1 minute 
3 1 72°C 5 minute 
4 1 4°C Hold 
 
After the post-capture PCR program was complete the 96 well plate was briefly centrifuged 
and placed on a magnetic separation device for 2 minutes, or until the solution was clear. 




Purify the amplified captured libraries using AMPure XP beads 
A third AMPure XP bead clean-up was undertaken on the post-capture libraries. This 
followed the same protocol as described on page 47 with the following exceptions: 
 50 µl of AMPure XP bead was added to the post-PCR samples in the 96 well plate 
 25 µl nuclease- free water was added to each sample well after the beads were 
dried 
 25 µl of the post-capture libraries was transferred to a new 96 well plate 
Assess DNA quantity and quality post-hybridisation 
To assess the quantity and quality for the resulting post-capture DNA libraries, the 
individual samples were analysed on Agilent’s TapeStation 2200 using a DNA High 
sensitivity D1000 ScreenTape.  The individual sample should demonstrate a peak fragment 
size of approximately 200–400 bp in size on the electropherogram shown in Figure 2.5. 
 
Figure 2.5. Tapestation High Sensitivity D1000 electropherogram of pre-hybridisation library. 
Average peak size is 321 bp. Area under the peak was used to determine the concentration. 
 
2.2.4.3 Illumina Hi-Seq 2500 
Briefly, the DNA libraries are passed through an Illumina 2 lane flow cell. The flow cell has 
millions of DNA oligos adhering to its surface; these are complementary to adaptors 
(P5/P7) shown in Figure 2.3. The libraries are denatured before loading and binding to the 
P5/P7 oligos in a complementary manner. These are then amplified in-situ to generate 
amplicon clusters, via massively parallel bridge amplification. Following cluster generation, 
the dsDNA is denatured leaving only the amplicon strands, which are now extensions to 
the oligos adhered to the flow cell via a phosphodiester bond. These strands are then 
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sequenced by synthesis during the extension of the new complementary strand. In every 
cycle of sequencing (216 in total) complementary terminated florescent nucleotides were 
added, the florescence of each cluster read, and the termination molecule and fluorescent 
cleaved before moving on to the next cycle. Therefore, each cluster generates one 
sequence read, to be analysed by the bioinformatics pipeline. 
2.2.4.4 Pooling of Samples  
The initial loading concentration is critical to the density of library binding to the flow cell. 
The libraries used were quite small respectively (275 kbp), so it was possible to multiplex 
up to 96 samples in one sequencing run. Samples were pooled to give a final molarity of 
4nM. The calculation shown below was performed on each sample used to ensure the 
individual libraries were pooled equally. Molarity of each sample was calculated using the 
Agilent’s TapeStation. 
 
Volume of library (µl)  =  
Volume of final pool (µl) x Concentration of final pool (nM) 
Number of pooled samples x Concentration of library (nM) 
 
The pooled DNA libraries were made up to the final pool volume using Qiagen’s buffer EB 
with 0.1% tween-20 added and stored at 2-8°C overnight or at -20°C for longer periods.  
2.2.4.5 Loading the Hi-Seq 2500 
5 µl of the 4nM pooled DNA libraries was added to a 1.5 ml tube labelled ‘DNA 20’. In a 
second tube 2 µl of PhiX and 3 µl of EB buffer with 0.1% tween-20 was added ‘PhiX 20’. 
PhiX is a pre-manufactured library and is used as an internal control. To each tube 5 µl of 
0.2N NAOH was added, the tubes were then vortexed and centrifuged briefly. The tubes 
were incubated at room temperature for 5 minutes. The next HT1 dilution steps were 
completed in a cold block at 0°C. 990 µl of pre-chilled HT1 buffer was then added to each 
tube, briefly vortexed and centrifuged. 270 µl of HT1 buffer was then added to 2 fresh 1.5 
ml tubes labelled DNA 11 and PhiX 11. 330 µl of ‘DNA 20’ was transferred to the ‘DNA 11’ 
tube and 330 µl of PhiX 20 was transferred to the PhiX 11 tube, briefly vortexed and 
centrifuged. In a final tube 495 µl of ‘DNA 11’ and 5µl ‘PhiX 11’ was added. The final tube 
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was then incubated at 95°C for 2 minutes then stored on ice prior to loading on the Hi-Seq 
2500. At this point the respective molarity based on the dilutions was 11 pM. 
The Hi-Seq was set up according to the manufacturers’ instructions using Illumina’s HiSeq 
Rapid SBS Kit v2 (200 cycles). The following sequencing parameters were used during set 
up for analysis of SureSelect libraries. A two lane flow cell was used with the Hi-Seq in rapid 
run mode.  
 Select Paired End 
 Select Custom 
 Enter 108 cycles for Read 1 
 Enter 8 cycles for Index 1 
 Leave Index 2 as 0 
 Enter 108 cycles for Read 2 
 
2.2.4.6 Low Allelic Fraction controls for NGS 
No commercial low allelic frequency standards are available for NF1. Therefore, to test the 
lower limit of detection in relation to samples with low tumour contents or intra-tumour 
heterogeneity, we created a 3.13% allelic fraction dilution. The dilution was made from 
two FFPE derived tumour gDNA samples that had previously been sequenced using the 
methods described in section 2.2.4. Both samples had a similar QFI (59% and 60%) and DIN 
(6.1 and 6.2) scores demonstrating similar amounts of amplifiable DNA. Multiple 
heterozygote single nucleotide polymorphisms (SNP) were identified in sample 00136 that 
were homozygote wildtype at corresponding coordinates in sample 00107.  To reduce the 
bias introduced by the already heterogeneous sample (00136) only heterozygote SNPs 
with a percentage of reads from 45-55% were considered, all others were excluded from 
analysis.  One of the SNPs was also Sanger sequenced as described in section 2.2.4.7 to 
confirm via a different method. It is important to note it was necessary to go beyond the 
regions dictated by the BED file and panel design described in section 2.2.4.1 to identify 
multiple heterozygote or homozygote in the corresponding samples. Both samples were 
diluted to 4 ng/µl prior to being serial diluted to create the 3.13 % allelic fraction as shown 





Figure 2.6.Illustration of the dilution series used to create the 3.13% allelic fraction control. 
 
2.2.4.7 Sanger sequencing  
To confirm one of the NF1 heterozygote and homozygote SNPs, in samples to be used in 
the NGS low allelic fraction dilutions, Sanger Sequencing was used as an alternate method 
of confirmation.  Primers were designed flanking the SNP rs55747230 shown in Table 2.18. 
M13-tails were also added to the primer sequences so the sequencing could fit into a SCH 
diagnostic workflow. The regions of interest were amplified using a PCR master mix 
prepared according to Table 2.19. PCR cycling conditions: 94°C x 1 min, (94°C x 30 sec, 57°C 
x 1 min, 68°C x 1 min) x 33 cycles, 15°C hold. 
 
Table 2.18. Primers flanking rs55747230 in NF1  
  Sequence (5'->3') 
rs55747230 
Forward primer  CACGACGTTGTAAAACGACTGGAATTGTGCAGAGTGTGG 
Reverse primer  CAGGAAACAGCTATGACCACATTGGACATACAGTTGAGAGA 






Table 2.19. PCR reagent volumes 
Reagent 
Volume for 1 reaction 
(µl) 
OneTaq  10 
Primer F 10 µM 0.5 
Primer R 10 µM 0.5 
Molecular H20 4 
Genomic DNA (7ng/ µl) 5 
Total 20 
 
Following the amplification, amplicons and no template controls (NTC) were analysed on 
the TapeStation using a D1000 tape to determine product size, non-specific product, and 
contamination issues. The amplicon products were then diluted in 50 µl H2O. 2 µl of a 1 in 
5 dilution of ExoProStar 1-Step was added to 5 µl of the diluted amplicon. This was 
incubated at 37°C x 15 mins then at 80°C x 15 mins. Following this forward and reverse 
BigDye master mixes were prepared according to Table 2.20 using M13 forward and 
reverse primers. These forward and reverse reactions were then run on a thermocycler 
using the following parameters 95°C x 1 min, (95°C x 15 sec, 55°C x 10 sec, 60°C x 1 min) x 
25 cycles, 15°C hold. 
 
Table 2.20. BigDye reagent volumes 
Reagent Volume for 1 
forward reaction (µl) 
Volume for 1 
reverse reaction (µl) 
BigDye Ready React v1.1 Terminator Mix 1 1 
Better Buffer 7 7 
H2O 3.8 3.8 
Sequencing primer @ 1pmol/μl 3.2 3.2 
Exostarred and diluted PCR product 5 5 





The forward and reverse amplicons were cleaned-up using Agencourt CleanSEQ in a 96 
well plate. 10 µl of Agencourt CleanSEQ was added to each reaction, then 62 µl of 85% 
ethanol before been vortexed at 1200 rpm for 30 seconds. The 96 well plate was then 
added to a magnetic separation device. When the solution was clear (approximately 3 
minutes), whilst still on the magnet, the solution was aspirated without disturbing the 
pelleted beads. Keeping the plate on the magnet, 100 μl of freshly-prepared 85% ethanol 
was added to each sample well and incubated for 30 seconds before aspirating the 
ethanol. The 96 well plate was left on the magnet for approximately 10 minutes to allow 
any residual ethanol to dry off. The 96 well plate was removed from the magnet and 40 µl 
of nuclease-free water was added to each sample well to elute the sequencing product 
from the beads. The plate was placed back on the magnet prior to the supernatant 
containing sequencing product being transferred to a new 96 well plate. This was then 






Figure 2.7. rs55747230 sequence trace. A) Reverse trace of sample 00136 the heterozygote 
spike showing a G and A base. B) Reverse trace of sample 00107 shown to be homozygote G. 






2.2.5.1 Generation of aligned BAM files 
The primary sequencing output generated by the HiSeq 2500 is a base call file (BCL) format. 
This file contains reads from each of the clusters and quality scores. The HiSeq 2500 
automatically de-multiplexes the samples based on the individual indexes. The BCL files 
were converted into a FASTQ format using bcltofastq conversion software v1.8.4. 
Following this the reads were aligned to GRCh37/hg19 using Burrows-Wheeler Alignment 
tool (BWA) v0.7.15. Once aligned the SAM files produced by BWA were converted to a 
BAM format using samtools v1.4. The files could then be visualised using software such as 
the integrated genomic viewer or Alamut. The Genome analysis tool kit software Picard 
was used to remove optical duplicates from analysis. Samtools was used to generate QC 
metrics relating to the sequencing quality. The BAM files then underwent a local 
realignment and a base quality score recalibration resulting in the Phred score for each 
individual base sequenced. 
2.2.5.2 Somatic variant detection  
VarScan2 v2.4.0 was used to screen the aligned BAM files for potential variants including 
nucleotide substitutions, insertions and deletions (indels). VarScan2 is a somatic variant 
calling software which uses a heuristic/statistic approach to call variants. This is 
accomplished by defining requirements that need to be met in order for VarScan2 to 
identify any suspected variant including; desired thresholds for read depth, base quality, 
variant allele frequency, and statistical significance. VarScan2 outputs a human readable 
variant call format (VCF) file.  
Default VarScan2 parameters: 
 Minimum supporting reads at a position to call variants [2] 
 Minimum base quality at a position to count a read [15] 
 Minimum variant allele frequency threshold [0.01] 
VarScan2 uses a tumour sample and a matched normal sample to determine somatic 
variants. However, to initially screen the tumour samples we used the commercially 
available genome in a bottle (GIAB) (NA12878) as the normal matched sample. GIAB is a 
highly characterised genome in which variants have been determined, in parallel, using 
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five sequencing platforms, seven different aligners and variants determined using three 
different variant callers. GIAB is used as a validation control for platforms and software. 
Using this as the normal matched control reduced the need to sequence normal matched 
samples when variants were not detected. Samples with variants detected then had their 
matched paired sample sequenced to determine if the variant was somatic or germline in 
origin.  
 
2.2.5.3 Variant Calling and Annotation 
VCF files produced by VarScan2 includes annotation on the variants identified from 
sequencing. The software program VCFminer was used to filter the files. Criteria for variant 
exclusion included: 
 All GIAB only variants 
 Variants outside NF1 exons ±25 bp and -800 bp of promoter sequence, EGFR exons 
19-21, BRAF exon 11, and KRAS exons 2 – 3 
 Variants with a population frequency >1% based on the Genome Aggregation 
Database (gnomAD r2.0.2) 
 Variants with a sample AF <3% 
 Variants with <15 supporting reads 
 Variants that correspond to NF1 pseudogenes were flagged and removed if no 
other variant were identified within the specific read 
The remaining variants were cross-referenced with the NCBI’s Single Nucleotide 
Polymorphism database (dbSNP) and ClinVar. Variants including indels and nucleotide 
substitutions were then analysed for possible pathogenicity and loss of function using 
combination of online resources and in-silico tools. 
Interactive Biosoftware’s Alamut Visual v2.9 was used to interpret sequence variants 
including missense (synonymous and non-synonymous), nonsense, and indels. This 
enabled annotation and predictions on frameshifts and downstream premature stop 
codons. Alamut Visual also has five fully integrated in-silico splicing prediction algorithms. 
These algorithms are: SpliceSiteFinder-like (Zhang, 1998), MaxEntScan, (Yeo and Burge, 
2004), NNSPLICE (Reese et al., 1997), GeneSplice, (Pertea et al., 2001), and HSF (Desmet 
et al., 2009). 
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Non-synonymous missense variants were also subjected to further in-silico analysis using 
a number of algorithms. SNPs&GO is a machine-learning algorithm which predicts the 
effect of amino acid changes on protein function (Calabrese et al., 2009). SNPs&GO also 
uses and outputs from 2 other algorithms; Predictor of human Deleterious Single 
Nucleotide Polymorphism (PhD-SNP) (Capriotti et al., 2006) and Protein Analysis Through 
Evolutionary Relationships (PANTHER) (Thomas et al., 2003). PANTHER classifies proteins 
according to family and subfamily, molecular function, and biological process by aligning 
the sequence in question to protein families and subfamilies in its own library. All three 
programmes output a substitution classification; disease or neutral based on a probability 
score (neutral≤ 0.5) and a reliability score of 1-10 to inform confidence level. 
Pmut is another pathogenic mutation predictor which uses neural networks and sequence 
based information to predict either pathological or neutral effect on protein function 
(Ferrer-Costa et al., 2004). Sequence based information includes; assessing structural 
information, residue sequence, and evolutionary properties. The programmes output is a 
substitution classification; disease or neutral based on a pathogenicity index ranging 0-1 
(neutral ≤ 0.5) and a reliability prediction (%). 
PROtein Variation Effect Analyser (PROVEAN) is another mutation predictor, which clusters 
multi-sequence alignment and calculates a score across clusters. If the score is >-2.5 the 
variant is considered deleterious whereas <-2.5 is considered neutral in its effect on 
possible pathogenicity (Choi et al., 2012). 
Finally Poly-phen-2 is a supervised learning programme which uses evolutionary 
conservation to access the impact of the variants on the function of the region (Adzhubei 
et al., 2010). The output is a score 0–1 with 1 being probably damaging, the programme 
also calculates sensitivity and specificity. For our dataset we used the HumVar output, this 
is trained on the differences between human disease-causing mutations and common 




2.2.6 Mutual Exclusivity 
To determine if the variants observed between NF1 and BRAF, KRAS, or EGFR had any 
tendency towards mutual exclusivity or co-occurrence we calculated the odds ratio using 
the calculation below as described by (Gao et al., 2013). 
 
Odds ratio  = 
(A x D) 
(B x C) 
 
Where A = the number of samples where both genes have variants, B = the number of 
samples with variants in gene 1, C = the number of samples with variants in gene 2, D = 
the number of samples with no variants in both genes. Possible outcomes shown in Table 
2.21.  
 
Table 2.21. Mutual exclusivity based on odds ratio 
Odds Ratio Outcome 
0.0 < Odds ratio < 0.1 Strong tendency toward mutual exclusivity  
0.1 < Odds ratio < 0.5 Tendency toward mutual exclusivity 
0.5 < Odds ratio < 2.0 No association 
2.0 < Odds ratio < 10 Tendency towards co-occurrence 
Odds ratio > 10 Strong tendency towards co-occurrence 
 
 
2.2.7 NF1 Pseudogenes 
Luijten at al. (2000) and Luijten at al. (2001) reported 7 possible NF1 pseudogenes in their 
studies. More recent searches on databases including; NCBI and Ensembl now report 12 
NF1 pseudogenes. FASTA sequences for all exonic regions of the functional NF1 gene and 
NF1 pseudogenes ±100 bp of intronic sequence and full intron exon transcripts were 
downloaded from Ensembl using genome build GRCh38/hg38. 
NCBI’s alignment tool BLAST was used to calculate homology of pseudogenes compared 
to the functional NF1 gene. To identify differences in coding regions a local alignment of 
all exonic regions ±100 bp for all 12 known pseudogenes was performed against the 
functional NF1 gene. This was done utilising European Bioinformatics Institute’s 




2.2.8 Copy Number Analysis 
2.2.8.1 ddPCR for copy number Analysis 
To investigate copy number variation (CNV) of the NF1 locus within the tumour samples 
we employed droplet digital PCR (ddPCR). Briefly, ddPCR partitions a single PCR reaction 
into 20,000 droplets, in theory; each droplet contains one copy of the target region or 
endogenous reference and functions as an individual PCR reaction. Samples can be 
multiplexed containing two individual targets using fluorescent probes. Ribonuclease 
P/MRP Subunit P30 (RPP30) was used as the endogenous reference alongside the target 
of interest NF1. Post PCR each droplet is read individually for florescence and scored either 
positive for florescence or negative. This yields four possible outcomes when multiplexing 
2 targets Figure 2.8. 
 
 
Figure 2.8. 2D plot of droplet florescence amplitude. Black represents negative droplets with 
no florescence. Blue NF1 positive droplets. Green RPP30 positive droplets. Orange both NF1 and 




Between 0.2 and 136 ng of FFPET derived gDNA was added to each reaction, which was 
analysed in 2 X technical replicates. Bio-Rad NF1 copy number variation probes were used 
to target NF1 labelled with a FAM fluorophore (dHsaCP2507122) and RPP30 labelled with 




Table 2.22. ddPCR reagent volumes 
Reagent Volume for 1 reaction 
(µl) 
Volume for 8 reactions plus 
dead volume (µl) 
ddPCR Supermix (no dUTP) (2X) 10 88 
NF1 probe and primers (20X) 1 8.8 
RPP30 probe and primers (20X) 1 8.8 
Molecular H20 7 61.6 
Total 19 167 
 
20.9 µl of mastermix was added to each well used on a 96 well plate. 1.1 µl of gDNA was 
added, the plate was vortexed at 1600 rpm for 1 minute followed by a brief centrifugation 
at 500 g for 2 seconds. 20 µl was then transferred to a Bio-Rad DG8 cartridge, 70 µl of 
droplet generation oil was also added to the DG8 cartridge.  A gasket was attached to the 
cartridge before loading it into the QX20 droplet generator. Once complete 40 µl of 
emulsified sample was transferred to a fresh PCR plate which was sealed with a foil heat 
seal and run on a thermocycler using the following parameters, 95°C x 10 mins, (94°C x 30 
sec, 55°C x 1 min) x 40 cycles, 98°C x 10 min, 4°C x hold. 
After thermocycling the sealed 96 well plate was placed in the QX200 Droplet Reader. 
QuantaSoft Software was set up for copy number variation, ddPCR Supermix for Probes 
(No dUTP) was used as the supermix type, Ch1 and Ch2 were labelled with the relevant 
fluorophores (FAM or HEX) and the target names. The QX200 Droplet Reader was then run 
to analyse the wells. Once data acquisition was complete the data was analysed using 
QuantaSoft 1.7.4. Thresholds were set using the 2D amplitude plot shown in Figure 2.8. 
 
2.2.8.2 ddPCR NF1 3 copy number control  
Commercial standards to use for validation purposes are not available for NF1 CNV. Briefly, 
to manufacture a DNA control we amplified the region where the ddPCR primers target, 
calculated the copy number, and spiked the amplicon into genomic DNA known to be 
diploid for the NF1 locus to create a 3 copy number control. 
Bio-Rad would not disclose their primer sequence for the NF1 copy number assay, but did 
provide a context sequence containing the ddPCR target region. To create the amplicon 
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spike, primers were designed to encompass as much of this sequence as possible shown 
in Table 2.23.  A PCR master mix was prepared according to Table 2.24 . PCR cycling 
conditions: 94°C x 1 min, (94°C x 30 sec, 53°C x 1 min, 68°C x 1 min) x 33 cycles. 
 





B  Sequence (5'->3') 
 Forward primer  ACCAGTTCACCTTAACCATTGC 
 Reverse primer  CCAGCGGGTCCGGATATGAA 
A) Bio-Rad context sequence which encompasses their assay target region resulting in a 70 bp 




Table 2.24. PCR reagent volumes 
Reagent Volume for 1 reaction 
(µl) 
OneTaq  12.5 
Primer F 10 µM 0.5 
Primer R 10 µM 0.5 
Molecular H20 6.5 
Genomic DNA  5 
Total 25 
 
AMPure XP bead clean-up was undertaken on the amplicon. This followed the same 
protocol described on page 47 with the exceptions: 
 50µl of AMPure XP bead was added to the post-PCR sample  
 40 µl nuclease- free water to each sample well after the beads were dried 
The resulting amplicon was analysed on Agilent’s TapeStation 2200 using DNA D1000 
ScreenTape. One clear band was observed at 104 bp in size, no signs of non-specific binding 
and no primer dimers were observed. The amplicon copy number was calculated using the 
concentration and size of the amplicon and the formula below. The same calculation was 
used to determine the copies in the genomic DNA been used as the 2 copy diluent. 
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Number of copies = (Amount (ng) x 6.022x1023) / (length (bp) x 109 x 650) 
8690 copies were calculated to be present in 30 ng 2 copy diluent. A serial dilution of the 
amplicon was used to create a 4345 amplicon standard which was spiked into the 2 copy 
number diluent. This was used as the 3 NF1 copy number standard. A set of standards 
representative of a 3, 2.8, 2.6, 2.4, 2.2 copy numbers were created to represent a 3 copy 
number change in an 80, 60, 40, and 20 % tumour content sample. 
 
2.2.9 NanoString Gene Expression Analysis 
To investigate the gene expression signatures related to the MAPK pathway we decided to 
utilise the Nanostring nCounter platform. This platform was chosen because it has been 
shown to be tolerant of RNA analysis from degraded FFPET (Veldman-Jones et al., 2015). 
Furthermore, it has been validated using both cell lines and clinical tissue for the gene 
expression signatures we were interested in (Brant et al., 2017, Ahn et al., 2017). 
Briefly, it uses in solution hybridisation to bind mRNA targets using a reporter probe and a 
capture probe. The capture probe was used to pull down target regions, whilst the reporter 
probe contained a target specific florescent barcode. The unbound RNA was then washed 
off and the barcodes read using the Nanostring digital analyser. 
2.2.9.1 NanoString CodeSets 
The NanoString CodeSet contains previously reported MEK and RAS gene expression 
signatures (Brant et al., 2017, Dry et al., 2010a, Loboda et al., 2010a). The MEK signature 
proposed by Dry and colleagues consists of 18 up-regulated genes in relation to MEK 
activation (Dry et al., 2010a). The RAS signature consists of 147 genes in total, 105 of which 
are up regulated and 47 down regulated in relation to RAS activation (Loboda et al., 2010a). 
Both signature CodeSets are shown in appendix 6. 
In addition to this, three NF1 probes were designed. These probes were not only used to 
measure NF1 expression but could also differentiate between the two most common NF1 


















Exon numbers related to the longest encoding NF1 transcript 2 (NM_001042492.2). Reporter 
probe (R), Capture Probe (C) 
 
2.2.9.2 Nanostring mRNA Hybridisation Preparation 
Tumour tissue was enriched via macro-dissection based on pathologist assessment and 
mark up. Approximately 50-100 mm2 of tumour tissue was used for each RNA extraction 
taken from 1-8 10µM slides. RNA extraction described in section 2.2.2.5. The RNA was then 
quantified using the Qubit RNA high sensitivity kit and diluted to 20 ng/µl where possible 
using nuclease free water. 
The following was made for each 12 reactions. The reporter CodeSet and capture ProbeSet 
reagents were thawed at room temperature; these were both inverted 5 times to mix once 
thawed, followed by a brief centrifugation at 500 g for 2 seconds. A mastermix was created 
by adding 70 µl of hybridization buffer to the tube containing the reporter ProbeSet. This 
was inverted 5 times to mix, followed by a brief centrifugation at 500 g for 2 seconds.  8 µl 
of the described mastermix was added to strip tubes. 5 µl of 20 ng/µl of RNA was then 
added to each of the tubes followed by 2 µl of the capture ProbeSet. The tubes were 
capped and flicked to mix, and centrifuged for 2 seconds in a microfuge. These were then 
incubated at 65°C for 21 hours.  
Post hybridisation the strip tubes were loaded into the NanoString nCounter prep station. 
The prep station was then set up using the manufacturers’ on screen instructions adding 
the following: nCounter cartridge, nCounter prep plates, racked tips and foil piercers. The 
prep station then washed the hybridised RNA and loaded it to the cartridge. Once 
complete the cartridge was sealed and transferred to the NanoString nCounter digital 
analyser. The CodeSet RLF file was uploaded to the digital analyser, this contains the 
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barcodes and related gene names. The cartridge was read within an hour of the prep 
station finishing at the highest optical setting: 550 fields of view. Once complete the gene 
count is downloaded as a RCC file for analysis using nSolver v4.0.  
2.2.9.3 nCounterData analysis and Gene Expression Calculations  
All Nanostring nCounter data were normalised using nSolver Analysis Software version 4.0. 
In the first instance batch data was QC checked using nSlover.  
 Imaging QC: Flag lanes when field of view registration is less than 90%  
 Binding Density QC:  Flag lanes when binding density is outside the range 0.1 – 2.25 
 Positive Control Linearity QC: Flag lanes when positive control R2 value is less than 
0.95 
 Positive Control Limit of Detection QC: Flag lanes when 0.5fM positive control is 
less than or equal to 2 standard deviations above the means of the negative 
controls 
 Manual visualisation of the RAW count data to confirm all RNA controls have 




Raw Nanostring data were then normalised in a three step process. 
1. The background thresholding was adjusted using the mean of the internal negative 
controls plus 2 standard deviations 
2. The geometric mean of the internal positive controls was used for technical 
normalisation 
3. Finally the geometric mean of the 21 housekeeping genes was used to normalise 
for initial differences in input of starting material 
The RAS signature score was calculated as described by Loboda at al., (2010). The gene 
counts were expressed as the Log10 ratio. The mean of the 47 gene down-regulated arm 
were then subtracted for the mean of the 105 gene up-regulated arm resulting in the final 
score per sample. 
The MEK signature score was calculated as described by Dry at al., (2010). The gene 
expression counts were expressed as the Log2 ratio. The mean for the 18 genes was then 
calculated. The optimised NSCLC MEK signature score as described by Brant at al., (2017) 
was calculated as the 18 gene signature but only using 6 genes. 
2.2.9.4 Housekeeping genes  
Housekeeping genes were determined suitable or unsuitable using AstraZeneca’s in 
house algorithm. The algorithm analysed the housekeeping genes in two ways 
 Correlations  
o The correlation matrix between each gene was calculated and then, for 
each gene, the average correlation for each gene was calculated. The 
average correlations and overall average correlation was calculated and 
any gene which has an average correlation which is less than overall 
average -2SD is considered potentially unsuitable. 
 
 Standard deviation of average differences  
o The average difference and standard deviation of that average difference 
between each gene pair was calculated over all samples, and then for 
each gene the average standard deviation was calculated. From the gene 
average standard deviations, an overall average standard deviation was 
calculated and any gene which has an average standard deviation which is 





2.2.10 The Cancer Genome atlas Pan-Lung data set 
To make up for shot falls in our cohort we utilised The Cancer Genome atlas (TGCA) using 
the Pan-Lung data set. This data set was generated in Campbell et al. (2016) publication 
and includes 660ADC and 484 SQCC cases. This was accessed via the University of California 
Santa Cruz’s xenabrowser.net. Gene expression RNAseq was downloaded as gene-level 
transcription estimates, as in log2(x+1) transformed RSEM normalized count. The CMAP 
PI3K/AKT/mTOR 190 gene expression signature heatmap was generated using Broad 
Institutes Morpheus software. Hierarchical clustering was performed via a Euclidean 
distance metric, using an average linking method and grouped by genotype. Genes used in 
the CMAP gene expression signature are shown in Appendix 7. 
2.2.11 Statistical Analysis and Visualisation 
All statistical analysis was performed using SSPS v.22. Unless otherwise stated all 
assumptions for statistical test used were not violated. GraphPad Prism was used for visual 
representation. Cbioportal.org was used to generate gene specific oncoprints and lollipop 
plots (Gao et al., 2013, Cerami et al., 2012). NanoString nSolver 4.0 was used for gene 





Optimisation and Validation of Next 






Next Generation Sequencing 
NGS has become an immensely powerful tool for analysis of genetic sequence; and is 
becoming the gold standard in genomic research and diagnostic laboratories. NGS 
targeted chemistry and workflows are commonly used for detection of germline and 
somatic mutations including; single nucleotide variations (SNV) and indels. Illumina offers 
high throughput sequencing using aftermarket commercial custom designed panels. 
To generate reproducible next generation sequencing data, pre-analytical requirements 
include high molecular weight DNA (Arreaza et al., 2016). This is generally obtained from 
fresh frozen tissue, cell cultures, or from leukocytes. However, diagnosis of lung cancer 
requires both imaging data and histological review. The histological review is based on 
analysis of FFPET, as it helps retain the tissues morphological features for the pathologist 
to examine. Unfortunately, as fresh frozen tissue (the optimal source material for 
downstream genetic analysis) is rarely available, this makes FFPET the primary source for 
detection of genetic mutations in solid tumours. FFPET is not ideal for the storage of 
nucleic acids as extracted DNA is fragmented, of low quality, and is often low in yield. This 
is the result of the pre fixation time, in which the tissue becomes anoxic, as well as the 
actual fixation process itself (Srinivasan et al., 2002). Other types of DNA damage induced 
in this process include: DNA nicks, gaps, protein-DNA crosslinks, C > T / G > A nucleotide 
transitions, and oxidised bases (Sikorsky et al., 2007). 
DNA Extraction 
Sikorsky and colleagues have shown DNA fragmentation, nicks, gaps, DNA – protein 
crosslinks and oxidised bases can all inhibit PCR, a key step of NGS library preparation. It is 
therefore important to get the maximum DNA yield from the samples and determine if 
different extraction methods are detrimental to DNA quality. The quantity and quality of 
the DNA within our patient samples is an unknown variable so in order to maximise 
sequencing data quantity and quality from the FFPET samples we initially investigated the 
pre-analytical step of DNA extraction. This investigation included comparing extraction 
methods and various DNA quantification tools to ensure we obtained as much information 
as possible from the patient samples. 
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To address the quality of the DNA extracted, we employed a recent update to the Agilent 
2200 software (version 2.1.38.8716). This update gives the ability to calculate the DIN 
score. The DIN score is based on the level of fragmentation which is seen as a smear on 
the gel. As score of 1 indicates highly degraded DNA and 10 represents high molecular 
weight DNA. There is little information in the literature on DIN scores and NGS, but more 
recent NGS protocols such as Agilent’s XT HS kit utilise the score and concentration to 
determine changes in the library preparation protocol at key steps. It is therefore logical 
to compare this score across the extractions to determine any effect on DNA quality. 
NGS Low Allelic Fraction 
Biopsies and surgical specimens of tumours are rarely 100% tumour, but even if they are 
then intra-tumour heterogeneity must be considered. We aim to validate our NGS 
sequencing protocol to be able to identify somatic variants in samples with as little as 6% 
tumour content.  
Droplet Digital PCR 
ddPCR is an emerging method of measuring copy number changes in clinical samples.  It 
has been shown to tolerate degraded FFPET samples and has demonstrated high 
correlation to more established methods; such as florescence in-situ hybridisation (FISH), 
immunohistochemistry (IHC), and SNP arrays (Heredia et al., 2013, Zhang et al., 2016a). 
ddPCR also removes the subjective judgment that pathologists make with FISH and IHC 
and is far more cost effective and adaptable than SNP arrays. As with NGS, we investigated 





NGS library preparation relies on fragmentation of the genome, and hybridisation 
enrichment is based on homology. Both of these steps could lead to NF1P being enriched 
and mapped back to NF1 during alignment to the reference genome, which could result in 
false positive variants. NGS data analysis alignment does provide some level of security 
through mapping quality metrics of independent reads. Cunha and colleagues navigated 
this problem by only using reads with a Q score of >20 (Cunha et al., 2016). Different 
approaches used include; discarding all reads from analysis that map back to two genomic 
positions (Pasmant et al., 2015). However, this could result in true positive variants been 
lost. To address this, we mapped back all NF1P to the functional gene to calculate 
homology and determine variants/differences. These differences will be exploited to flag 






3.2 Comparison of DNA extractions from FFPET 
To address the optimal method for gDNA extraction from FFPE tissue, three extraction 
methods were compared; Qiagen’s EZ1 automated method (EZ1), Qiagen’s QIAamp FFPE 
tissue extraction kit (QIAamp FFPE), and Covaris’s truXTRAC FFPE DNA kit (truXTRAC). 
Anonymised lung FFPE tissue was provided by the SCH histology department for validation 
purposes. Excess paraffin was removed prior to extraction leaving a surface area of 100 
mm2, of which 48 mm2 was tissue. 10 µM scrolls were sectioned and 6 scrolls used in each 
replicate. Each experiment was run with three replicates per extraction method. Three 
methods of quantification were used; NanoDrop, Qubit, and TapeStation. The fragment 
size of the genomic DNA was calculated using the TapeStation. The experiment was 
repeated on three separate occasions to assess inter-extraction variability. 
All A 260 / A 280 ratios were >1.8 for all three extraction methods as determined by the 
NanoDrop, suggesting protein contamination is not an issue with any of the 
methodologies.  
3.2.1 Variability of DNA quantification methods 
Variable measurement of concentration of the same DNA sample across multiple 
platforms is a common problem and could provide downstream analytical challenges  
(Mathot et al., 2013). To investigate this, three methods of quantifying DNA were tested 
across the three different extraction methods used. All three extraction methods use the 
same elution volume.  
The concentration of extracted DNA via the three different extraction methods was 
measured by the Qubit, TapeStation, and NanoDrop. All were normally distributed as 
assessed by Shapiro-Wilk's test (p > 0.05). A Levene’s test showed that homogeneity of 
variances was not assumed for the QIAamp FFPE and truXTRAC extractions (p < 0.05), but 
was assumed for the EZ1 method (p = 0.304). A Welch ANOVA demonstrated a difference 
between methods of DNA quantification (p < 0.001). A post hoc Games-Howell test 
determined a significant difference between the NanoDrop vs. Qubit (p < 0.001) and 
NanoDrop vs. TapeStation (p < 0.001). No significant difference was observed between the 
Qubit vs. TapeStation (p > 0.775) (Table 3.1). To confirm the results from the EZ1 method, 
in which homogeneity of variances was assumed an ANOVA followed by Tukey post hoc 
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analysis, was also performed in parallel. This resulted in identical grouping, data not 
shown. 
 
Table 3.1. Games-Howell Post-hoc analysis showing the variance between 
DNA quantification methods using three different extraction methods. 
QIAamp FFPE  Sig 
 Qubit vs. TapeStation p = 0.888 
 Qubit vs. NanoDrop p < 0.001 
 TapeStation vs. NanoDrop p < 0.001 
truXTRAC   
 Qubit vs. TapeStation p = 0.838 
 Qubit vs. NanoDrop p < 0.001 
 TapeStation vs. NanoDrop p < 0.001 
EZ1   
 Qubit vs. TapeStation p = 0.775 
 Qubit vs. NanoDrop p < 0.001 






The NanoDrop estimated an increase of >2.5 fold when compared to the TapeStation and 
Qubit from all extraction methods shown in Figure 3.1. As the Qubit and TapeStation 
quantification method showed no statistical differences, we proceeded with Qubit 
quantification which was the most reproducible. 
 
 
Figure 3.1. Analysis of Variance of DNA Quantification Methods. 9 biological replicates 
analysed from the QIAamp FFPE extraction method. SD (small whiskers), mean (large whisker) 
shown on the graph. Statistically significant differences between quantification methods 
determined by Welch ANOVA (P < 0.001). Significance between individual extractions 
determined by Games-Howell post-hoc test. The Qubit and TapeStation demonstrated similar 
means, Qubit (30.4 ng/µL) and TapeStation (31.3 ng/µL) with the NanoDrop displaying a >2.5 






3.2.2 Variability of DNA yield across three extraction methods 
To determine the extraction method which delivers the greatest DNA yield in a 
reproducible manner, the Qubit concentrations across the three extraction methods were 
compared. This was done using three intra-batch replicates repeated on three 
independent occasions to assess intra/inter-batch reproducibility. 
The concentrations from the QIAamp FFPE, truXTRAC, and EZ1 were normally distributed 
as assessed by a Shapiro-Wilk's test (p > 0 .05). A Levene’s test showed that homogeneity 
of variances was not assumed for any of the three methods (p < 0.05). A Welch ANOVA 
demonstrated a statistically significant difference in DNA yield between extractions (p < 
0.001). A post hoc Games-Howell test determined a significant difference (p < 0.001) in 
DNA yield between the QIAamp FFPE vs. EZ1 and truXTRAC vs. EZ1. No statistical difference 
was observed between the QIAamp FFPE vs. truXTRAC (p > 0.556). However, the QIAamp 
FFPE extractions demonstrated greater reproducibility (coefficient of variation (CV) = 
9.97), compared to truXTRAC (CV = 24.63) (Figure 3.2). 
 
Figure 3.2 Analysis of Variance of Concentration Yield Between Extraction Methods. Qubit 
measurement of DNA extracted via three different methods. 3 intra batch biological replicates 
were analysed on three separate occasions giving 9 replicates in total. Significant difference 
between groups as determined by Welch ANOVA (P < 0.001). Difference between individual 
extractions determined by Games-Howell post-hoc test shown on the above graph. The 
truXTRAC (34.41 ng/µL), and QIAamp FFPE (30.37 ng/µL) demonstrating a >3 fold increase in 
yield when compared to the EZ1 (10.04 ng/µL). 
81 
 
3.2.3 DNA Quality 
Agilent’s DNA Integrity Score 
The DIN score for the 9 biological replicates for each of the three extraction methods were 
normally distributed as assessed by a Shapiro-Wilk's test (p > 0.05). A Levene’s test showed 
that homogeneity of variances was assumed for the QIAamp FFPE, truXTRAC, and EZ1 
methods (p > 0.05). A one-way ANOVA demonstrated no statistical difference between 
extraction methods and the DIN score (p = 0.373) with all extractions having a rounded 
mean of 2.3. As expected Agilent software failed to calculate a DIN score for the negative 
control and fresh leukocyte extracted DNA had a high score of 9.3.  This indicates the 
anonymised FFPET sample used is highly degraded. While all three extractions had similar 
means the QIAamp FFPE had the lowest (Standard deviation (SD) = 0.06) compared to 
truXTRAC (SD = 0.10) and EZ1 (SD = 0.09). The Pseudo-gel image for 3 replicates for each 
extraction method is shown in Figure 3.3. 
 
Figure 3.3. Agilent’s TapeStation genomic tape pseudo-gel image. QIAamp FFPE lanes A1-C1. 
EZ1 lanes D1-F1. truXTRAC lanes G1-H2. 48.5 kilobase ladder C2(L). Blank lane D2. Anonymised 
Leukocyte extracted DNA lane H4 demonstrating high molecular weight DNA. Yellow warning 
(E1, F1, H4) sample concentration outside recommended range for quantification. Red warning 
(D2) sample outside functional range for DIN. 
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3.3 NF1 Pseudogenes 
NCBI’s BLAST was used to compare the whole pseudogene sequence (exon and introns) 
back to its pseudogene genomic location to confirm the sequence downloaded from 
Ensembl an alternate source. All pseudogene FASTA sequences from Ensembl matched 
NCBI sequences 100% with E values of 0.0. The whole NF1P sequences were then aligned 
with the functional NF1 gene. This demonstrated that all NF1P intronic and exonic regions 
have ≥90% homology with the functional NF1 gene. Homology and pseudogene size shown 
in Table 3.2. 












NF1P1 ENST00000604105.1 15 18973 97 90 
NF1P2 ENST00000556855.1 15 18985 97 91 
NF1P3 ENST00000457709.1 21 4353 79 91 
NF1P4 ENST00000549579.2 14 9460 98 91 
NF1P5 ENST00000588287.1 18 4342 79 91 
NF1P6 ENST00000426025.1 22 9451 98 91 
NF1P7 ENST00000612076.1 14 9732 96 92 
NF1P8 ENST00000415351.1 2 7660 97 91 
NF1P9 ENST00000629326.1 15 19041 97 91 
NF1P10 ENST00000613227.1 14 3166 99 91 
NF1P11 ENST00000621292.1 14 7300 98 91 
NF1P12 ENST00000549593.1 12 962 100 93 
 
In order to compare the exons of NF1Ps to NF1 to identify specific variants/differences we 
aligned all NF1P exons ±100 bp to the corresponding functional NF1 exons. 2818 
differences across the 12 pseudogenes including SNV and indels were identified. These 
variants were then cross-referenced with NCBI’s dbSNP. Surprisingly, over 11% of the 
variants from our alignments were reported as functional NF1 SNPS in dbSNPs. Homology 




 Table 3.3. NF1 Exonic pseudogene homology  




NF1P1 5908 17 18-29, 32-36 91 
NF1P2 5568 16 18-29, 32, 34-36 91 
NF1P3 1250 4 9-11, 15 94 
NF1P4 3881 11 13, 16-24, 36 93 
NF1P5 1248 4 9-11, 15 94 
NF1P6 3849 11 13, 16-24, 36 92 
NF1P7 3730 11 13, 16-24, 36 93 
NF1P8 3261 9 16-24 92 
NF1P9 5523 16 18-29, 33-36 91 
NF1P10 1742 5 21-24, 36 92 
NF1P11 2882 8 17-18, 20-24, 36 92 
NF1P12 983 2 12-22 93 




3.4 NGS Low Allelic Fractions 
To test the limits of the NGS protocol and its abilities to detect low level variants we used 
a 3% allelic fraction standard (6% tumour content) as described in section 2.2.4.6. The 3% 
mixed standard was sequenced and analysed using the method described in section 2.2.4-
2.2.5 using GIAB as the normal matched tissue. Varscan2 was run with default parameters. 
All variants identified in the sample 00107 (homozygote diluent) and 00136 (heterozygote 
spike) that did not meet initial criteria described in 2.2.5.3 were excluded from analysis. 
Remaining variants included the 3% 00136 and false positives. False positives are described 
here as variants not observed in any of the original samples used to create the 3% allelic 
fraction (AF) control. 
NTC were run on each NGS library preparation batch up to the pre-hybridisation quality 
check described in section 2.2.4.2. All 8 known SNPs in NF1 were identified within the 3% 
dilution with allelic frequencies of 1.85–5.22% and variant read depths of 2-46. 46 false 
positive were also identified with allelic frequencies of 1–3.85% and read depths of 2- 12 
shown in Figure 3.4. Receiver operating characteristic (ROC) analysis for AF the area under 
the curve (AUC) was 0.962 (95% CI, 0.902 to 1.000) using a cut off of 3.1% AF 
demonstrating a specificity of 87.5% and a sensitivity of 95.7%. ROC analysis of the variant 
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read depth revealed similar results, AUC 0.899 (95%CI, 0.740 to 1.000), using a cut off of 








Figure 3.4. True positives and false positives identified across NF1. Eight known SNV at 3% 
allelic fraction (black circles). Grey crosses indicate variants that were not observed in either of 
the two initial samples used to create the dilution (false positives). NF1 was aligned to the 
reference genome hg19. A) Allelic fraction (AF) of all variants observed across NF1. ROC analysis 
demonstrated 87.5% specificity and 95.7% sensitivity using a 3.1% AF cut off. B) Number of 
variant reads identified. ROC analysis demonstrated 75.0% specificity and 95.7% sensitivity using 
a 10 read cut off. 
 
 
To reduce the false positive background a threshold of a minimum of 300 X total read 
depth was included. This reduced the 8 known 3% AF SNPs down to 6, known positives 
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g.29654974 and g.29678242 fell below the 300 X threshold. Using 300 X as a cut-off point 
was not detrimental to analysis as all exonic regions in the validation controls display >500 
X. Excluding all coordinates with less than 300 X depth demonstrated a 4 fold reduction in 
the number of false positives identified. The 6 known SNPs in NF1 were all identified with 
allelic frequencies of 3.33–5.22%. 10 false positives were also identified with allelic 
frequencies of 1.06–1.70%. This gave 2 distinct groups in relation to the AF% with no 
overlap observed between true positives and false positives resulting in 100% specificity 
and 100% sensitivity with a 2.5% threshold. The 2 distinct groups were also observed with 
the variant read depth demonstrating 100% specificity and 100% sensitivity with a 14.5 











Figure 3.5. True positives and false positives identified across with a > 300 X total read depth. 
Six known SNV spiked at 3% allelic fraction (black circles). Grey crosses indicate false positives. 
NF1 aligned to reference genome hg19. A) Allelic fraction (AF) of all variants observed across 
NF1. ROC analysis demonstrated 100% specificity and 100% sensitivity with a 2.5% AF cut off. B) 
Number of variant reads identified. ROC analysis demonstrated 100% specificity and 100% 





To assess the reproducibility of the library preparation, sequencing, and data analysis, 
three inter batch runs and two intra batch runs using different sequencing indexes were 
performed using the same 3% AF dilution. The 6 known SNPs in NF1 were identified in all 
inter / intra batches with allelic frequencies of 2.54–5.45%, false positives ranged between 
1.03–1.70%, demonstrating 100 % specificity and 100 % sensitivity with a 2.1% cut-off, 
Figure 3.6. However, when analysing the variant reads of the independent batches the 
inter C batch displayed an overlap of false positives and true positives. When considering 
all inter / intra batch analysis this resulted in 90% specificity and 100% sensitivity using a 
14.5 variant read cut-off shown in Figure 3.6 . No pseudogene variants were identified. 7 
false positives were observed in more than one inter batch run, the most frequent been a 










Figure 3.6. Inter / intra batch true positives and false positives identified across NF1 with a > 
300 X total read depth  Grey crosses indicate false positives. Black circles represent true 
positives spiked at 3%. g.coordinates in reference to hg 19. A) Allelic fraction (AF) of all variants 
observed across NF1. ROC analysis demonstrated 100% specificity and 100% sensitivity with a 
2.1% AF cut off. B) Number of variant reads identified. ROC analysis demonstrated 90% 





To determine if using GIAB for the matched tumour had any influence over variant 
identification the bioinformatics was repeated using 00107 as the normal matched. 100% 
concordance was observed with all true positives and false positives. 
 
Table 3.4. Allelic Frequency and read depth of false positives and true positives 
Genomic 
coordinates 
Inter A Inter B Inter C Intra A Inter B 
VR VAF % VR VAF % VR VAF % VR VAF % VR VAF % 
NF1 TP           
17:29652147 21 3.33 57 5.17 23 2.54 25 3.11 10 3.28 
17:29653293 27 5.01 30 3.88 22 3.4 23 4.68 13 2.90 
17:29654876 39 4.76 31 2.62 56 4.98 48 5.45 25 4.24 
17:29663624 21 4.38 19 3.14 13 2.65 15 2.64 17 4.59 
17:29679246 62 5.22 68 4.82 71 4.17 46 3.20 42 4.81 
17:29685660 48 3.74 89 4.82 64 3.27 63 4.17 34 3.68 
NF1 FP           
17:29422184 4 1.36 NC NC NC NC NC NC NC NC 
17:29422543 9 1.14 NC NC NC NC NC NC NC NC 
17:29508788 NC NC NC NC NC NC NC NC 8 1.23 
17:29508855 NC NC NC NC NC NC NC NC 4 1.20 
17:29557853 NC NC NC NC 14 1.19 NC NC NC NC 
17:29559045 8 1.56 NC NC NC NC NC NC NC NC 
17:29559086 NC NC NC NC NC NC NC NC 5 1.15 
17:29559090 7 1.48 NC NC NC NC NC NC NC NC 
17:29559093 NC NC NC NC NC NC NC NC 5 1.01 
17:29559131 NC NC 1.26 12 NC NC NC NC 9 1.54 
17:29647382 NC NC 4 1.30 NC NC NC NC NC NC 
17:29508768 12 1.63 NC NC NC NC NC NC NC NC 
17:29508790 12 1.7 NC NC NC NC NC NC 9 1.47 
17:29508811 9 1.54 NC NC NC NC NC NC 7 1.41 
17:29559035 8 1.59 10 1.55 NC NC NC NC 7 1.67 
17:29559057 5 1.04 NC NC NC NC 9 1.35 5 1.25 
17:29647386 3 1.06 5 1.42 3 1.03 4 1.37 NC NC 
Variant reads (VR). Variant allelic frequency (VAF). NF1True positives (NF1TP). NF1 false positives 
(NF1FP). No call (NC) indicates no variant identified. 
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3.5 ddPCR low allelic frequencies  
To test the limits of the ddPCR protocol and its ability to detect copy number changes at 
low AF, a 3 NF1 copy number control was manufactured as described in section 2.2.8.2. 
RPP30 was used as the endogenous reference as reports of amplification and deep 
deletions are only observed in 0.4% of ADC and SQCC cases (Campbell et al., 2016). A series 
of validation dilutions standards was created to represent a 3 copy number change of NF1 
in 100, 80, 60, 40, 20 and 0% tumour content samples. These were analysed in duplicate 
on each batch, Figure 3.7. 
 
 
Figure 3.7. ddPCR Intra batch analysis. Dilutions standards representative of a 3 copy number 
change of NF1 in 100, 80, 60, 40, 20 and 0% tumour content samples. The graph shows both 





The copy number of the validation standards were measured in three independent inter 
batch runs shown in Table 3.5. In addition, commercially sourced DNA from the cell line 
SW48 was analysed. SW48 is reported to be diploid at the 17q11.2 and 10q23.31, the loci 
of NF1 and RPP30 (Knutsen et al., 2010). A NF1 homozygote loss control (NF1 1 copy) 
provided by SCH with supporting array comparative genomic hybridization data was also 
analysed. In addition to this, one low quality FFPET sample NF1-115 was tested (DIN 2.4, 
QFI 3.4%) in two inter batch runs. 
Table 3.5. ddPCR Intra batch reproducibility. 
 Batch 1 Batch 2 Batch 3    
 R1 R2 R1 R2 R1 R2 Mean SD CV 
100% 3.13 2.99 2.92 3.13 3.06 3.06 3.05 0.08 2.68 
80% 2.77 2.78 2.84 2.77 2.78 2.88 2.80 0.05 1.64 
60% 2.54 2.54 2.6 2.55 2.59 2.58 2.57 0.03 1.04 
40% 2.39 2.39 2.3 2.38 2.45 2.4 2.39 0.05 2.03 
20% 2.16 2.24 2.22 2.27 2.24 2.09 2.20 0.07 3.02 
0% 1.91 2.09 2 2.01 2.06 2.02 2.02 0.06 3.06 
SW40 2.03 2.03 2.07 1.96 2.00 2.05 2.02 0.04 1.92 
FFPET 2.03 2.1 2.13 2.10 N/A N/A 2.09 0.04 2.03 
NF1 1 copy 0.98 0.99 1.02 1.02 0.98 0.99 1.00 0.02 1.66 
NTC 0.00 0.00 0.00 0.00 0.00 0.00 - - - 
Replicate 1 (R1), replicate 2 (R2) 
 
The 3 copy number standards and controls showed good reproducibility across the three 
inter batch runs with all CVs below 3.06% shown in Table 3.5. SW40, NF1 loss, and the 
tumour content standards all came up as expected. Whilst there is a clear threshold 
between 0% and ≥40% standards there was an overlap between the 0% and 20% standards 
show in Figure 3.7. ROC analysis looking at the assays ability to detect a 3 copy number 
change in a 20% tumour content sample displayed 100% sensitivity and 83.3% specificity 






FFPET pathological analysis is a primary method used to differentiate and diagnose solid 
tumours. This also makes it a valuable primary and readily accessible source of genetic 
material. Unfortunately, FFPET is a far from ideal method for preserving and storage of 
nucleic acids. The process induces multiple types of DNA damage including; DNA 
fragmentation, DNA nicks, protein-DNA crosslinks, nucleotide transitions, oxidised bases, 
and ultimately yields low volumes of DNA during extraction (Srinivasan et al., 2002). 
Here we demonstrate that different extraction methods have significant effects on DNA 
yield returned. Of the extraction methods we assessed, the truXTRAC and QIAamp 
methods showed a >3 fold increase in DNA yield compared to the EZ1 method. We 
postulate the reason for this is a lack of a de-paraffinisation step prior to the EZ1 protocol 
being run. The mean DNA concentration extracted from the truXTRAC and QIAamp FFPE 
showed no significant difference (p = 0.556) shown in Figure 3.2. DNA quality as assessed 
by Agilent’s DIN score demonstrated no statistical differences between the three 
extraction methods. This suggests all three extraction methods have the same effect on 
DNA damage. 
Based on these data, the truXTRAC and the QIAamp FFPE kits are the optimal methods of 
extracting DNA from FFPET. However, the truXTRAC suffers from more random variance 
than the QIAamp FFPE method shown in Figure 3.2. Other drawbacks of the truXTRAC 
include that it is labour intensive, taking approximately 2-3 hours longer than the other 
methods. Furthermore, loading FFPET scrolls into the truXTRAC microtubes is challenging 
and thus increases the risk of contamination introduced by excess sample handling. For 
these reasons we chose to move forward using the QIAamp FFPE method, which proved 
the more robust method of extraction with reduced sample handling from FFPE tissue. 
Downstream genetic analysis can be further impacted by the variance in quantification 
methodology. We have shown that there is a significant difference between the NanoDrop 
measurement of replicate DNA, compared to the Qubit and TapeStation. The NanoDrop 
demonstrated a 2 to 3 fold increase over the other two methods shown in Figure 3.1. 
Similar observations have been described in other studies (Mathot et al., 2013). One 
explanation is the NanoDrop measures all nucleic acids that absorb at 260 nM (RNA, ssDNA 
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and nucleotides), whilst the Qubit uses a dsDNA binding dye and only measures dsDNA. 
Simbolo and colleagues demonstrated this, showing the Qubit is insensitive to RNA 
contamination when measuring DNA concentration (Simbolo et al., 2013).  
NGS of FFPET derived DNA is challenging. Initial attempts to perform NGS from FFPET using 
Illumina’s TruSight cancer panel, Agilents QXT, and XT kits proved unreliable (data not 
shown). This was due to a number of reasons including; the enzymatic fragmentation step 
used in Illumina TruSight and Agilents QXT kit could not be optimised for highly degraded 
FFPET. Agilent’s XT kit had issues with DNA loss due to its multiple clean up steps, making 
it unsuitable for low yield samples. However, new NGS library preparations kits, such as 
Agilent’s XT HS released in October 2017 are more suitable for sequencing of FFPET due to 
their low DNA input requirement and removal of DNA clean up steps. This makes it possible 
to sequence and identify variants even in samples with very low tumour content. 
Early NSCLC genomic profiling studies by (Ding et al., 2008, Hammerman et al., 2012, 
Collisson et al., 2014) only sequenced samples with >60% tumour content. Here we were 
able to identify variants with a theoretical 6% tumour content (3% allelic fraction). We 
have demonstrated, using a minimum read depth of 300 X, the specificity and sensitivity 
was increased to 100% with a 2.1% AF cut off, and 90% and 100% respectively using a 14.5 
read cut off. This is reflective of early work by Kerick and colleagues who demonstrated 
that increasing read depth increased variant concordance between fresh frozen and 
matched FFPET samples (Kerick et al., 2011).  
Whilst many papers have acknowledged the presence of NF1 pseudogenes when analysing 
genetic sequence using NGS, few have addressed potential issues of how to resolve these 
pseudogenes mapping back to the functional gene (Pasmant et al., 2015, Cunha et al., 
2016). Whilst no pseudogene reads were observed in our validation controls we have 
provided a further measure of security against this issue.  
It is important to note that we earlier described false positives as variants not seen in either 
of the two samples used to create the 3% variant control. However, several false positive 
variants were observed in multiple inter / intra batches shown in Table 3.4. This suggests 
they are not just sequencing or PCR artefacts, which would be randomly distributed (Oh et 
al., 2015, Spencer et al., 2013). As no potential pseudogene variants were identified, this 
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suggests the false positives are either low level variants not identified in the initial 
sequencing of the two samples, contamination, or FFPET artefacts. FFPET artefacts can 
originate from degradation of cytosine to uracil, which post PCR results in a C>T and G>A 
transition in the sequence product distributed (Oh et al., 2015, Spencer et al., 2013). The 
potential false positive 17:29647386 observed in 4/5 of the batches was a C>T transition 
and could have originated from this degradation process. However, based on our data it is 
not possible to confirm this. While this highlights the challenges when sequencing and 
identifying low level variants, it is beyond the scope of our work to investigate this further. 
Unlike NGS, ddPCR has shown to be more tolerant of FFPET samples as source material for 
analysis (Heredia et al., 2013, Zhang et al., 2016a). However, contaminating surrounding 
tissue is an issue that needs to be addressed when investigating copy number changes. 
Here we show ddPCR is highly reproducible at detecting these changes of the NF1 locus. 
We have shown that a three copy number change can be detected in samples with as little 
as 20% tumour content with 100% sensitivity and 83.3% specificity using a 2.08 copy 
number cut off point. This will enable us to move forward without the need for macro-
dissection in any samples with >20% tumour content.  
In summary this set of validation data and pre analytical requirements enable generation 
of high quality sequence from low quality FFPET samples. These validation data will give 




Screening Patients for NF1, BRAF, 





Genomic anomalies are the defining traits of cancer. These traits lead to characteristics 
which are the hallmarks of the disease (Hanahan and Weinberg, 2011). Over the last two 
decades our ability to identify these genetic anomalies has grown almost exponentially, 
largely due to advances in genetic screening technology. This has led to ADC and SQCC 
subtypes being further characterised based on their genotype of recurrent aberrations. In 
limited cases the genotype can also be used to predict pathological response to targeted 
therapeutics. Genetic profiling studies of NSCLC highlighted and confirmed many of the 
recurrent aberrations of potential drivers and tumour suppressor genes (Ding et al., 2008, 
Hammerman et al., 2012, Collisson et al., 2014, Campbell et al., 2016). The same studies 
also demonstrated the high mutation burden that the ADC and SQCC subtypes carry. This 
makes the separation of potential driver events in relation to benign passenger anomalies 
a challenge.  
Oncogenic variants which activate the MAPK pathway are well established drivers of ADC. 
These are largely somatic SNV or small indels which result in constitutive activation of this 
pathway. These drivers account for up to 60% of all ADC cases and are predominately 
found in KRAS, EGFR and BRAF. The drivers for the remaining 40% of cases have still to be 
identified (Collisson et al., 2014). Conversely, SQCC lacks many of the known MAPK driver 
mutations seen in ADC. Somatic copy number aberrations are frequently observed in 
SQCC. Copy number increase of the 3q26-28 locus is the most common variation, observed 
in 30-40% of all SQCC cases. This region includes potential drivers PIK3CA and SOX2. 
Somatic mutations in the PI3K/AKT pathway account for 47% of cases (Hammerman et al., 
2012). These results have also been confirmed in more recent studies, suggesting SQCC 
drivers are largely MAPK independent (Campbell et al., 2016). 
Whilst ADC and SQCC share few potential genetic drivers, they do share common somatic 
mutations of tumour suppressor genes. The most prevalent are somatic SNVs of TP53, 
which are observed in 86% and 54% of SQCC and ADC cases respectively. Deletion of 
chromosome 9p21.3, the locus of CDKN2A and CDKN2B, is another common anomaly, with 
deep deletions observed in 27% of SQCC and 17% of ADC cases (Campbell et al., 2016). The 
functional consequence of these somatic aberrations has been well characterised (Kathryn 
et al., 2014, Kim et al., 2016). 
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Another recurrent event in SQCC and ADC is that NF1 aberrations are observed in 8-12% 
of both populations (Collisson et al., 2014, Hammerman et al., 2012, Ding et al., 2008). No 
study has addressed the functional relevance of NF1 somatic variants in clinical NSCLC 
cases. NF1 somatic mutations are in part responsible for Neurofibromatosis pathogenesis, 
leaving individuals more susceptible to development of benign and malignant tumours of 
the peripheral nerve sheaf (Upadhyaya et al., 2004). Knock down of NF1 can drive cellular 
proliferation through activation of the MAPK pathway in ADC cell based models, which is 
enough to confer resistance to TKI treatment (de Bruin et al., 2014a). More recently 
Selumetinib, a MEK inhibitor, was granted orphan drug designation by the US Food and 
Drug Administration for treatment of Neurofibromatosis. These findings all suggest NF1 
loss of function could contribute to the upregulation of the MAPK pathway. 
The first step to investigate these aberrations of NF1 and their ability to drive the MAPK 
pathway was to recruit and consent NSCLC patients. This enabled access to their archived 
tumour tissue and non-identifiable clinical data. We used a combination of approaches to 
screen patients for somatic changes to NF1 and key activators of the MAPK pathway. The 
NGS methods described in Chapter 3 produced a robust workflow with the capabilities we 
required to screen for genetic variants in FFPET. The validation data demonstrates its 
sensitivity and specificity at identifying somatic variants at low allelic fractions, which is to 
be expected in low content tumour and heterogenic cases.  
In addition to this we have also utilised ddPCR to investigate NF1 copy number variation. 
This platform is more commonly known for its ability to detect SNV at low AF. However, it 
has demonstrated potential in its tolerance to degraded FFPET samples (Zhang et al., 
2016a), and our validation data demonstrates its ability to detect copy number changes in 
samples with as little as 20% tumour content. 
We demonstrated that both of these methods of analysis have the potential for identifying 
variation in cases with low tumour content. However, the methods have yet to be fully 
established in consideration to the full variability of quality and quantity of FFPE derived 
DNA from clinical cases. We will also continue to investigate the effect that the various 
methods of measuring quality and quantity of degraded DNA can have on downstream 
analysis using these workflows.  
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4.2 Patient Recruitment and Sample Acceptance 
We recruited 86 of a planned 100 patients from WPH lung cancer clinics from 2015 to 2018 
using the eligibility criteria described in section 2.2.1.2. After reviewing the first cohort of 
patient samples it became apparent many were insufficient for downstream analysis. We 
required a minimum of 10 ng of DNA for screening of NF1, EGFR, BRAF and KRAS and 100 
ng of total RNA for downstream gene expression analysis. The lower limit of starting 
material for ddPCR analysis was not known at this point; theoretically the assay is based 
on a simple ratio of endogenous reference to target. We therefore assumed 2 ng of DNA, 
which is equivalent to over 600 haploid copies, should be sufficient to calculate this ratio. 
Based on this, we defined criteria for pre-analytical sample rejection: samples with less 
than 4mm2 area of surface tissue based on the H+E section would not be viable for 
downstream analysis. Another factor considered was exhausting available tissue, as 
further diagnostic results could be required to aid future patient treatments. Based on 
these criteria 23 samples were not viable for analysis. Rejected samples were either 
bronchial brushing or bronchoscopies, none of which matched their respective size as 
described in histology reports. The reports described these initially rejected samples as 
between 2 mm to 20 mm in size, however, we observed samples with no visible tissue to 
1 mm. Based on this first cohort we decided to only recruit patients with surgical tissue 
available. Four samples were never received from STH histology. With only 59 samples 
remaining, we requested to access a further 40 samples from the ReSoLuCENT study.  
Post extraction analytical quality checks for the 99 clinical samples included quantification 
via Nanodrop, qPCR, and Qubit. In addition to this, two methods of DNA quality 
assessment were utilised; the DIN score was calculated using the Agilent’s TapeStation 
2200 and the QFI score based on the Qubit concentration and qPCR as described in section 
2.2.3. A 260 / A 280 ratios for all samples as determined using the NanoDrop were >1.88. 
Samples with <5 ng DNA yield as assessed by Qubit or QPCR had the extraction process 
repeated. 7 samples failed this QC step and it is important to note DNA yield was not 
reflective of tissue size with 3 surgical samples, all with a tissue surface area of >100 mm2 
failing at this stage. 
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4.3 Sample quantity and quality 
As with the validation samples described in the previous chapter, Nanodrop quantification 
of the samples was significantly greater than that of the Qubit. In addition, the qPCR 
method of quantification is significantly lower than the Qubit. Both of these differences 
are highlighted in the non-overlapping 95% confidence intervals shown in Table 4.1 
Bivariate Pearson correlation coefficients (r) demonstrated a strong linear correlation 
between the methods of measurement; NanoDrop vs. Qubit 0.835 (p < 0.01), qPCR vs. 
Qubit 0.823 (p < 0.01), and NanoDrop vs. qPCR 0.590 (p < 0.01). When assessing the two 
different methods of determining DNA quality via QFI and the DIN score, Pearson 
correlation coefficient again demonstrated a strong linear correlation between the 
methods of quality assessment 0.759 (p < 0.01) shown in Table 4.2. When assessing our 
cohort of samples using the DIN score 45% (n = 41) fell below the lower limit of the 95% CI 
(3.3). Similarly utilising the QFI score, 49% (n = 45) fell below the lower limit of the 95% CI 
(24.8%). The range of yield and quality observed by the various methods of measurement 
all agree there is a large degree of variability across the samples.  
 












NanoDrop 1 0.835 (17 – 1706) 446.0 381.6 – 510.4 
Qubit 0.835 1 (1.6 – 780) 131.8 103.0 – 159.8 
qPCR 0.590 0.823 (0 – 434) 48.8 32.8 – 64.9 
Pearson’s Correlation of quantification values (r) values. Statistical evidence for a linear 






Table 4.2. Range and Correlation DIN score vs. QFI score. 
 (r) P value Range Mean 95% CI 
DIN Score 
0.759 P < 0.01 
1.3 – 6.7 3.6 3.3 – 3.9 
QFI Score 0.1 – 101 % 29.8 % 24.8 – 34.6 
Pearson’s Correlation of quantification values (r) values. Statistical evidence for a linear 
relationship was observed between DIN and QFI scores. 
 
 
4.4 Variant Screening 
4.4.1 Library preparation 
92 samples passing initial criteria had library preparations undertaken using the methods 
described in section 2.2.4. Starting DNA material ranged from 1.6 ng to 300 ng as 
determined by qPCR, or 64 ng to 5171 ng by Qubit. Libraries were prepared for two of the 
samples (NF1-230 and NF1-229) with insufficient DNA, as quantified by qPCR. However, 
utilising the Qubit concentrations these should have been adequate to sequence, with 
2015 ng and 726 ng of starting material respectively. These and two other samples (NF1-
235 and NF1-236) were rejected at the pre-hybridisation QC step, based on poor recovery, 
Table 4.3.  
Table 4.3. Samples rejected pre-hybridisation 
Sample 
Starting amount 
QFI DIN Pre hyb (ng) 
Qubit (ng) qPCR (ng) 
NF1-229 726 7.8 1.1 2.8 1.3 
NF1-230 2015 1.6 0.08 1.5 3.2 
NF1-235 1510 11.1 0.74 1.7 2.4 
NF1-236 2155 50.0 2.3 2.6 19.6 





NF1-229 and NF1-236 had surplus tissue available; DNA was re-extracted using more 
starting tissue and library preparation repeated. Whilst low pre-hybridisation was still 
observed we continued with the hybridisation, in order to test lower limits of input 
material for this step. 34% (n = 29) of our samples fell below Agilent’s minimum 
recommendation of 500 ng. Of these, 6 samples had insufficient post-hybridisation yield 
for sequencing, shown in Table 4.4. Previously rejected samples (NF1-229 and NF1-236) 
failed again, in despite of increase starting material. All cases with >170 ng resulted in 
sufficient post-hybridisation yield to sequence. 
 
Table 4.4. Samples which demonstrated the lowest pre-hybridisation yield 
 Starting amount 




(pmol/l) Sample ID Qubit (ng) qPCR (ng) 
NF1-236 5171 120.0 2.3 2.6 62.88 16 
NF1-226 1489 150.0 10.1 2.5 74.4 255 
NF1-215 306 130.6 42.7 3.8 92.16 5050 
NF1-213 220 62.5 28.3 2.7 110.28 5220 
NF1-229 2342 25.0 1.1 2.8 133.2 572 
NF1-174 173 20.7 11.9 2.5 135.6 6470 
NF1-219 1546 50.0 3.3 2.1 151.2 231 
NF1-231 335 100.0 29.8 2.2 170.4 4880 
NF1-238 474 173.5 36.6 3.3 219.6 7780 
NF1-237 588 105.5 17.9 4.6 223.2 8510 






4.4.2 Patient Samples and Demographics  
The age at biopsy for the remaining cases ranged from 20 to 86 years with a mean age of 
62.5 years (95% CI, 60.1 to 65.0). Unfortunately, not all fields of patient data collected for 
the ReSoLuCENT trial correlated with data fields for our study, and some areas had missing 
data. Fields for which ReSoLuCENT data differed included; smoking status excluded and 
several NSCLC subtypes were classified as not otherwise specified (NOS). As the samples 
were provided in an anonymised manner mortality status was unobtainable. However, 
data we could collate included; gender, age and stage at biopsy, and whether this was a 
biopsy of primary tumour or metastatic tissue, Table 4.5. Disease stage was translated 
from TNM grading following the American Joint Committee on Cancer Staging Manual 
(Edge and Compton, 2010). 
 
Table 4.5. Summary of patient pathology, gender, stage and smoking status 









Gender     
 Male  45 23 17 5 
 Female 41 25 13 3 
Disease Stage     
 Stage 1 4 1 3 0 
 Stage 2 25 16 9 0 
 Stage 3 42 23 15 4 
 Stage 4 15 8 3 4 
Smoking Status     
 Current or ex 43 25 18 0 
 Never Smoked 9 8 1 0 
 Unknown 34 15 11 8 
Biopsy Site     
 Primary  69 40 26 3 
 Metastatic 17 8 4 5 





4.4.3 Pathological Review 
Pathological review of our cases revealed tumour content from 0 to 90%, based on nuclei 
ratio to normal non-tumour nuclei, shown in Table 4.6. Based on this, four of our remaining 
cohort had no visible tumour content. NF1-234 was a surgical resection, NF1-203 and NF1-
204 were bronchial biopsies, and NF1-232 was a lymph node biopsy. As patients had been 
diagnosed based on these samples and pathological review is subjective, we decided to 
continue with analysis of these cases. For future reference all NF1-1XX samples were 
recruited in this study and were surgical resections of primary tumours. NF1-2XX cases 
originated from the ReSoLuCENT study and are comprised of surgical resections, 
bronchoscopies, or metastatic biopsies. 





















NF1-107 30 NF1-151 70 NF1-174 50 NF1-214 60 
NF1-115 50 NF1-152 60 NF1-175 30 NF1-215 30 
NF1-117 50 NF1-154 50 NF1-176 10 NF1-216 40 
NF1-119 50 NF1-155 50 NF1-177 70 NF1-217 60 
NF1-120 30 NF1-156 50 NF1-178 30 NF1-218 60 
NF1-122 60 NF1-157 50 NF1-179 50 NF1-220 40 
NF1-126 50 NF1-158 70 NF1-180 60 NF1-221 60 
NF1-130 40 NF1-159 90 NF1-181 60 NF1-222 70 
NF1-132 60 NF1-160 30 NF1-182 50 NF1-223 10 
NF1-134 40 NF1-161 30 NF1-183 30 NF1-224 60 
NF1-136 40 NF1-162 20 NF1-184 30 NF1-225 70 
NF1-138 10 NF1-163 30 NF1-185 70 NF1-227 50 
NF1-139 30 NF1-164 30 NF1-201 70 NF1-231 50 
NF1-140 80 NF1-165 40 NF1-203 0 NF1-232 0 
NF1-141 10 NF1-166 50 NF1-204 0 NF1-233 70 
NF1-142 30 NF1-167 20 NF1-205 10 NF1-234 0 
NF1-144 10 NF1-168 50 NF1-206 50 NF1-237 60 
NF1-145 80 NF1-169 30 NF1-207 40 NF1-238 80 
NF1-146 90 NF1-170 40 NF1-210 50 NF1-239 20 
NF1-147 60 NF1-171 40 NF1-211 20 NF1-240 50 
NF1-148 70 NF1-172 50 NF1-212 80   
NF1-150 60 NF1-173 60 NF1-213 30   
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4.4.4 Sequencing Metrics 
To ensure the sequencing of the 86 cases and GIAB had passed initial criteria for 
downstream analysis, we considered the following sequencing metrics and QC checks. 
Cluster density for the pooled samples was 926 K/mm2, this demonstrated initial sample 
dilution to 11 pM for HiSeq loading was within recommended limits for cluster generation 
(800–1100 K/mm2). Illumina Q-scores showed 97% of clusters passing the filter were >Q30. 
This was generated from 324 million independent reads which resulted in a total yield of 
70.4 Gbases. We used the de-multiplexed sample read percentage to confirm equimolar 
pooling. Individual samples ranged from 0.5-2.0% shown in Figure 4.1. 
 
 
Figure 4.1. Percentage of reads per sample. Lowest sample NF1-165 highlighted in red. Range 





4.4.5 Assessment of Sequencing Depth 
As described in the previous chapter, a minimum read depth of 300 X is required to call 
variants in a sample with 6% tumour content based on diploid genome, with a specificity 
of 100% and 90%, using a 2.1% AF cut off or a 14.5 read cut off limit respectively. After 
discarding optical duplicates the average read depth for NF1, EGFR, BRAF and KRAS was 
1650 X, ranging from 230 X to 3200 X, (95% CI, 1530 to 1771). These data demonstrate 
multiplexing 87 samples with a 275 kb capture region is adequate for deep coverage in 
order to confidently call low AF variants for this study. The average on target reads across 
all samples was 76%, ranging from 54% to 88%, (95% CI, 74.9 to 77.0). NF1-233 was the 
only sample to have <500 X mean coverage, but as the tumour content was 70% and we 
still had an average of 230 X, any ubiquitously expressed somatic mutation should be 
observed at higher than 3% AF. Whilst NF1-165 took the lowest percentage of reads from 




4.5 Variant Identification and Annotation  
Following de-multiplexing, the individual BCL files were run through the bioinformatics 
pipeline, as described in section 2.2.5. The workflow for variant annotation or exclusion is 
shown in Figure 4.2. 
 
 





4.5.1 MAPK Oncogenic Variant Identification 
We used the VCFs outputted by VarScan2, described in section 2.2.5 and filtered for EGFR, 
BRAF, and KRAS regions. Variant analysis of the 86 samples using the workflow shown in 
Figure 4.2 and the criteria described in section 2.2.5.3 resulted in the identification of 
known oncogenic mutations in 29% (n = 25) of the samples. This included EGFR mutations 
in 8% (n = 7) of the cohort, shown in Table 4.7. KRAS mutations were identified in 17% (n 
= 15), shown in Table 4.8. Finally, BRAF mutations were identified in 3% (n = 3) of the cohort 
and are shown in Table 4.9. These oncogenic mutations were all mutually exclusive in all 
cases. 
 








RS number cDNA Protein 
NF1-119 192 16.77 rs121434568 c.2573T>G p.Leu858Arg 
NF1-142 1806 65.91 rs121434568 c.2573T>G p.Leu858Arg 






NF1-157 434 29.21 rs121434568 c.2573T>G p.Leu858Arg 






NF1-170 406 29.59 rs121434568 c.2573T>G p.Leu858Arg 







All EGFR variants such as exon 21 substitutions and exon 19 deletions as seen in our cohort 
are reported as oncogenic (Lynch et al., 2004). Both exon 21 and exon 19are recognised 
predictive biomarkers of response to target specific tyrosine kinase inhibitors. The EGFR 
variants from our study shown in Table 4.7 were more prevalent in ADC cases (7/7), 
females (5/7), whilst we only had 9 known never smokers in our cohort of 86, 3 of them 
displayed oncogenic EGFR variants. All variants in these patients displayed high variants 
read depths with the exception of NF1-205. 
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Whilst NF1-205 was below the detection criteria of >3% AF and 15 variant reads, the 
chance of a deletion of this size being observed in multiple independent reads is below 
that of a SNV. The patient’s clinical information had no reports on EGFR status. It did show 
the female patient with stage 3 disease was treated with Erlotinib in 2005, with a response 
being observed. The low pathology assessment of 10% tumour content also supports the 
6% tumour contents based on a 3% AF, in a diploid genome. This does suggest the EGFR 
result obtained is correct and not a false positive. 
For the patients with EGFR p.Leu858Arg variants, both NF1-119 and NF1-157 had the 
details reported in their clinical diagnostic history. The cases were both female and never-
smokers. NF1-119 had stage 2 disease and suffered disease recurrence 3 years after 
surgery. The patient was treated with Gefitinib for a year before disease progression. NF1-
157 had stage 3 disease which was not fully excised. The patient responded to Gefitinib for 
4 years before disease progression. NF1-142 and NF1-170 had not been tested for EGFR 
variants, both were males with stage 2 disease, no disease recurrence has been reported 
for 2 and 1 years respectively. The cases with exon 19 deletions, NF1-151 and NF1-164 had 
the variants reported in their clinical history. Both cases were female, former smokers, 
with stage 2 disease. NF1-151 had disease recurrence after 1 year, Gefitinib treatment is 
ongoing with stable disease. NF1-164 had disease recurrence after 2 years; treatment with 












RS number cDNA Protein 
NSCLC 
subtype 
NF1-107 669 34.08 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-130 771 47.68 rs121913530 c.34G>T p.Gly12Cys SQCC 
NF1-132 389 15.58 rs121913529 c.35G>A p.Gly12Asp SQCC 
NF1-163 186 8.35 rs121913529 c.35G>T p.Gly12Val SQCC 
NF1-165 203 19.08 rs121913529 c.35G>T p.Gly12Val ADC 
NF1-173 333 17.11 rs121913529 c.35G>C p.Gly12Ala ADC 
NF1-175 299 25.53 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-183 141 8.32 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-184 172 11.42 rs121913530 c.34G>C p.Gly12Ala SQCC 
NF1-185 323 21.55 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-206 336 23.40 rs121913529 c.35G>T p.Gly12Val ADC 
NF1-207 270 30.86 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-210 135 9.04 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-218 159 23.18 rs121913530 c.34G>T p.Gly12Cys ADC 
NF1-231 87 5.31 rs121913530 c.34G>T p.Gly12Cys ADC 
AF range from 5.31 to 47.68%. Female patients highlighted in red, males in black 
 
KRAS mutations such as, p.Gly12, as seen in our cohort are oncogenic, with compelling 
evidence to its role in many cancers and for being the most prevalent driver mutation in 
ADC (Garrido et al., 2017). Our cohort displayed KRAS mutations in 23% of the ADC cases, 
which is reflective of what has been reported in European cohorts  (Boch et al., 2013). 
However, we have a larger than reported prevalence in SQCC cases, 13% in total compared 
to the 6% Boch and colleagues reported. It is important to note that although the non-
specified subtype cases did not display any KRAS variants, these would still have influence 
over the final prevalence observed in our cohort. Whilst smoking status is not known for 
the ReSoLuCENT samples, 90% of the KRAS positive patients recruited to our NF1 in NSCLC 
study were known smokers. Of the patients with KRAS positive disease, 60% were female 
(n = 9) and 40% (n = 6) male. KRAS mutations are not routinely tested for diagnostically, as 
they are not currently predictive for any treatments, therefore we cannot correlate our 












RS number cDNA Protein 
NSCLC 
subtype 
NF1-148 572 28.57 rs121913348 c.1391G>T p.Gly464Val SQCC 
NF1-174 367 18.62 rs121913355 c.1406G>T p.Gly469Val ADC 




AF range from 18.6 to 33.5%. Female patient highlighted in red, males in black 
 
These BRAF mutations such as exon 11 SNV and di nucleotide variants leading to 
p.Gly464Val, p.Gly469Val, and p.Gly469Leu as seen in our cohort, are potential drivers of 
the MAPK pathway (Gautschi et al., 2013) BRAF p.Gly469 is the most prevalent locus for 
substitutions in this gene, with Glycine to Valine being the most prevalent substitution. 
p.Gly464Val is observed to a lesser extent in NSCLC. p.Gly469 mutations are observed in 
1.5% of ADC cases and <1% of SQCC cases (Campbell et al., 2016).  Our cohort displayed 
BRAF mutations in <2% (n = 1) of the ADC cases and in 6% (n = 2) SQCC cases. It is important 
to note NF1-237 was reported in the VCF as c.1405G>T and c.1406G>T, as these were on 
the same allele they would have resulted in a p.Gly469Leu substitution. As with KRAS, BRAF 
is not routinely tested for diagnostic purposes 
 
4.5.2 NF1 Variant Filtering, Identification, and Annotation 
Unlike known hotspots for the oncogenic gain of function mutations which can be 
targeted, NF1 potential loss of function mutations are sporadic in nature. As described in 
section 2.2.5.3 we employed VCFMiner to filter the individual VCF files. We excluded all 
GIAB only variants. After which we limited the VCF files to the defined genomic regions. All 
variants with >1% population frequency based on gnomAD r2.0.2 were excluded, along 
with variants demonstrating <15 reads and with <3% AF. At this point we had potential 
NF1 variants in 99% of the samples (n = 85). We then used the workflow shown in Figure 
4.2 to further filter variants. 1 of 2 specific intronic poly N indels was observed at the same 
genomic coordinates in all but 1 sample. c.730+32dupT was reported in 85% (n = 73) of all 
cases, or c.730+32delT in 15% (n = 12) of all cases. These were reported to be deletions or 
111 
 
insertions in an intronic 16 polyT region.  All observed at AF of 10% to 38%. Other recurring 
poly N indels included c.61-14delT observed in 7 % (n = 6) and c.1186-13delT in 2% (n = 2), 
both deletions were in a region of a 10 polyT repeats, AF ranged from 3% to 5%.  
 
4.5.3 Pseudogene Matching Variants 
We flagged 10 patients with potential NF1 pseudogene variants using the pseudo list as 
described in section 3.3, variants shown in Table 4.10. Two of these variants were of great 
interest as both had been reported in Neurofibromatosis patients. The variant observed in 
NF1-120, c.1466A>G, (p.Tyr489Cys) had been described as a germline variant in two 
related patients, both of whom also carried somatic mutations of NF1 (Laycock-van Spyk 
et al., 2011). The second was c.3721C>T, (p.Arg1241*) observed in NF1-168 and reported 
as a somatic mutation in a Neurofibromatosis patient (Upadhyaya et al., 2004). Based on 
these reports both were classified as pathogenic. One particular variant c.3114-7T>C was 
observed in 6 different samples at low AF. This variant was recorded on dbSNP from the 
Exome Aggregation Consortium with an unassessed clinical significance. Another intronic 
variant in NF1-146, c.4725-13A>C was flagged as potential pseudogene origin. This had not 
previously been reported. All 7 of the intronic variants had no predicted effect on splicing 
if originating from the functional gene.  The final potential pseudogene variant c.1018T>G, 












RS number cDNA Protein 
NF1-119 36 4.01 rs754931967 c.3114-7T>C - 
NF1-120 78 9.55 rs137854557 c.1466A>G p.Tyr489Cys 
NF1-146 28 6.26 N/A c.4725-13A>C - 
NF1-157 83 7.76 rs754931967 c.3114-7T>C - 
NF1-168 427 14.65 rs137854562 c.3721C>T p.Arg1241* 
NF1-211 35 3.19 rs754931967 c.3114-7T>C - 
NF1-220 23 3.07 N/A c.1018T>G p.Ser340Ala 
NF1-220 40 13.07 rs754931967 c.3114-7T>C - 
NF1-225 20 3.14 rs754931967 c.3114-7T>C - 
NF1-232 15 4.50 rs754931967 c.3114-7T>C - 






4.5.4 NF1 Promoter Variants 
We identified 5 potential mutations upstream of the NF1 transcription start site shown in 
Table 4.11. These have the potential to effect transcription of NF1 mRNA and therefore 
cause loss of function. No reports in the literature were found, but 4 variants were 
reported on dbSNP as indicated by the RS number. NF1-155 did have a corresponding entry 
on ClinVar and was deemed of uncertain clinical significance. 
 







RS number cDNA 
NF1-132 639 46.27 rs17879128 c.-459A>C 
NF1-148 273 19.63 rs922504932 c.-356C>T 
NF1-155 34 60.71 rs886052790 c.-209C>A 
NF1-172 54 6.38 N/A c.-93C>G 





4.5.5 Potential NF1 loss of function variants  
After filtering all the previously mentioned variants, 20% (n = 17) of cases displayed 22 
potential NF1 somatic mutations, shown in Table 4.12.  5 cases displayed multiple NF1 
variants. The total variants included; 9 non-synonymous (2 = non-sense, 7 = missense), 6 
synonymous, 3 indels (2 = deletions, 1 insertion), 1 exonic di-nucleotide substitution, and 
3 exonic SNV.  






cDNA Variant Protein 
NF1-115 208 24.21 c.3118A>G p.Lys1040Glu 




NF1-147 1011 58.98 c.3468C>T p.Asn1156Asn 
NF1-150 63 6.65 c.5269-14C>G - 
NF1-163 75 3.03 c.1897G>C p.Asp633His 
NF1-163 158 44.26 c.-22G>C - 
NF1-168 201 11.35 c.5785G>T p.Glu1929* 
NF1-170 111 5.70 c.3825C>T p.Phe1275Phe 
NF1-178 576 53.33 c.7595C>T p.Ala2532Val 
NF1-180 897 52.95 c.7245delA p.(Leu2416Tyrfs*2) 
NF1-201 109 9.00 c.435C>A p.Leu145Leu 
NF1-205 20 4.07 c.4311G>A p.Arg1437Arg 
NF1-210 51 4.68 c.169G>T p.Gly57Cys 
NF1-217 251 13.01 c.3634delG Val1212Serfs*3 
NF1-217 39 8.92 c.7339G>T p.Glu2447* 
NF1-225 761 58.72 c.6781C>T p.His2261Tyr 
NF1-227 24 4.53 c.6148-2A>T - 
NF1-233 69 35.57 c.2681T>C p.Phe894Ser 
NF1-233 19 10.50 c.2178G>A p.Val726Val 
NF1-233 54 29.83 c.2675_2676insA p.(Ser892Argfs*14) 
NF1-238 117 7.21 c.3481C>G p.Leu1161Val 
NF1-238 40 6.23 c.3249C>G p.Leu1083Leu 
NF1 variants remaining post VCF filtering. AF ranges from 3.03 to 58.98% and variant read 




The potential somatic variants were then subject to searches through literature and 
databases to determine if any had been previously reported. With the exception of the 
previously mentioned potential pseudogene variant, no others were reported in the 
literature and no functional studies had been undertaken. 8 of the mutations were located 
in online databases, but the clinical significance of these variants remains to be elucidated. 
Of these 8, NF1-163 (c.-22G>C) had the highest frequency population data, with gnomAD 
r2.0.2 reporting it as 0.38%, NF1-147 (c.3468C>T) and NF1-178 (c.7595C>T) were < 0.069% 
and < 0.079% respectively. All remaining variants were < 0.0057%. 15 of the variants were 
novel with no evidence of been previously reported. A summary of the results and 
potential clinical significance are reported in Table 4.13. 
As no evidence of functional studies had been reported, the 22 potential somatic 
mutations were subjected to in-silico analysis to determine the probability of causing loss 
of NF1 function. All computational in-silico algorithms are described in section 2.2.5.3. All 
samples with null variants (non-sense or frameshift) (n = 4) were classified as high 
probability of causing loss of function, shown in Table 4.13. NF1-217 had two null variants; 
however it is not possible to determine if these are in cis or in trans.  
Of the variants with the potential to affect mRNA splicing, NF1-150 (c.5269-14C>G) was 
the only variant to have three out of five of the in-silico splicing packages reporting a 10% 
reduction in its acceptor site. This has the potential to result in c.5446 becoming a more 
favourable acceptor site. We classified NF1-150 as having an unknown significance of 
causing loss of NF1 function. This suggests the cases (n = 9) with potential splice site 
variants are likely benign and have a low probability of causing loss of function of NF1, 




Table 4.13. Reported NF1 variants reported and potential clinical significance 
Sample ID RS number cDNA Reported 
Clinical 
Significance 
NF1-120* rs137854557 c.1466A>G 
Laycock-van Spyk et. 
al 2011 
Pathogenic 
NF1-168* rs137854562 c.3721C>T 
Upadhyaya M 
et. al 2003 
Pathogenic 
NF1-115 N/R c.3118A>G ClinVar Uncertain 
NF1-150 N/R c.5269-14C>G N/R N/R 
NF1-163 N/R c.1897G>C N/R N/R 
NF1-178 rs148154172 c.7595C>T dbSNP / ClinVar Uncertain 
NF1-210 N/R c.169G>T N/R N/R 
NF1-233 N/R c.2681T>C N/R N/R 
NF1-225 rs750869272 c.6781C>T dbSNP / ClinVar Likely benign 
NF1-238 N/R c.3481C>G N/R N/R 
NF1-168 N/R c.5785G>T N/R N/R 
NF1-180 N/R c.7245delA N/R N/R 
NF1-217 N/R c.3634delG N/R N/R 
NF1-217 N/R c.7339G>T N/R N/R 
NF1-233 N/R c.2675_2676insA N/R N/R 




dbSNP / ClinVar Uncertain 
NF1-147 rs147955381 c.3468C>T dbSNP / ClinVar Uncertain 
NF1-163 rs556823296 c.-22G>C dbSNP / ClinVar Likely benign 
NF1-170 N/R c.3825C>T N/R N/R 
NF1-201 N/R c.435C>A N/R N/R 
NF1-205 rs1060503896 c.4311G>A dbSNP / ClinVar Likely benign 
NF1-233 rs369590240 c.2178G>A dbSNP / ClinVar Likely benign 
NF1-227 N/R c.6148-2A>T N/R N/R 
NF1-238 N/R c.3249C>G N/R N/R 
Not previously reported (N/R),*Potential pseudogene origin. The two potential pseudogene 
variants reported as pathogenic in the literature. Sample IDs highlighted in red (n = 5) have strong 
evidence of loss of function based on the variant identified alone and are classified as high 
probability. NF1-217 displaying 2 null variants. Samples in green (n = 10) have little or no 
supporting in-silico evidence that the variants affect mRNA splicing and are classified as likely 
benign. Samples in black (n = 10) have in-silico analysis which suggests the variants could 





The 7 remaining non-synonymous variants were then analysed through 7 different in-silico 
algorithms to help predict potential loss of function, shown in Table 4.14. For the variant 
to be considered unknown significance of causing loss of function >65% of the tools had to 
be in agreement of damaging consequences. If >65% demonstrated neutrality the variants 
were classified as likely benign. NF1-178, NF1-210, NF1-225, and NF1-238 did not yield any 
result through the PANTHER package. Based on these criteria; 5 of the missense variants 
fell into the unknown significance bracket and 2 into the likely benign bracket shown in 
Table 4.14. 
 








PMut PROVEAN SIFT PolyPhen2 
NF1-115 Disease Disease Disease Disease Deleterious Damaging 
Possibly 
damaging 
NF1-163 Neutral Neutral Disease Neutral Neutral Tolerated 
Possibly 
damaging 
NF1-178 Neutral N/A Disease Neutral Neutral Tolerated 
Possibly 
damaging 
NF1-210 Neutral N/A Disease Neutral Deleterious Damaging 
Possibly 
damaging 
NF1-233 Disease Disease Disease Disease Deleterious Damaging 
Possibly 
damaging 
NF1-225 Disease N/A Disease Disease Deleterious Damaging 
Possibly 
damaging 
NF1-238 Disease N/A Disease Disease Deleterious Damaging 
Possibly 
damaging 
The final prediction as indicated by 7 independent in-silico analysis tools. Samples in Red have 






4.5.6 NF1 Germline Sequencing  
To determine if the 22 variants observed were somatic in nature or germline, we 
sequenced matched blood samples. Unfortunately, we did not have paired blood for NF1-
168, NF1-170, and NF1-233. Library preparation and sequencing protocols used were as 
previously described with the following exceptions; we excluded the qPCR quantification 
step, and the samples were sequenced on the MiSeq. All DIN values were >8.3 and 200 ng 
of starting material was used. The sequencing metrics demonstrated 92.9% of reads were 
>Q30 and had a cluster density of 1152K/mm2. For the tumour samples with paired blood 
available, we repeated the bioinformatics pipeline using the actual paired sample. The 
same variant filtering was applied with the exception that we did not have to remove GIAB 
variants.  
Analysis determined both NF1-146 variants were germline, heterozygote in origin, 
alongside NF1-147, NF1-163 (c.-22G>C), NF1-178, and NF1-225. When comparing these 
back to the loss of function prediction, all but NF1-225 fall into the low probability bracket. 
This can also be seen looking at the AF of the tumour samples, all germline variants are 
found between 44% to 59% AF, shown in Table 4.12. Since all germline variants fall into 
this AF bracket, it suggests that NF1-168 and NF1-170 are somatic in nature, with the AF 
being 11.35% and 5.70% respectively. All variants found within the protein coding regions 
of NF1 are shown in Figure 4.3. 
 
 
Figure 4.3. Illustration of variants and loci within NF1 protein. Figure includes somatic variants,   
three possible pseudogene variants, and germline variants.  Black circles; (n = 5) truncating 





4.5.7 Prevalence of Identified Variants within Tumour Content 
To further investigate if the variants we observed were expressed ubiquitously throughout 
the tumour we compared the sequencing AF against expected frequency. The expected 
frequency was based on the assumptions the tumour is diploid and tumour content is 
correct. As the pathology tumour content is subjective and there is variation in the 
sequencing AF, we set ±30% thresholds of the expected AF. 
48% (n = 12) of the 25 oncogenic variants fell within ±30% of the expected frequency, 
shown in Table 4.15. The samples falling into the diploid bracket suggests a heterozygote 
genotype, consisting of wildtype and mutant allele, with this genotype being ubiquitously 
expressed throughout the tumour. 28% (n = 7) of the mutations fell below the 30% 
threshold. These frequencies are suggestive of intra-tumour heterogeneity with the 
oncogenic mutations being prevalent in only a percentage of the tumour. Whilst copy 
number loss is also a factor to consider, it is less prevalent in BRAF, KRAS, and EGFR and 
only seen in 14%, 13%, and 8% of cases respectively. 25% of the variants (n = 6) 
demonstrated a >30% increase in AF. This could be suggestive of copy number gain of the 
variant allele, the variant being homozygote, or copy number loss of the wildtype allele. 
Based on our data it is not possible to draw a conclusion on this. However, copy number 
gain is a common event for BRAF, KRAS, and EGFR in NSCLC and seen in 42%, 41.6%, 52% 












Expected variant AF (%) Observed variant 
AF (%) <30% >30% 
NF1-148 BRAF 70 24.5 45.5 28.57 
NF1-174 BRAF 50 17.5 32.5 18.62 
NF1-237 BRAF 60 21 39 33.49 
NF1-119 EGFR 50 17.5 32.5 16.77 
NF1-142 EGFR 30 10.5 19.5 65.91 
NF1-151 EGFR 70 24.5 45.5 34.25 
NF1-157 EGFR 50 17.5 32.5 29.21 
NF1-164 EGFR 30 10.5 19.5 18.54 
NF1-170 EGFR 40 14 26 29.59 
NF1-205 EGFR 10 3.5 6.5 2.88 
NF1-107 KRAS 30 10.5 19.5 34.08 
NF1-130 KRAS 40 14 26 47.68 
NF1-132 KRAS 60 21 39 15.58 
NF1-163 KRAS 30 11.5 19.5 8.35 
NF1-165 KRAS 40 14 26 19.08 
NF1-173 KRAS 60 21 39 17.11 
NF1-175 KRAS 30 10.5 19.5 25.53 
NF1-183 KRAS 30 10.5 19.5 8.32 
NF1-184 KRAS 30 10.5 19.5 11.42 
NF1-185 KRAS 70 24.5 45.5 21.55 
NF1-206 KRAS 50 17.5 32.5 23.40 
NF1-207 KRAS 40 14 26 30.86 
NF1-210 KRAS 50 17.5 32.5 9.04 
NF1-218 KRAS 60 21 39 23.18 
NF1-231 KRAS 50 17.5 32.5 5.31 
Green sample ID indicates the observed AF was within ±30% of the expected heterozygote AF. 
Blue sample ID indicates the variant was below 30% of the expected. Red indicated the variant 





Based on the AF observed and tumour content we have 18/25 samples in which the 
oncogenic mutations of the MAPK pathway appear to be expressed ubiquitously 
throughout the tumour in a clonal manner. The remaining 7 variants appear to be only 
expressed in certain sub-clonal populations of the tumour. Looking at the variants 
independently and comparing the subcolonal percentage of cases we observed similar 
results to the first 100 cases from TRAcking Cancer Evolution through therapy (Rx) 
(TRACERx) shown in Table 4.16 (Jamal-Hanjani et al.,2017). 
 
 
The same analysis as shown in Table 4.15 was repeated for the NF1 variants, with the 
exception any cases with germline variants, were classified as 50% expected frequency 
shown in Table 4.17. All five germline variants fell within 10% of the expected frequency.  
After removing the germline variant from our cohort of NF1 patients we were left with 20 
NF1 somatic variants, of this 80% (16/20) proved to be low level heterogenic, therefor just 
expressed in sub-clonal populations of the tumour analysed. Of the remaining somatic NF1 
variants 20% (4/20) were within ±30%, with only NF1-180 above this threshold, shown in 
Table 4.17. The three potential pseudogene variants were just below the -30% threshold, 
they were however within -40% of the expected AF. NF1 has also been reported to be sub-
clonal in the analysis of the first 100 lung cancer patients in the TRACERx study. The study 
reported 50% of NF1 variants were described as sub-clonal. When looking at the individual 
subtypes TRACERx reported 2/2 (100%) of the NF1 variants in the SQCC population were 
sub-clonal, whereas 3/8 (38%) of the ADC cases were sub-clonal (Jamal-Hanjani et al., 
2017). 
 
Table 4.16. Percentage of patients with subcolonal MAPK driver variants in 
the first 100 patients of TRACERx in relation to this study (NF1 in NSCLC) 
Gene 
TRACERx (% of sub-
clonal cases) 
This study (% of sub-
clonal cases ) 
KRAS 33 21 
EGFR 29 20 















  <30% >30% 
NF1-115  50 17.5 32.5 4.21 Heterogenic 
NF1-120* 30 10.5 19.5 9.55 Heterogenic 
NF1-146** 90 35 65 48.05 Ubiquitous 
NF1-147** 60 35 65 58.98 Ubiquitous 
NF1-150 60 21 39 6.65 Heterogenic 
NF1-163 30 10.5 19.5 3.03 Heterogenic 
NF1-163** 30 35 65 44.26 Ubiquitous 
NF1-168 50 17.5 32.5 11.35 Heterogenic 
NF1-168* 50 17.5 32.5 14.65 Heterogenic 
NF1-170 40 14 26 5.70 Heterogenic 
NF1-178** 30 35 65 53.33 Ubiquitous 
NF1-180 60 21 39 52.95 Ubiquitous 
NF1-201 70 24.5 45.5 9.00 Heterogenic 
NF1-205 10 3.5 6.5 4.07 Ubiquitous 
NF1-210 50 17.5 32.5 4.68 Heterogenic 
NF1-217 60 21 39 13.01 Heterogenic 
NF1-217 60 21 39 8.92 Heterogenic 
NF1-220* 40 14 26 13.07 Heterogenic 
NF1-225** 70 35 65 58.72 Ubiquitous 
NF1-227 50 17.5 32.5 4.53 Heterogenic 
NF1-233 70 24.5 45.5 35.57 Ubiquitous 
NF1-233 70 24.5 45.5 10.5 Heterogenic 
NF1-233 70 24.5 45.5 29.83 Ubiquitous 
NF1-238 80 28 52 7.21 Heterogenic 
NF1-238 80 28 52 6.23 Heterogenic 
Green sample ID indicates the observed AF was within ±30% of the expected heterozygote AF. 
Blue sample ID indicates the variant was below -30% of the expected. Red indicated the variant 
AF was greater than +30% of the expected. Black represents variants below the -30% expected. 
Samples were classified as heterogenic if the variant was expressed <30% of expected, as all 





Next we investigated possible relationships between these oncogenic variants observed in 
BRAF, EGFR, and KRAS and the potential loss of function variants in NF1. The oncoprint 
shown in Figure 4.4 illustrates variants in each case. Mutual exclusivity was observed for 
all oncogenic mutations in BRAF, EGFR, and KRAS. The same relationship was observed 
with BRAF and NF1. For the remaining we calculated the odds ratio to determine 
tendencies of co-occurrence or mutual exclusivity. The odds ratio was calculated as 
described in 2.2.6. NF1 and KRAS showed a strong tendency towards mutual exclusivity 
with an odds ratio of 0.756, whilst NF1 and EGFR showed a tendency of co-occurrence with 
a ratio of 2.23. 
 
 






4.5.8 PAN-Lung Cancer TGCA Analysis 
Our initial identification of 25 NF1 variants in 20 samples was encouraging.  However, many 
of the in silico prediction tools as described in section 2.2.5.3 for the NF1  missense variants 
resulted in an outcome of being likely begin or unknown significance in relation to loss of 
NF1 function. As only the GAP domain and SEC-PH domain have had their crystal structure 
resolved, it was not possible to interpret functional effects of missense variants further 
using in silico tools. Our initial data demonstrated 5 NF1 null variants in 4 cases (NF1-168, 
NF1-180, NF1-217, and NF1-233), shown in Table 4.12, which are highlighted in Figure 4.5 
below. After taking into consideration the sub-clonal variants which are observed at low 
AF, only NF1-180 and NF1-233 appeared to be expressed clonally, demonstrated by their 
high AF in relation to tumour content, shown in Table 4.17. However, only NF1-233 would 
result in a truncation upstream of NF1s GAP domain. de Bruin et al. (2014) demonstrated 
that transfection of just NF1s GAP domain was enough to rescue sensitivity to erlotinib 
through deactivation of KRAS in NF1 knock down models; therefore, it is not possible to 
predict the functional relevance of null variants downstream of the GAP domain. Out of all 
the cases with unknown significance variants only NF1-225 was clonal. 
With only one NF1 null variant clonally expressed case upstream of the GAP domain case 
NF1-233) in our study, we decided to investigate data from the PAN-Lung cancer trial which 
is accessible via The Cancer Genome Atlas. 979 samples (ADC = 498, SQCC = 481) had 
genetic and transcriptional data which could be accessed. Of the 979 patients 11% 
(111/979) displayed NF1 variants, of which 59 were null variants resulting in NF1 
truncation. All NF1 variants were analysed as described in section 4.5.5 to predict potential 
loss of function, with the exception that only null variants downstream of the GAP domain 
were classed as high probability loss of NF1 function, as were 3 cases with homozygote 
NF1 deletions. By only classing null variants downstream of NF1s GAP domain as high 
probability will ensure heterozygote loss of this active domain which negatively regulates 
KRAS. We also investigated RASA1 variants which have been shown to increase both MAPK 
and PI3K pathway activity when co-occurring with NF1 variants in cell based models 









Figure 4.5. Lollipop illustration of NF1 variants a) 5 null variants in this studies cohort of 
patients. NF1-233 and NF1-217 are the only 2 cases to have a null variant downstream of the 
GAP domain. Only NF1-233 and NF1-180 are clonal and expressed ubiquitously throughout the 
tumour b) 59 null variants from Pan-Lung cancers TGCA data. 17 of which are downstream of 
the GAP domain and did not co-occur with RASA1 variants. 16 of these null variants had a 
sequencing AF of ≥ 0.20. There were also 3 homozygote NF1 deletions which were included in 
the NF1 high probability loss of function group.  Whilst the lollipop plot shows more than 17 NF1 
variants downstream of the GAP domain, the NF1 null variants  that were not counted from the 
17 co-occur with RASA1 variants. 
 
The total frequency of cases with NF1 null variants from this study was 5% (4/86) compared 
with 6% (59/979) from the Pan-Lung study. Of the 59 NF1 null variants from the Pan-Lung 
study 17 were downstream of the of the NF1s GAP domain and did not co-occur with 
RASA1 variants. In total we had 10 cases with co-occurring NF1 and RASA1 variants which 
were ≥ 0.20 AF based on the PAN-Lung sequencing data. 
We then grouped the Pan-Lung TGCA cases based on genotype, in addition to how we 
divided the MAPK oncogenic variants (EGFR, BRAF, KRAS) described in section 4.5.1, we 
also included PIC3CA and PTEN cases shown in Table 4.18. Furthermore, we examined 
RASA1 which is another member of the GTPase family of proteins. Only 2 cases from the 
Pan-Lung dataset displayed AKT E17K variants and one of these also had a PIK3CA E542K 
substitution, therefore we did not create a AKT group. Of the 111 cases with NF1 variants, 
6 also displayed co-occurring KRAS variants, and 2 displayed co-occurring EGFR variants, 
these were included in the EGFR and KRAS groups. 13 cases demonstrated co-occurrence 















Unlike TRACERx which used multi-region sampling to generate intratumor heterogeneity 
status, our study and the data generated in the TGCA cohort only used single sampling, 
therefore the heterogeneity % is only based on the section of the tumour analysed in this 
study. For the intention of this study this will be utilised in the next chapter to exclude 
cases with low heterogeneity, as these will affect the gene expression signatures, it is not 
respective of overall tumour heterogeneity. The pathology reports of Pan-Lung TGCA data 
are unavailable for every sample, but their pathology criteria was inclusion of only samples 
with >60% tumour content. In table 4.18 below we have excluded samples with < 0.2 AF 
based on the sequencing data. Based on 60% tumour content variants ≥ 0.20 AF would 
translate to the variants being expressed in a minimum of 66% of the region sampled, using 




Table 4.18. Oncogenic MAPK, PIC3CA,  NF1, and RASA1 variants in the Pan-Lung cohort 
of patients   
 
Gene 
No of cases 
Number of ADC / 
SQCC 
Number of cases 
with ≥ 0.20 AF 
KRAS (G12, G13,and Q61) (152, 10, 2) 163 / 4 136 
EGFR (L858R, exon 19 indels) (22, 35) 55 / 2 33 
BRAF (V600E, G469, G466, G464) (9, 9, 8, 2) 23 / 5 21 
NF1 and RASA1 13 3 / 10 10 
NF1 H (NF1 null variants 
upstream of the GAP domain) 
20 10 /10 19 
NF1 M (Unknown significance) 52 30 / 22 30 
NF1 L (likely benign) 18 7 / 11 12 
RASA1 H (RASA1 null variants) 26 8 / 18 18 
RASA1 M(Unknown significance) 3 0 / 3 1 
RASA1 L (likely benign) 2 0 / 2 2 
MAPK PI3K negative 387 185 / 202 NA 
PIK3CA (E545K, E542K, H1047R, 
H1047L) 
(17, 17, 3, 0) 7 / 31 26 
PIK3CA (amplification) 153 5 / 148 NA 
PTEN (homozygote deletion) 16 2 / 14 NA 
 Total 979  Total 864 
All PIK3CA cases displaying both amplification and a oncogenic variant were placed in the PIK3CA 
(E545K, E542K, H1047R, H1047L) group. The MAPK PIK3CA negative group is only negative for the 
variants displayed in this table. For NF1 and RASA1 (H) represents high probability of loss of 
function based on in silico analysis, (M) represents unknown significance, and (L) represents 
potentially benign. The number of cases with ≥ 20AF highlighted based on sequencing frequency 




4.6 NF1 Copy Number Variation 
All 86 samples were then subjected to NF1 copy number analysis using the protocol 
described in section 2.2.8.1. Any samples with ≤20% tumour content (n = 8) were macro 
dissected prior to DNA extraction. All samples were run in duplicate technical replicates 
and the mean used for annotation. Three independent batches were run to analyse all 
samples, each of which included, a NTC, and 1, 2, and 3 NF1 copy number controls with 30 
ng of starting material. All NTC had the expected 0 copy number change. The controls for 
1 and 2 NF1 copy number were calculated as expected, with a mean copy number of 0.99, 
range 0.038 and 1.98, range 0.14 respectively across the 6 intra batch replicates. The 3 
copy number control did demonstrate more variance, with an intra batch mean of 3.15 
and range of 0.26 across the 6 replicates.  The greatest variance observed in the validation 
set reported in section 3.5 was 0.21 for both intra and inter replicates, again seen in the 3 
copy number control. 
Starting amounts of DNA ranged from 1.6 ng to 260 ng, quantified by the Qubit and 0.2 ng 
to 136 ng by qPCR. 88% (n = 76) of the samples demonstrated a SD of <0.1 difference 
between technical replicates, representing <0.15 copy number change. 7 % (n = 6) of the 
samples demonstrated a SD >0.149, which represents a >0.21 copy number difference. 
These cases had differences between technical replicates ranging from 0.23 to 0.37 copies. 
4 of the 6 samples with a poor SD >0.149 all had low starting material of 0.4 ng to 0.7 ng 
based on qPCR, which equates to 121 to 212 functional haploid copies. NF1 copies across 
all cases ranged from 0.87 to 3.3 copies without factoring in the tumour content. The full 





















NF1-107 1.91 NF1-151 2.06 NF1-174 1.86 NF1-214 0.87 
NF1-115 2.23 NF1-152 1.91 NF1-175 1.60 NF1-215 1.63 
NF1-117 1.77 NF1-154 2.15 NF1-176 1.73 NF1-216 1.42 
NF1-119 1.92 NF1-155 1.93 NF1-177 1.51 NF1-217 1.95 
NF1-120 1.51 NF1-156 1.50 NF1-178 1.90 NF1-218 1.87 
NF1-122 3.35 NF1-157 1.72 NF1-179 2.00 NF1-220 1.50 
NF1-126 2.64 NF1-158 2.51 NF1-180 1.84 NF1-221 1.37 
NF1-130 2.01 NF1-159 1.54 NF1-181 1.55 NF1-222 1.28 
NF1-132 1.76 NF1-160 1.75 NF1-182 2.09 NF1-223 1.21 
NF1-134 1.85 NF1-161 1.99 NF1-183 2.10 NF1-224 1.32 
NF1-136 2.27 NF1-162 2.16 NF1-184 1.84 NF1-225 1.63 
NF1-138 1.69 NF1-163 1.95 NF1-185 2.09 NF1-227 1.32 
NF1-139 1.69 NF1-164 2.31 NF1-201 1.98 NF1-231 1.07 
NF1-140 1.99 NF1-165 2.16 NF1-203 1.30 NF1-232 1.25 
NF1-141 1.29 NF1-166 2.07 NF1-204 0.99 NF1-233 1.57 
NF1-142 2.18 NF1-167 1.75 NF1-205 0.90 NF1-234 2.13 
NF1-144 1.22 NF1-168 2.00 NF1-206 1.53 NF1-237 2.37 
NF1-145 1.76 NF1-169 1.67 NF1-207 1.15 NF1-238 1.60 
NF1-146 1.49 NF1-170 1.88 NF1-210 1.53 NF1-239 1.33 
NF1-147 2.61 NF1-171 1.94 NF1-211 1.19 NF1-240 1.51 
NF1-148 2.19 NF1-172 1.80 NF1-212 2.29   
NF1-150 1.66 NF1-173 1.86 NF1-213 1.35   
NF1 copy number analysis. Not corrected for tumour content. Sample IDs shown in red were 
macro dissected prior to analysis. Four cases with no visible tumour content highlighted in 




Initial analysis showed 3 out of 4 of the samples with no visible tumour content (NF1-203, 
NF1-204, and NF1-232) showed copy number loss. Initially we investigated the clusters and 
thresholds to determine possible errors which may have occurred during analysis. 
However, all clusters were clearly defined, NF1-203 showed the greatest interference from 
rain (droplets which appear to fall from the positive cluster back to the negative) as shown 
in Figure 4.6. Adjusting the threshold had little effect on the result of this sample, 





Figure 4.6. 1D plot of ddPCR analysis. A) FAM florescent amplitude for NF1 probes, positive droplets 
shown in blue, negative droplets show in black, NTC. B) HEX florescent amplitude for PRR30 probes. 
Positive droplets shown in green, negative droplets show in black. Wells B01-02, 2 copy number 
control, B06-07 NF1-203, C11-12 NF1-204, and H11-12 NTC. 
 
We then investigated the starting amount of DNA to determine any correlations between 
this and copy number change. The three samples with no tumour content which should 
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have a 2 copy number ratio all had <1.6 ng of starting material. We know from the 
validation data and the controls 30 ng of 100% functional DNA produces accurate 
reproducible results. We also demonstrated reproducibility with a low quality FFPE sample 
with a 7 ng of functional starting material. To investigate this, cases were split based on 
qPCR amount of starting material using 5 independent threshold groups with high and low 
arms; <30> ng, <20> ng, <10> ng, <5> ng, and <2.5> ng. Within each one of these groups 
we compared high and low starting material and NF1 copy number using an independent 
t-test. All five groups displayed significant differences in NF1 copy number in relation to 
high and low starting material (p < 0.04) as shown in Table 4.20. A decrease in NF1 copy 
number mean was observed in relation to reduced starting material. 
 











CNV <30 ng 69 0.449 1.72 
0.038 
CNV >30 ng 17 0.170 1.95 
CNV <20 ng 53 0.454 1.67 
0.009 
CNV >20 ng 33 0.308 1.91 
CNV <10 ng 38 0.490 1.61 
0.002 
CNV >10 ng 48 0.309 1.88 
CNV <5 ng 22 0.370 1.44 
<0.0001 
CNV >5 ng 63 0.372 1.88 
CNV <2.5 ng 11 0.333 1.28 
<0.0001 
CNV >2.5 ng 74 0.379 1.82 
 
To determine if the decreasing trend was significant, we performed an ANOVA across the 
high and low arms of each threshold group. No significant difference (p = 0.664) was 
observed in NF1 copy number across the high arms (>30, 20, 10, 5, and 2.5 ng). A difference 
in NF1 copy number was observed between the low arms (p = 0.007). A Tukey HSD post 
hoc analysis demonstrated no significant difference between the <30 ng group and <20 
and <10 ng (p > 0.796). However, the <5 ng and <2.5 ng group did show a significant 
difference (p = 0.39 and p = 0.021) respectively, shown in Figure 4.7 . This does support 
132 
 
the observation that reduced starting material does have an effect on copy number 
analysis using this method. As <30 ng to <5 ng groups formed a homogeneous subset we 
define 5 ng starting material as a lower limit for analysis. A final Independent t-Test 
between the high and low arms using 30 ng as the threshold demonstrated no significance 
(p = 0.411) with all <5 ng samples removed.  
 
Figure 4.7. Comparison of starting material and NF1 copy number analysis. Whiskers represent 
high and low. The NF1 copy number data was analysed using five different thresholds (30 to 2.5 
ng) dividing the copy number data into high and low arms. Red represents the high arms. Black 
represents the low arms. Corresponding threshold groups all displayed significant differences in 
CNA between the high and low arms as determined by independent t-tests (p < 0.04). ANOVA 
demonstrated no significant difference in CNV between the high arms of the various threshold 
groups (p = 0.664). A significant different was observed between the low arms (p = 0.007). Tukey 
HSD post hoc analysis determined a significant difference between <30 ng and <5 ng low arms 





Employing the 5 ng cut off limit for starting material excluded 22 cases from NF1 copy 
number analysis. 20 of the cases were from the ReSoLuCENT cohort.  Lower yield was to 
be expected of these samples as all were smaller in physical size compared to the surgical 
specimens. Included in the 22 excluded cases were the three with no visible tumour 
content, all of which had <1.6 ng starting material. With 64 samples remaining we 
calculated the actual copy number changes based on tumour content. The following 
calculation was used and is based on the assumptions that pathology tumour content is 
correct and all non-tumour tissue is diploid. 
 
(CN x 100) – (2 x NT) 
= Tumour copy number 
TC 
 
Where CN is the raw copy number, NT is percentage of normal tissue, TC is tumour content 
percentage. 
As the highest observed variance between replicates in the clinical samples remaining was 
0.34, we implemented this as a threshold from the expected 2 copy number (<1.66 copy 
number loss, >2.34 copy number gain). 45% of the samples (n = 29) were calculated as 
diploid, 39% (n = 25) showed some degree of NF1 copy number loss, and 16% (n = 10) with 
copy number gain. Campbell and colleagues work demonstrated 47% of their cohort to be 





4.6.1 NF1 Copy Number Change and Clinical Information 
To investigate any correlations in NF1 copy number between subtype, gender, and stage 
we used a 3 way ANOVA. The two remaining non-specified subtypes were removed from 
analysis. Stage 1 and 2 were grouped together and stage 3 and 4 patients to form stage 1-
2, and stage 3-4 groups. No significant 3 way interaction was observed between gender, 
subtype, or stage (p = 226). Further analysis using the 3 way ANOVA demonstrated no 
further significance when comparing all possible two way interaction (p ≥ 0.571). Plots for 
these independent groups are shown in Figure 4.8, in addition to a primary vs metastatic 










Figure 4.8. NF1 copy number change NSCLC sub-type, gender, primary or metastatic sites. 
Whiskers represent 10 to 90 percentile. A) Adenocarcinoma and Squamous cell carcinoma. B) 





To briefly investigate NF1 copy number change, we analysed the 14 germline cases we 
sequenced in the samples previously in this chapter. Starting concentrations as assessed 
using the Qubit ranged from (13.8 to 150 ng). All of the cases demonstrated a copy number 
ratio between 1.88 and 2.01 as shown in Figure 4.9. 
 
 
Figure 4.9. ddPCR copy number analysis of NF1 in the paired germline cases. Replicates merged 







We successfully recruited 86 out of our target of 100 patients from one site in less than 
three years. This was a high recruitment rate when compared to larger multisite studies 
such as ReSoLuCENT. We demonstrated that qPCR, for quantification of DNA derived from 
FFPET, is an essential requirement to get the most from the tissue / DNA available. Using 
this, in combination with the NGS protocol described in section 2.1.4, provides a robust 
platform for analysis of highly degraded DNA. We demonstrated that this technology is 
highly efficient at identifying clinically important genetic information, even when only 
expressed at low allelic fractions. Finally, we demonstrated that ddPCR has great potential 
for future applications, including copy number analysis. However, before this can be used 
in a clinical setting further validation work to fully define its limitations is required. 
FFPET is challenging to work with for genetic analysis, but remains the primary source of 
material available for the identification of genetic variations in solid tumours. 23 of our 
samples did not match their reported size in histology reports and proved to have 
insufficient tissue available for analysis. The samples which were deemed sufficient 
demonstrated a high degree of variability in quality of functional DNA recovered. This 
variability is largely dependent on how anoxic the excised tissue has become in the 
timeframe between patient surgery and formalin fixation, and the actual fixation process 
itself. Findings in this study demonstrate this variability is not site or laboratory dependent; 
it fluctuates on a case by case basis. Our cohort of surgical samples (n = 59) were excised 
and fixed in the same hospital and laboratory. These samples demonstrated DIN scores 
ranging from 1.9 to 6.7 and QFI scores of 3.3 to 98%. We observed large fluctuations in 
DNA yield and quality, even in samples excised and processed within a 24 hours of each 
other. NF1-158 and NF1-185, both were similar sized specimens, NF1-158 had a DNA 
concentration of 8.4 ng/µl, DIN score of 2.6, and QFI of 3.3%, whilst NF1-185 had a 
concentration of 51.5 ng/µl, DIN score of 5.6, and QFI of 51.6%. These differences are 
sufficient to determine whether or not a reliable genetic result can be obtained. 
However, over the last decade with the exponential growth of technologies such as NGS, 
genetic methods are being optimised to enable confident analysis of DNA derived from 
FFPET. Here we initially demonstrated the differences in quantification methods of FFPET 
derived DNA. Whilst the three methods used in this study all display linear relationships to 
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each other they are actually measuring different nucleic acid states. This leads to the 
NanoDrop and Qubit overestimating the actual amount of functional DNA, which can have 
significant consequences on downstream genetic analysis. Similar findings were reported 
by Sah and colleagues (Sah et al., 2013). qPCR quantification is not perfect, it is largely 
based on the assumption that the genome is degraded uniformly in relation to the small 
locus you are actually quantifying. However, for NGS and ddPCR we have shown it to be 
the most reliable method of quantification to enable successful downstream analysis. 
Another benefit of qPCR analysis is its ability to determine the actual level of degradation 
in relationship to actual dsDNA as determined by the Qubit. We demonstrated the QFI 
score has a linear relationship to the DIN score; however, as with DNA quantification these 
are measuring different aspects in order to determine the level of degradation. 
All samples which had adequate starting material as determined by both Qubit and qPCR 
but still failed NGS library preparation, had low QFI scores of ≤10.1%. This affects the 
underlying kinetics of library preparation as over 89% of the DNA is actually non-functional 
and has an inhibitory effect. Whether this is due to enzyme saturation /exhaustion in the 
pre-PCR steps, or just overloading the PCR reaction remains to be determined.  
Using the methods describe in section 2.2.4 we were able to obtain quality sequence for 
86 of the 92 cases which were not rejected at the QC steps. We also demonstrated that 
using these methods it is possible to successfully hybridise and enrich for target regions 
with >170 ng of pre-hybridisation PCR material. This enabled the synthesis of sequence 
from 29 of the samples which would have been rejected following the manufactures’ 
protocol. Only one sample did not meet the minimum sequence depth of 300 X required 
for calling variants at 3% AF. 
No oncogenic variants were identified in the four samples with no reported tumour 
content in the pathology reports. Overall a total of 25 oncogenic mutations known to 
activate the MAPK pathway were identified: 7 EGFR oncogenic variants, 4 of which were 
previously reported by orthogonal methods of detection in the patients’ notes. The 
remaining 3 cases were not tested for EGFR variants elsewhere. Included in these was an 
EGFR exon 19 deletion, at just below 3% AF in a highly degraded sample (DIN 1.9 and QFI 
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14.4%). This variant would have not been identified it we had relied on the bioinformatics 
pipeline alone to filter variants based on our criteria of ≥3% AF and ≥ 15 supporting reads. 
The overall percentage of identified EGFR variants in our cohort 8% (7/86) was below what 
is generally reported for overall NSCLC prevalence (14%) in the European population. 
However, just analysing the ADC population we observed 15% (7/48) EGFR positive cases 
which is slightly below meta-analysis reported frequency (17.5 to 21.8%) (Zhang et al., 
2016b). Our data also agreed with observations that these variants are more frequently 
observed in females and non-smokers (Zhang et al., 2016b).  
17% (15/86) of our total cohort displayed KRAS (G12) activating mutations which is the 
same frequency as reported by Pan-Lung TGCA data 17% (187/1144). 23% (11/48) of our 
KRAS G12 variants were observed in ADC cases and 13% (4/30) in SQCC cases, which differs 
to the previously published report of 28% (187/660) and <1% (2/484) respectively in the 
Pan-Lung study (Campbell et al., 2016, Boch et al., 2013). 90% of patients recruited to our 
study with KRAS mutations were current or ex-smokers which is reflective of these variants 
been more prevalent in smokers (Paik et al., 2012). No KRAS G13 or Q61 variants were 
identified in our study, Campbell et al. (2016) reported <2% G13 and <1% Q61 variants, so 
this difference could be due to the small population used in this study. 
BRAF variants (G464, G466, G469) were observed in 3% (3/86) of our total cohort which is 
slightly above the 2% (22/1144) level that the Pan-Lung study reported, just counting these 
specific variants Campbell et al. (2016). Considering just the ADC BRAF cases our data 1% 
(1/86) is just below the reported frequency of 2% (18/660) in the Pan-Lung study. Of the 
remaining BRAF variants observed in the SQCC cases we observed 2% (2/86) frequency 
which is above that of the Pan-Lung study which reported <1% (4/484) (Campbell et al., 
2016).  
Whilst our results looking at the frequency of the MAPK oncogenic variants was similar to 
that observed in the Pan-Lung study, we did see an increase of BRAF and KRAS variants in 
the SQCC population. One potential reason could be the small cohort of 86 cases used in 
this study compared to the 1144 cases analysed in the Pan-Lung study. Excluding any 
potential sample mix up or errors in documentation, another potential reason for this 
discrepancy could be mixed histology. Adenosquamous carcinoma is the most common 
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mixed-histology lung cancer pattern and accounts for up to 3.4% of all NSCLC cases (Deng 
et al., 2013). Therefore, it is possible the two BRAF variants in our SQCC cases, which were 
both clonal, could potentially be due to mixed histology for NF1-148 and NF1-238. Mixed 
histology could also partially explain the increase in frequency of KRAS variants in our SQCC 
cases. Another potential cause for the KRAS variants observed in our SQCC population 
could be the increased sensitivity observed in our study. 3 of the KRAS variants were 
reported at low AF, these would not have been detected using our variant detection 
criteria when only sequencing to a depth of 100X, which is the mean depth observed in 
the Pan-Lung study (Campbell et al., 2016), compared to deep sequencing used in this 
study which had a mean of 1560X across the G12 genomic loci. 
Screening for NF1 potential loss of function variants, we identified 22 variants in 17 cases. 
We also identified 10 possible cases with potential pseudogene variants mapping back to 
NF1. Furthermore, 5 variants were identified in the promoter region. Of the potential 
pseudogenes variants two were of great interest, p.Tyr489Cys and p.Arg1241*. Both of 
these were reported as pathogenic in Neurofibromatosis patients (Laycock-van Spyk et al., 
2011, Upadhyaya et al., 2003). Based on our current data it is not possible to determine if 
these are NF1 variants or pseudogene in origin. This would require longer sequence reads 
to identify any up or downstream variants which match the pseudogene or functional NF1. 
As they are reported in the literature as pathogenic we classed them as high potentials for 
NF1 loss of function. The other 7 potential pseudogenes variants were intronic and would 
have no predicted effect on mRNA splicing, if they are actual NF1 variants. The final 
potential pseudogene variant was only reported at 3% AF in a sample with an expected 
20% AF based on tumour content and classed as likely benign. 
Five cases exhibited variants upstream of the transcription start site, within the promoter 
region. Whilst we did not sequence the matched blood samples to determine if these were 
somatic or germline line in nature, the low AF of NF1-148 and NF1-172 does suggest these 
are somatic, with the remaining being germline. These variants have the potential to 
downregulate or indeed upregulate NF1 expression. 
Of the remaining 22 NF1 variants 14 were novel with no previous reports in the literature 
or databases. We classified variants; high potential NF1 loss of function, unknown 
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significance, and likely benign based on in-silico analysis. 9 synonymous, intronic SNVs, or 
dinucleotide variants, which had no predicted effect on splicing, were classified as low. 
NF1-150 was the only case with a variant with the potential to effect splicing and was 
classified as unknown significance. Of the non-synonymous variants 2 were classified as 
likely benign and 5 unknown significance, based on analysis using 7 different predictive 
tools. Finally, we identified 5 null variants in 4 cases which were all classified as high 
potential. When we compared the frequency of null variants in our cohort 5% (5/86) with 
the cases from the Pan-Lung TGCA data 6% (59/979) we observed similar frequencies even 
with our relatively small cohort.  
Our cohort of NF1 variants in NSCLC was above 12% reported in the literature, 22% (n = 
19) cases displaying a total of 25 variants. However, variants reported in these studies only 
investigated the exonic regions ±2bp. Removing the intronic variants beyond ±2bp in our 
cohort resulted in 17% (n = 16) still displaying NF1 variants. To investigate this further we 
interrogated the Pan-Lung sequencing data (Campbell et al., 2016).  The mean sequencing 
depth of the variants identified in NF1 was 98 X, ranging from 16 to 542 X. 37% of the 137 
NF1 variants identified had less than 15 supporting reads which ranged from 4 to 91. Whilst 
our variant calling criteria was more stringent than Campbell and colleagues, our greater 
sequencing depth enabled more sensitivity at picking up low level variants. We tested this 
using Campbell’s 4 reads minimum to call variants and reducing our read depth to 100 X 
and adjusting the number of variant reads respectively. This resulted in 13% (n = 11) of 
cases displaying NF1 variants.  
We then had to consider the AF in relation to tumour content and its potential to null any 
effect on the MAPK pathway the variants could have. Cases with low AF and high tumour 
content suggest low level intra-tumour heterogeneity of the variant population. We could 
not select for this limited population when enriching for tumour content for downstream 
gene expression signature analysis. 20 (n = 4) of the NF1 variants have supporting AF that 
suggests they could be ubiquitously expressed throughout the tumour. The remaining 80% 
(n = 16) were only found in a sub population of the tumour and represents intra-tumour 
heterogeneity. Of the ubiquitously expressed, only four matched variants which resulted 
in NF1 medium or above loss of function potential. This is lower than we anticipated, based 
on previous reports of inter tumour heterogeneity in NSCLC (de Bruin et al., 2014b). The 
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two potential pseudogene reads reported as pathogenic fell just below the ±30% 
threshold. This leaves a reduced potential NF1 loss population when considering the gene 
expression signatures. 
When we compared intra-tumour heterogeneity in the KRAS, EGFR, and BRAF positive 
cases against that of the first 100 samples to be analysed from the TRACERx study we 
observed similar degrees of correlation shown in Table 4.16. However, there was a 
significant difference in intra-tumour heterogeneity of the NF1 variants with TRACERx 
reporting 50% to be only observed in sub-colonal populations, in relation to on 80% 
reported in this study. It is important to note the reasons for investigating this and the 
method of doing so is different for both studies. TRACERx is tracking tumour evolution 
through genetic changes leading to intratumour heterogeneity, whereas this studies goal 
was to determine if the MAPK and NF1 variants were expressed throughout the section of 
the tumour analysed for potential downstream effects when comparing the gene 
expression signatures. Because of this, different methods of analysis were used; TRACERx 
used multi-region (2 – 8 regions) of sample collection from each tumour, whereas our 
study just used single region sampling. TRACERx, therefore has a more comprehensive 
view of the tumours mutational landscape as a whole. This explains why the clonal variants 
(KRAS, EGFR, and BRAF) between the studies are of similar frequency, however with more 
sub-clonal variants such as NF1 will experience more variability in single region sampling. 
 
NF1 Copy Number Analysis 
Our investigation of ddPCRs ability to measure NF1 copy number displayed issues. Whilst 
all the controls functioned as expected, three samples with no visible tumour content 
displayed unexpected NF1 copy number variation. Our previous validation work was based 
largely on none FFPET derived DNA and the lower limits of starting material were not 
assessed. We did not validate for the variance observed in quality and low yield of our 
cohort. 
Analysis suggested one potential cause of false positive NF1 copy number changes was low 
level starting material. When comparing the low starting material with NF1 copy number 
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a trend was observed. Using specific upper and lower threshold limits we determined a 
significant decline in copy number at 5 ng starting material as assessed by qPCR. Using this 
as a threshold excluded 22 cases, including the three with no visible tumour content. 
Whilst this unforeseen copy number loss in these three samples did give us reason to 
question the data, low starting material gave us a possible explanation. We therefore 
continued with copy number analysis of the remaining 64 cases.  
Taking tumour content into consideration and setting a threshold based on the assay 
variance, our data suggested 45% of our remaining cases were diploid, 39% displaying 
some level of copy number loss, and 16% with NF1 gain. Campbell reported 19% copy 
number loss and 33% gain. However, earlier work suggests the diploid prevalence is 93% 
and 73% in ADC and SQCC respectively, with low levels of copy number gain / loss 
(Hammerman et al., 2012, Collisson et al., 2014). Different methods are also a 
consideration, as total concordance is rarely observed between platforms. However, data 
from the previously mentioned genetic profiling studies did not correlate on NF1 copy 
number prevalence using the same Affymetrix Genome-Wide Human SNP Array 6.0. This 
could suggest NF1 copy number change is highly variable in NSCLC cases. Copy number 
increases are more commonly observed in oncogenes as they give the cell a distinct growth 
advantage. While copy number loss is more common in TSG as, this would give the cell a 
growth advantage. As NF1 is understood to be a TSG there would be no known advantage 
for the cancer with NF1 copy number increase. One potential reason for the NF1 copy 
number increase observed in NSCLC is that NF1 copy number increase could just be a 
passenger in close chromosomal proximity to a gene which would confer a growth 
advantage such as ERBB2. Campbell et al. (2016) data did show the amplification of ERBB2 
and NF1 co-occurred in 66% of the NF1 amplification cases, which supports this 
hypothesis. Both NF1 and ERBB2 are located on adjacent bands the q arm of chromosome 
17, suggesting the growth advantage could come from ERBB2 amplification and NF1 is just 
a passenger.  
Our analysis of the different clinical and demographic groups including; subtype, gender, 
and disease stage, demonstrated that neither of the groups had any influence over NF1 
copy number changes. ddPCR demonstrated great promise for analysis of copy number 
variation. The initial validation work was highly accurate and reproducible. The analysis of 
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the germline samples provided expected results. However, before this method can be 
transferred confidently to FFPET there are areas which require addressing. It requires the 
lower starting limit defining, and the effects on inhibition from non-functional DNA 
assessing. Another key area is the requirement of running at least 2 reference genes to 
compensate for potential reference copy number changes. Whilst other options are 
available for CNA including; low pass whole NGS approaches which have been shown to 
detect copy number changes in low AF cases (Silva et al., 2018), or more established 
methods, such as FISH. We explored ddPCR for its low cost and potential to reduce analysis 
and turnaround time over NGS and FISH.  
To conclude we have identified oncogenic variants and potential NF1 loss of function 
variants which correlate with previous reports. However, not all of these are expressed 
ubiquitously throughout the tumour. This has to be a major consideration in the next stage 
of analysis. Another consideration is NF1 loss in a subset of patients. This could also have 
influence over the MAPK mRNA gene expression signatures, which will be explored in the 
next chapter. Whilst mRNA expression and copy number changes are not always reflective 









To investigate the functional relevance of NF1 variants in NSCLC we required a method 
capable of measuring MAPK pathway activation in clinical FFPET samples. One option 
which has demonstrated promising results in degraded FFPET is the use of gene expression 
signatures. There have been several publications over the last decade reporting gene 
expression signatures relating to activation of the MAPK pathway. In 2010 two different 
signatures, a MEK signature and a RAS signature were reported, both demonstrating 
promising results in multiple cancer cell lines (Dry et al., 2010a, Loboda et al., 2010b). The 
RAS pathway signature comprised 147 genes, 105 up-regulated and 42 down-regulated in 
response to RAS activation. The MEK signature consisted of 18 genes which were up-
regulated during MAPK activation. Both signatures were developed from publically 
available microarray expression datasets. The signatures shared some target genes 
including; DUSP4, DUSP6, S100 calcium binding protein A6 (S100A6), serpin family B 
member 1 (SERPINB1), and zinc finger protein 106 (ZFP106). 
The RAS signature was suggested to be a more effective predictor to MEK inhibition and 
MAPK dependence than KRAS mutations. Work in cell lines demonstrated that the RAS 
signature score was directly related to MEK phosphorylation. It further demonstrated that 
the score decreased in KRAS positive cell lines when treated with a MEK inhibitor (Loboda 
et al., 2010b). The RAS signature was shown to have a high sensitivity (>90%) for detecting 
KRAS mutations in various cancer cell lines and lung cancer clinical samples. However, it 
lacked specificity (50%), with high signature scores also found in many cases with wildtype 
KRAS status. One explanation, which was not previously investigated, that could account 
for this low specificity is potential oncogenic upstream or downstream effectors of MAPK 
signalling. 
The second gene signature relating to the MAPK pathway was proposed by Dry et al. 
(2010). Work in breast, colon, melanoma, and lung cancer cell lines suggested the RAS 
signature could predict sensitivity to MEK inhibition. Dry and colleagues demonstrated 
knock down and transfection of MEK in these models correlated with decrease or increase 
in this signature respectively. Dry and colleagues suggested the signature was more 
consistent across cell lines at predicting sensitivity to selumetinib compared to measuring 
pERK or using BRAF and RAS status.  
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Whilst both signatures were promising for predicting MAPK activation, both Loboda’s and 
Dry’s data was generated via microarray analysis in cell models or fresh frozen tissue. 
Microarrays are widely established platforms for gene expression profiles, however they 
do require high quality RNA which cannot be guaranteed from FFPET (Wu Thomas et al., 
2009). Dry et al. (2010) investigated transferring the MEK signature to reverse 
transcription (RT) qPCR platform, but noted that not all genes were detectable in 10% of 
cases. While 18 genes is manageable using RT-qPCR, the analysis of Loboda and colleagues 
147 gene panel is more challenging. Another drawback of RT-qPCR is the inhibition of the 
enzymatic reaction by degraded nucleic acid. We have already demonstrated a large 
degree of variability of nucleic acid quality in our samples in Chapter 3. 
The Nanostring nCounter is an alternative to the two afore-mentioned platforms. This 
platform demonstrated high correlation to the Affymetrix GeneChip (R2 = 0.79) and RT-
QPCR (R2 = 0.95) when measuring gene expression (Geiss et al., 2008). The Nanostring 
nCounter has also proved to be more tolerant to FFPET samples than microarrays or RT-
qPCR methods, demonstrating a Pearson correlation of r = 0.94 between fresh tissue and 
FFPET samples (Reis et al., 2011). A further advantage is that the RAS and MEK signatures 
have been transferred to the Nanostring platform (Brant et al., 2017). Brant and colleagues 
undertook validation work to compare the NanoString vs. microarray data. A R2 coefficient 
between specific genes measured by the platforms ranged from 0.75 to 0.96, 
demonstrating a good degree of correlation. They also acknowledged the large degree of 
variability observed when working with FFPET and established the optimum starting 
amount of RNA to be 100 ng. The MEK signature was initially developed using multiple 
mixed cancer cell lines. Brant et al. (2017) went on to refine this signature, making it 
disease specific for NSCLC. This refinement condensed the 18 gene signature down to 6 
genes; DUSP4, DUSP6, pleckstrin homology like domain family A member 1 (PHLDA1), ETS 
variant gene 4 (ETV) 4, ETV5, and sprouty like homolog 2 (SPRY2). 
In this chapter we aim to test the ability of these three signatures to predict KRAS positive 
samples. We know NF1 is a negative regulator of KRAS, thereby NF1 loss and its potential 
effects on RAS signalling should be quantifiable using these signatures.  
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5.2 Gene Expression Analysis via the NanoString nCounter 
To determine the ability of the NanoString CodeSet to detect complementary mRNA 
targets we used a commercially sourced RNA human reference control. The control had a 
RNA integrity number (RIN) of 7.5 with both 18s and 28s ribosomal bands being clearly 
observed, Figure 5.2. The control was analysed on 3 independent occasions, using 100 ng 
of RNA. All Nanostring QC criteria described in section 2.2.9.3 were satisfied. Initial analysis 
of the RAW gene count highlighted multiple genes within the RAS signature which were 
below the mean +2SD of the internal negative controls. These included DRD4 and RFPL3S, 
which belong to the down-regulated arm of the RAS signature and CXCL5, and IL13RA2, 
which belong to the upregulated arm. All other genes within the MEK and RAS signatures 
were counted above the internal and external (RNA free water) negative controls. The 
external negative controls displayed > 99.9 % of all genes in the mRNA signatures to have 
lower counts than the mean +2SD of the internal negative controls. The positive control 
read counts ranged from 9 for IL13RA2, to 168740 for the endogenous reference 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (95% CI, 2184 to 5321). We plotted 
the RAW Log2 gene expression data of the 3 inter batch positive control replicates against 
each other. All three demonstrated R2 coefficients of > 0.994 demonstrating a high degree 
of inter batch reproducibility observed in Figure 5.1. 
 
 
Figure 5.1. RAW Log2 gene expression of the NanoString CodeSet. Three RNA replicates 
(Control-a/b/c) across three independent batches. Control-b and c plotted against control-a.  
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5.3 Reproducibility of the Gene expression Signatures in Degraded 
Samples 
Reproducibility in the positive controls is not representative of what was observed in the 
FFPET samples, as demonstrated earlier in the ddPCR data. To address this we utilised five 
FFPET controls, three had an EGFR, KRAS or BRAF oncogenic variant, one had a loss of 
function NF1 variant, and the final had no known MAPK activating variant. These cases 
were then set up in duplicate, in three independently prepared batches. The RIN score for 
these FFPET controls ranged from 1.2 to 1.4, the average fragment size for all of the 
controls was <200 bp, and the ribosomal bands were not visible demonstrating a high level 
of degradation, shown in Figure 5.2. 100 ng starting material was used for all replicates. 
 L A B C D E F  
 
Figure 5.2. Agilent’s TapeStation genomic tape pseudo-gel RNA image.L) 6000 kb RNA ladder. 
A) Total RNA human reference control with both 18s and 28s ribosomal bands being clearly 
observed. Yellow warning sign indicate the sample is out of range for quantification. B) EGFR 
positive FFPET RNA. C) KRAS positive FFPET RNA. D) BRAF positive FFPET RNA. E) NF1 positive 
RNA. F) No known MAPK variant. None of the 5 FFPET controls (B–F) display evidence of the 18s 





All Nanostring QC criteria described in section 2.2.9.3 were satisfied. Compared to the 
positive control used previously the RAW data demonstrated DRD4 was expressed 
consistently in the no MAPK and the BRAF samples, RFPL3S in the no MAPK sample, 
IL13RA2 in the EGFR sample, and CXCL5 expressed in all but the BRAF sample. This does 
suggest the RNA control is not expressing these genes and it is not an issue with the 
CodeSet. Each of the 6 total replicates for the five FFPET samples were normalised together 
using nSolver 4.0 as describe in section 2.2.9.3. Negative and positive controls were 
removed prior to normalisation. We utilised AstraZeneca’s in house normalisation tool to 
determine if any of the 21 housekeeping genes were unsuitable, shown in Figure 5.3. G6PD 




Figure 5.3. RAW Log2 expression for the 21Housekeeping genes across the three independent batches. 
Intra batch replicates we run in adjacent lanes for the cartridge. EGFR variant replicates (1, 2, 11, 12, 22, 
21, and 22), KRAS (3, 4, 13, 14, 23, and 24), No known MAPK variants (5, 6, 15, 16, 25, and 26), NF1 variant 






The normalised gene expression Log2 data based on the 20 remaining housekeeping genes 
was plotted against intra and inter batch technical replicates, Figure 5.4. As with the 
commercial control we observed a high level of reproducibility. Of the 5 independent 
samples run across three batches the average coefficient was R2 = 0.99 and ranged from 
0.977 to 0.996. This demonstrates the CodeSet was again highly reproducible even with 





Figure 5.4.Normalised Log2 gene expression of the NanoString CodeSet. Six FFPET RNA replicates 
run in three independent batches. Top left EGFR replicates. Top right, KRAS replicates. Middle, No 




We then calculated the RAS signature and the 2 MEK signatures for all six technical 
replicates across the inter and intra batch runs, shown in Table 5.1. All three different 
signatures demonstrated a high degree of reproducibility with the greatest range between 
replicates being observed in the MEK 6 and MEK 18 gene signature of 0.13 (SD = 0.03). The 
MEK 18 and MEK 6 signature demonstrated a higher score for all the three controls with 
known MAPK oncogenic variants in relation to the NF1 loss and no MAPK controls. KRAS 
had the highest score using the RAS signature with the no MAPK controls demonstrating 
the lowest score. Unlike the MEK signatures the BRAF signature score was almost half of 
that observed in the KRAS, with the EGFR signature score being barely indistinguishable 
from the MAPK negative score. 
 
Table 5.1. Reproducibility of the mRNA signatures across independent batches.  
 Batch 1 Batch 2 Batch 3   
MEK 18 R1 R2 R1 R2 R1 R2 Range SD 
EGFR + 9.00 8.91 8.96 8.97 8.96 8.94 0.09 0.03 
KRAS + 9.05 9.06 9.07 9.07 9.07 9.07 0.02 0.01 
BRAF + 8.98 8.98 8.99 9.04 8.91 9.01 0.13 0.04 
NF1 + 8.35 8.35 8.39 8.39 8.36 8.40 0.06 0.02 
MAPK - 7.90 7.89 7.86 7.88 7.96 7.92 0.10 0.03 
MEK 6         
EGFR + 9.17 9.12 9.15 9.14 9.18 9.11 0.06 0.03 
KRAS + 8.71 8.71 8.79 8.77 8.77 8.76 0.07 0.03 
BRAF + 8.58 8.65 8.64 8.66 8.61 8.68 0.07 0.04 
NF1 + 8.05 8.08 8.08 8.10 8.07 8.14 0.06 0.03 
MAPK - 7.68 7.61 7.61 7.56 7.69 7.63 0.13 0.05 
RAS         
EGFR + 0.11 0.11 0.12 0.12 0.13 0.11 0.02 0.01 
KRAS + 0.56 0.55 0.55 0.56 0.56 0.53 0.03 0.01 
BRAF + 0.24 0.25 0.24 0.24 0.22 0.23 0.02 0.01 
NF1 + 0.31 0.30 0.33 0.31 0.30 0.31 0.03 0.01 






5.4 Sample Analysis 
Two FFPET cases were returned to STH for further diagnostic analysis and were not 
accessible for this stage of analysis. The 84 remaining samples were all macro-dissected to 
enrich the tumour content. Three cases were below the recommended starting amount of 
100 ng, NF1-216 (86 ng), NF1-223 (68 ng), and NF1-240 (41 ng). The RIN score of our 
samples ranged from (1 to 2.5) with 85% of them being ≤1.5. No linear correlation was 
observed between the DIN and RIN scores with a R2 value of 0.076. The 84 samples were 
divided into 9 independent batches, each including a negative and positive control. These 
batches were hybridised, prepared, and had their reads counted on the NanoString digital 
analyser independently of each other. All the 9 independent RCC files generated by the 
digital analyser from the batches were normalised together in one experiment. During 
initial QC analysis all but 2 samples passed nSolver’s internal QC checks. NF1-211 and NF1-
223 displayed an mRNA content flag. We continued with analysis of these two samples as 
both still had >63% of the probes above the threshold. Analysis of the external negative 
controls displayed >99.9 % of all genes in the mRNA signatures to have less counts than 
the mean +2SD of the internal negative controls. The positive controls, as described earlier 
had low or extremely low counts for DRD4, RFPL3S, CXCL5, and IL13RA2. This trend was 
also observed in the majority of the samples. As these genes are spread evenly between 
the RAS up and down arms we did not exclude them from the RAS signature analysis. 
Plotting the RAW Log2 expression data from the batch independent positive controls 
against each other demonstrated all R2 coefficients to be >0.993 demonstrating a high level 
of reproducibility between the batches. Analysis of the 21 housekeeping genes again 
flagged G6PD as unsuitable for normalisation. The full housekeeping gene plot is shown in 




Figure 5.5. RAW Log2 expression for the 21 housekeeping genes across nine independent 





5.5 NF1 Gene Expression  
In the NanoString codeSet we designed three NF1 probes which in theory could 
differentiate between the two most common mRNA transcripts. The probe NF1-A and NF1-
B would detect all three transcripts (NM_001042492.2, NM_000267.3, and 
NM_001128147.2). NF1-C would only detect the transcript (NM_000267.3). We used an 
ANOVA to compare the differences in expression measured between the three different 
probes across all the samples. This revealed a significant difference in transcription 
measured between the three probes (p < 0.001). A Tukey HSD post hoc analysis 
demonstrated there was a significant difference between all the NF1 probes (p < 0.001), 
as shown in Figure 5.6. 
 
 
Figure 5.6. Expression of NF1 in 84 NSCLC cases. Whiskers represent 5–95 percentiles. NF1-A 
spans exon 7-8 and NF1-B spans exon 22-23 both probes detect the two most common NF1 
mRNA transcripts. NF1-C spans exon 30-32 and only identifies NF1 transcript 2 (NM_000267.3). 
An ANOVA followed by a Tukey HSD analysis demonstrated significant differences between 





We expected to see a lower expression of NF1 transcript 2 (NM_000267.3) targeted by 
NF1-C, as it is said to be predominately expressed in neurons (Hinman et al., 2014). 
However, the difference found between NF1-A and NF1-B was not anticipated. One 
potential cause for this being observed in all samples could be simply a difference in affinity 
of the capture probes to their mRNA targets. However, based on our data alone this is 
something we cannot investigate further. Another potential cause could be the 
transcription of a pseudogene. NF1P9 and NF1P10 have been reported by Emsembl as 
having the potential to be transcribed, and both contain exon 22-23 homologs as shown 
in Table 3.3. 
We compared the expression of the three probes on a sample-by-sample basis including 
the controls. Whilst not obvious in the grouped analysis shown in Figure 5.6, all samples 
showed greatest expression of NF1-B (exon 21-22) and lowest of NF1-C (exon 30-32), with 
NF1-A falling in the middle, Figure 5.7. We used NF1-A (all transcripts) to compare against 
the transcription of NF1-C which only detects NF1 transcript 2. By considering the 
differences in expression between them, it became apparent that NF1 transcript 2 is the 
most prevalently expressed. The fold change measured across all the samples 
demonstrated a mean increase from transcript 2 to transcript 1 of 0.44 fold. The total 
range of this across all the samples was 0.0 (100% transcript 2) to 1.0 (50% transcript 2). 
The four NSCLC samples with no visible tumour content as well as the commercially 
sourced standards also fell within this range. Figure 5.7 also highlighted the fact that the 
RNA controls had the lowest NF1 expression compared to the NSCLC samples. An 
independent T test demonstrated significant decrease (p < 0.001) in expression of all three 




Figure 5.7. Expression of NF1 in 84 NSCLC cases and the RNA controls. NF1-A & B detect NF1 
transcript 1 & 2. NF1-C detects transcript 2. The 9 lowest inverted peaks represent the controls. 
An Independent Student T test demonstrated all controls had reduced expression in all probes 
compared to the NSCLC samples (p = 0.001).  
 
 
5.5.1 NF1 Copy Number and NF1 mRNA Transcription 
When investigating the relationship between NF1 copy number and NF1 mRNA expression 
initial analysis demonstrated no clear linear relationship with a R2 coefficient of 0.064.  As 
there appeared to be a monotonic relationship, a Spearman correlation assessment was 
utilised. The correlation coefficient (rs) did demonstrate a slight positive correlation (rs = 




5.5.2 NF1 copy number and promoter variants 
To investigate the possibility that the variants observed within the promoter region could 
have an effect on NF1 transcription we looked at the expression of the samples and where 
they fell within the total percentile range. Only NF1-220 fell below the 5th percentile with 
all other cases with promoter variants being expressed at similar levels. This does suggest 
c.-468A>T could function as an inhibitor of NF1 transcription; however this is only 
circumstantial and cannot be confirmed using this dataset alone.  
 
Table 5.2. NF1 mutations upstream of the transcription start site.  
Sample 
ID 





NF1-132 rs17879128 c.-459A>C 9.49 50 -75 
NF1-148 rs922504932 c.-356C>T 8.94 10 -25 
NF1-155 rs886052790 c.-209C>A 9.3 25 -50 
NF1-172 N/A c.-93C>G 9.55 50 -75 




5.6 NF1 Copy Number Change and Clinical Information 
To investigate any correlation in NF1 transcription between subtype, gender, and stage we 
used a 3 way ANOVA. Stage 1 and 2 were grouped together and stage 3 and 4 patients to 
form stage 1-2, and stage 3-4 groups. A significant 3 way interaction was observed 
between gender, subtype, and stage (p = 0.014). Further analysis using a 2 way ANOVA 
demonstrated there was a statistically significant simple two-way interaction between 
stage and subtype (p = 0.018) for males. Males with ADC and stage 1 or 2 disease 




5.7 Are the MEK and RAS Gene Expression Signatures Predictive of BRAF 
and EGFR Variants? 
Whilst the RAS and MEK signatures have both been shown to be predictive of KRAS 
oncogenic drivers, it has yet to be established whether these signatures are predictive of 
EGFR or BRAF drivers (Dry et al., 2010a, Ahn et al., 2017, Brant et al., 2017, Loboda et al., 
2010a). Our gene expression signature reproducibility work suggested that the MEK 
signatures have the ability to predict EGFR and BRAF mutation status. The RAS signature 
demonstrated that the threshold between KRAS and the MAPK negative controls has 
distinct margins, but the threshold between EGFR and the MAPK negative controls were 
almost indistinguishable. 
To further investigate this, we divided our patients into EGFR positive, KRAS positive, BRAF 
positive, and MAPK negative groups. Comparing the signature scores across the groups 
would indicate if they could be predictive of not only KRAS, but also EGFR and BRAF 
variants. The grouped samples included BRAF (n = 3), EGFR (n = 7), KRAS (n = 15), and no 
known activating mutations (n = 44). The four samples which displayed both MAPK and 
NF1 variants were placed in the MAPK positive group. In addition, to determine the effect 
that low allelic fraction of variants have on the gene expression signature, we repeated the 
analysis but excluded oncogenic samples with <30% of the expected AF in relation to 
tumour content. This reduced the EGFR (n = 5) and the KRAS group (n = 10) in size. Three 
of the samples which displayed both MAPK and NF1 variants were in the excluded group. 
Initial analysis via boxplots determined we had one extreme outlier in the MEK 18 and 6 
signatures from the same sample within the MAPK negative group. NF1-126 demonstrated 
a MEK 18 signature score of 7.11 and a MEK 6 score of 6.21. As this violated an assumption 
for ANOVA analysis we replaced the low outliers with the second lowest score, 7.11 was 
replaced with 7.97 and 6.21 was replaced with 7.40. To confirm this had minimal effect on 
the results described in this chapter we repeated the analysis keeping the outlier. No 
changes to any of the overall significant differences or similarities based on the ANOVA 




5.7.1 EGFR, BRAF and KRAS Analysis via the MEK 18 Gene Expression Signature  
We analysed the MEK 18 signature score for all BRAF, EGFR, KRAS, and MAPK negative 
groups based on genotype alone with a one way ANOVA. A Levene’s test showed that 
homogeneity of variances was not assumed (p < 0.05). The Welsh ANOVA demonstrated 
significant differences between groups (p = 0.011). A post hoc Games-Howell test 
determined two significant differences. One between the MAPK negative and the KRAS 
groups (p < 0.001) and the other between the MAPK negative and EGFR groups (p = 0.47), 
shown in Figure 5.8A. 
The analysis was repeated excluding the samples with variants at low AF. A Levene’s test 
showed that homogeneity of variances was not assumed (p < 0.05). The Welsh ANOVA 
demonstrated significant differences between groups (p = 0.008).  A post hoc Games-
Howell test determined two significant differences. One between the MAPK negative and 
the KRAS groups (p < 0.001) and the final between the KRAS and EGFR group (p = 0.033) 
shown in Figure 5.8B. No significance was observed between MAPK negative and EGFR (p 
= 0.132) 
For both sets of analysis with and without low level variants using the MEK 18 signature 
demonstrated the KRAS cases to have an increased signature score over the MAPK 
negative. Removing the low AF variants did not correlate with the low signature score 
within the groups. The two EGFR variants excluded were the ones with the highest MEK 
18 signature score. This resulted in the significance displayed when including the low AF 
samples between MAPK negative and EGFR groups being lost. The five removed from the 
KRAS group did include the one with the lowest signature score, the rest were mid-level 
(9.25–9.54) signature scores. Both sets of analysis suggest the MEK 18 signature score is 
predictive of KRAS but not BRAF oncogenic variants. Whilst initially EGFR did show an 
increased score compared to the MAPK negative, removing the low AF variants resulted in 




5.7.2 EGFR, BRAF and KRAS Analysis via the MEK 6 Gene Expression Signature  
We analysed the MEK 6 signature for BRAF, EGFR, KRAS, and MAPK negative groups based 
on genotype alone using a one way ANOVA. A Levene’s test showed that homogeneity of 
variances was not assumed (p < 0.05). The Welch ANOVA demonstrated significant 
differences between the groups (p = 0.005). A post hoc Games-Howell test determined two 
significant differences. One between MAPK negative and the KRAS group (p < 0.001), 
shown in Figure 5.9A, and the second between the MAPK negative and the EGFR group (p 
= 0.001). 
The analysis was repeated excluding the samples with variants at low AF. A Levene’s test 
showed that homogeneity of variances was not assumed (p < 0.05). The Welch ANOVA 
demonstrated significant differences between the groups (p = 0.004). A post hoc Games-
Howell test determined two significant differences. One between MAPK negative and the 
KRAS group (p < 0.001), shown in Figure 5.9B, and the second between the MAPK negative 
and the EGFR group (p = 0.001). 
For both sets of analysis with and without low level variants using the MEK 6 signature 
demonstrated identical groupings. The MEK 6 signature showed an increased significance 
in predicting not only KRAS drivers but also EGFR drivers over the MEK 18 signature. Unlike 
the MEK 18 signature scores, three out of the four KRAS samples excluded due to low AF 
were the ones with the lowest signature scores. As with the MEK 18 signature the EGFR 









Figure 5.8. MEK 18 signature scores. A) Groups based on genotype alone. B) Groups bases on 
genotype with low allelic fraction samples excluded. Both A and B demonstrate the overall 








Figure 5.9. MEK 6 gene expression signature scores. A) Groups based on genotype alone. B) 
Groups bases on genotype with low allelic fraction samples excluded. Both A and B demonstrate 
identical grouping. The cases with KRAS and EGFR variants displaying significant differences to 




5.7.3 EGFR, BRAF, and KRAS Analysis via the RAS Gene Expression Signature   
We analysed the BRAF, EGFR, KRAS, and MAPK negative groups based on genotype alone 
using the RAS signature using a one way ANOVA. A Levene’s test showed that homogeneity 
of variances was assumed (p > 0.05). The ANOVA demonstrated significant differences 
between the groups (p = 0.012). A post hoc Tukey HSD test determined the one significant 
difference between MAPK negative and the KRAS group (p < 0.023), shown in Figure 5.10A. 
The analysis was repeated excluding the samples with variants at low AF. A Levene’s test 
showed that homogeneity of variances was not assumed (p < 0.05). The Welch ANOVA 
demonstrated significant differences between the groups (p = 0.012). A post hoc Games-
Howell test determined two significant differences, between MAPK negative and the KRAS 
group (p = 0.003), shown in Figure 5.10B, and the other between the KRAS and the EGFR 
group (p = 0.003).  
As with both the MEK 18 and MEK 6 signatures both sets of analysis with and without low 
level variants using the RAS signature demonstrated the KRAS group to have an increased 
score over the MAPK negative group. However, the analysis with the low AF variants 
excluded resulted in a significant difference also being observed between KRAS and EGFR. 
Unlike the MEK 18 and 6 signatures the EGFR variant excluded due to low AF was the one 
with the lowest signature score. KRAS lost the highest and the lowest signature scores 





Figure 5.10.RAS gene expression signature score. A) Groups based on genotype alone. B) 





5.8 Gene Expression Signatures, Sensitivity, and Specificity  
Our initial data demonstrated that all three signatures are predictive of KRAS positive cases 
in clinical samples. It also demonstrates that samples with low AF oncogenic variants have 
minimal influence over the signature scores. None of the signatures were able to predict 
BRAF status, however it has to be noted that the number of BRAF cases in our cohort was 
limited. Unlike the RAS and the MEK 18 signature the MEK 6 demonstrated the ability to 
be predictive of EGFR variants. 
To give further weight to these signature scores and their ability to predict MAPK activation 
we performed a ROC analysis. We initially investigated all the signatures potential to 
predict KRAS mutations in our patient samples. In addition our data suggested the MEK 
signatures have the potential to predict EGFR oncogenic variants. We therefore included 
them in the ROC analysis. The MAPK negative group included cases with no known MAPK 
oncogenic variants and no NF1 variants. The ROC analysis was performed excluding the 
oncogenic variants with low AF. 
All signatures provided an acceptable level of discrimination (AUC > 0.7) at predicting KRAS 
oncogenic variants, shown in Table 5.3. The MEK 18 and MEK 6 however provided an 
excellent level of discrimination (AUC > 0.8)  (Hosmer et al., 2013). The RAS signature 
displayed the lowest specificity which correlated with previous reports using the signature 
(Loboda et al., 2010a). Of the MEK signatures the MEK 6 provided an increased sensitivity 
and specificity over the MEK 18. In addition to this the MEK 6 signatures provided an 
excellent level of discrimination (AUC > 0.8) for detecting both EGFR and KRAS oncogenic 
variants in the cohort.  
Based on this we proceeded with both MEK signatures to determine NF1s functional 
relevance. Whilst both signatures have the ability to predict EGFR oncogenic variants we 




Table 5.3. Receiver operator characteristics for the three signatures 
Signature AUC 95% CI Cut off Sensitivity (%) 
Specificity 
(%) 
MEK 18 0.809 0.730 to 0.934 9.04 90 61 
MEK 18** 0.758 0.640 to 0.877 9.04 80 61 
      
MEK 6 0.855 0752. to 0.957 8.82 100 68 
MEK 6** 0.820 0.717 to 0.924 8.82 93 68 
      
RAS 0.799 0.674 to 0.923 0.125 90 50 




5.9 Functional Relevance of NF1 Variants in NSCLC 
To determine if the NF1 variants in our patient samples were functionally relevant and 
could upregulate MAPK activity we compared the cases with NF1 variants against the 
MAPK positive group and the MAPK negative group. This resulted in 44 MAPK negative 
samples for all signatures. As NF1 copy number demonstrated no correlation to NF1 gene 
expression we did not take copy number into consideration. The MEK 18 and 6 signatures 
had 10 KRAS positives as the MAPK positive group. Of the 19 samples with NF1 variants 
there were 9 which were predicted to be likely benign, 5 of which had high probability of 
NF1 loss of function, and 6 with unknown significance, shown in Table 5.4. The four cases 
which displayed co-occurrence MAPK drivers and NF1 variants were excluded from the 
NF1 group, leaving 15 NF1 cases. However, when cross-referenced with heterogeneity of 
the variants the number of high probability samples was reduced to 2 (NF1-180 and NF1-
233) and the unknown significance to one (NF1-225) which were ubiquitously expressed 




Table 5.4. NF1 variants and predicted clinical significance   
Sample ID cDNA Protein Heterogeneity Predicted Significance 
NF1-115 c.3118A>G p.Lys1040Glu Heterogenic Uncertain significance  




- Ubiquitous Likely benign 
NF1-147** c.3468C>T p.Asn1156Asn Ubiquitous Likely benign 
NF1-150 c.5269-14C>G - Heterogenic Uncertain significance 
NF1-163 c.-22G>C - Heterogenic Likely benign 
NF1-163** c.1897G>C p.Asp633His Ubiquitous High significance 
NF1-168 c.5785G>T p.Glu1929* Heterogenic High significance 
NF1-168* c.3721C>T p.Arg1241* Heterogenic Uncertain significance 
NF1-170 c.3825C>T p.Phe1275Phe Heterogenic Likely benign 
NF1-178** c.7595C>T p.Ala2532Val Ubiquitous Likely benign 
NF1-180 c.7245delA p.(Leu2416Tyrfs*2) Ubiquitous High significance 
NF1-201 c.435C>A p.Leu145Leu Heterogenic Likely benign 
NF1-205 c.4311G>A p.Arg1437Arg Ubiquitous Likely benign 
NF1-210 c.169G>T p.Gly57Cys Heterogenic Uncertain significance 
NF1-217 c.3634delG Val1212Serfs*3 Heterogenic High significance 
NF1-217 c.7339G>T p.Glu2447* Heterogenic High significance 
NF1-220* c.1018T>G p.Ser340Ala Heterogenic Likely benign 
NF1-225 c.6781C>T p.His2261Tyr Ubiquitous Uncertain significance 
NF1-227 c.6148-2A>T - Heterogenic Likely benign 
NF1-233 c.2178G>A p.Val726Val Heterogenic Likely benign 




p.(Ser892Argfs*14) Ubiquitous High significance 
NF1-238 c.3481C>G p.Leu1161Val Heterogenic Uncertain significance 
NF1-238 c.3249C>G p.Leu1083Leu Heterogenic Likely benign 
*Potential pseudogene origin. **Germline origin.  Samples shown in red are ubiquitously 
expressed throughout the tumour and of high or unknown significance of causing NF1 loss of 





5.9.1 Functional Relevance of NF1 using the MEK 18 Gene Expression Signatures 
To investigate the functional relevance of NF1 variants we compared samples grouped into 
MAPK positive, MAPK negative, and the 15 samples with NF1 variants using a one way 
ANOVA. As many of the NF1 variants were either, likely benign or low level heterogenetic, 
we expected to see no difference between the MAKP negative group and the NF1 group. 
A Levene’s test showed that homogeneity of variances was not assumed (p < 0.05). A 
Welch ANOVA demonstrated significant differences in the signature scores between the 
groups (p < 0.001). A post hoc Games-Howell test determined a significant increase in the 
MAKP positive group with a signature score mean of 9.32 log2 or 639 individual RNA counts 
compared to the MAPK negative group 8.91 (478 RNA counts) (p < 0.001). The same 
increase was also observed with the MAPK positive group and the NF1 loss group with a 
mean of 8.8 (452 RNA counts) (p < 0.001). As expected no significance was observed 
between the MAPK negative vs. NF1 loss groups (p = 0.464), shown in Figure 5.11. 
 
 
Figure 5.11. MEK 18 gene expression signature. Whiskers represent 5–95 percentiles. Cases 
with KRAS, oncogenic variants (MAPK +ve). Cases with no known MAPK activating variants 
(MAPK –ve). Cases which have a potential NF1 loss of function variant (NF1 loss). Significant 
differences observed between the MAPK positive group vs. MAPK negative (p < 0.001) and the 
NF1-loss group (p < 0.001). No significance was observed between the MAPK negative and the 
NF1 loss groups. 
Investigating the samples individually, one of the likely benign samples NF1-178 
(p.Ala2532Val) with a score of 9.18 (580 counts) was above the 9.02 (519 counts) cut off 
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limit (90% sensitivity and 62% specificity), shown in Figure 5.12. NF1-178 carried a germline 
NF1 variant which was ubiquitously expressed. The ubiquitously expressed high probability 
samples NF1-180 and NF1-233 had a score of 8.69 (413 counts) and 8.91 (481 counts) with 
the unknown significance case NF1-225 scoring 8.78 (440 counts). The previously reported 
pathogenic variants, NF1-168 and NF1-120, both of which were just below the –30% 
expected AF, were below the 9.02 cut off limit. 
 
 
Figure 5.12. MEK 18 gene expression signature of NF1 samples. Dotted line represents the 9.02 
cut off with a sensitivity of 90% and a specificity of 61%. Red ubiquitously expressed two high 
probability NF1 loss cases and one unknown significance NF1 variant. Black unknown significance 





5.9.2 Functional Relevance of NF1 using the MEK 6 Gene Expression Signature 
As with the MEK 18 signature we compared the grouped samples using a one way ANOVA. 
A Levene’s test showed that homogeneity of variances was not assumed (p < 0.05). A 
Welch ANOVA demonstrated significant differences in the signature scores between the 
groups (p < 0.001). A post hoc Games-Howell test determined a significant increase (p < 
0.001), in the MAPK positive group with a signature score mean of 9.24 or 605 counts 
compared to the vs. MAPK negative group 8.49 (360 counts). The same significant increase 
(p = 0.001) was also observed with the MAPK positive group compared to the NF1 loss 
groups with a mean score of 8.54 (372 counts). No significance was observed between the 
MAPK negative vs. NF1 loss groups (p = 0.942), shown in Figure 5.13. 
 
 
Figure 5.13. MEK 6 gene expression signature. Whiskers represent 5–95 percentiles. Cases with 
KRAS, oncogenic variants (MAPK +ve). Cases with no known MAPK activating variants (MAPK –
ve). Cases which have a potential NF1 loss of function variant (NF1 loss). Significant differences 
observed between the MAPK positive group vs. MAPK negative (p < 0.001) and the NF1-loss 






Utilising the MEK 6 signature, 4 samples were above the 8.82 (452 counts) cut off limit 
(100% sensitivity and 68% specificity). Two of the variants were in the likely benign group 
including, NF1-178 with a signature score of 8.86 (465 counts) also identified by the MEK 
18 signature and NF1-201 with 8.90 (478 counts). The MEK 6 signature also identified NF1-
115 and NF1-217 from the unknown significance group as just above the threshold. NF1-
217 was a high probability case with 2 null variants (Val1212Serfs*3 and p.Glu2447*), 
however, it was low level AF and calculated to be found in <30% of the tumour. NF1-115 
was also a low level AF sample calculated to be found in <20% of the tumour. As with the 
MEK 18 signature the ubiquitously expressed high probability samples NF1-180 and NF1-
233 had a score of 8.70 (416 counts) and 8.18 (290 counts) retrospectively, with the 
unknown significance NF1-225 having a score of 8.68 (396 counts). The previously reported 
pathogenic variants, NF1-168 and NF1-120 were also below the 8.82 cut off. 
 
Figure 5.14. MEK 6 gene expression signature of NF1 samples. Dotted line represents the 8.82 
cut off with a sensitivity of 100% and a specificity of 68%. Red ubiquitously expressed two high 
probability NF1 loss cases and one unknown significance NF1 variant. Black unknown significance 




5.9.3 MEK 6 Gene Expression Signature in the TGCA Pan-Lung Data Set: EGFR, 
BRAF and KRAS Analysis via the MEK 6 Gene Expression Signature  
We analysed the MEK 6 signature for BRAF, EGFR, KRAS, and MAPK PIK3CA negative groups 
using a one way ANOVA. A Levene’s test showed that homogeneity of variances was not 
assumed (p < 0.05). The Welch ANOVA demonstrated significant differences between the 
groups (p < 0.001). A post hoc Games-Howell test determined a significant increase in the 
MEK 6 signature in the KRAS, EGFR, and BRAF groups compared to the MAPK PIK3CA 
negative group Figure 5.15. The KRAS group demonstrated the largest increase (p < 0.001) 
with mean of 10.4 Log2 (1351 counts) compared to the 9.5 Log2 (724 counts) of the MAPK 
PIK3CA negative group demonstrating a 0.9 fold increase. 
 
 
Figure 5.15. Pan-Lung MAPK positive MEK 6 gene expression signature scores. Groups 
bases on genotype with low allelic fraction samples excluded.  MAPK PIK3CA negative (387), 





5.9.4 Pan-Lung Data Set: PI3K/AKT/mTOR pathway Analysis via the MEK 6 Gene 
Expression Signature  
Using the Pan-Lung dataset we investigated if the MAP 6 signature was influenced by the 
presence of PIK3CA oncogenic variants (E545K, E542K, H1047R, H1047L), PIK3CA 
amplification and PTEN homozygote loss, in relation to the MAPK PI3K negative group. A 
Levene’s test showed that homogeneity of variances was assumed (p > 0.05). A one way 
ANOVA demonstrated significant differences between the groups (p = 0.006). A post hoc 
Tukey HSD test determined significant reduction in the MEK 6 signature score between the 
PIK3CA oncogenic variants group (p = 0.041), and the PIK3CA amplification group (p = 
0.046) in relation to the MAPK PIK3CA negative group. No difference was observed 
between the MAPK PIK3CA negative group and the PTEN loss group. This and the results 
in section 5.10.1 suggest an increase in the MEK 6 signature is predictive of MAPK 




Figure 5.16. MEK 6 gene expression signature scores.  Groups bases on genotype with low 
allelic fraction samples excluded.  MAPK PIK3CA negative (n =387),PIK3CA +ve (E545K, E542K,  





5.9.5 Pan-Lung Data Set: MEK 6 Gene Expression Signature, Sensitivity and 
Specificity  
Analysis of the Pan-Lung data with the MEK 6 signature demonstrated a significant 
increase in the KRAS, EGFR, and BRAF groups in relation to the MAPK PIK3CA negative 
group. We next performed a ROC analysis to see if it correlated with the data from this 
study. The MEK 6 signatures provided an acceptable level of discrimination (AUC > 0.7) at 
predicting KRAS+EGFR+BRAF oncogenic variants as one group, shown in Table 5.5. The  
comparison of MAPK PIK3CA negative group and the KRAS group, the signature provided 
an excellent level of discrimination (AUC > 0.8) (Hosmer et al., 2013).  
The AUC demonstrated a high level of reproducibility for predicting KRAS oncogenic 
variants between our dataset (AUC 0.855) shown in Table 5.3 and the Pan-Lung data set 
(AUC 0.841) shown below. The MEK 6 signature also provided similar results at predicting 
KRAS and EGFR oncogenic variants; our study (AUC 0.820) compared to the Pan-Lung study 
(AUC of 0.797). The BRAF variants in our study did not show a significant difference to the 
MAPK negative group, but in the Pan-Lung dataset did demonstrate an acceptable level of 
discrimination with an AUC of 0.780 when comparing the KRAS, EGFR, and BRAF, cases 
with the MAPK PIK3CA negative group.  
 
Table 5.5. Receiver operator characteristics for the MEK 6 signatures 





KRAS 0.841 0.808 to 0.875 9.8 90 62 
KRAS EGFR 0.797 0.762 to 0.832 9.8 85 62 
KRAS EGFR BRAF 0.780 0.744 to 0.816 9.8 81 62 








5.9.6 Pan-Lung Data Set: Functional Relevance of NF1 and RASA1 using the MEK 6 
Gene Expression Signature 
Next to determine if the NF1 and RASA1 variants in our patient samples were functionally 
relevant in regulation of the MAPK pathway activity based on the MEK 6 signature we 
analysed the NF1, RASA1 groups, and MAPK PIK3CA negative groups using a one way 
ANOVA. A Levene’s test showed that homogeneity of variances was not assumed (p < 
0.05). The Welch ANOVA demonstrated significant differences between the groups (p < 
0.001). A post hoc Games-Howell test determined a significant increase in the MEK 6 
signature in the NF1 RASA1 group (p = 0.002) compared to the MAPK PIK3CA negative 
group which had a mean signature 9.5 (724 reads), Figure 5.17. All other NF1 and RASA1 
groups did not demonstrate a significant increase in the MEK signature in relation to the 
MAPK PIK3CA negative group. MAPK PIK3CA negative, NF1 (H, M, L), and RASA1 groups 
form a homogenous subset p = 0.947 with mean signature scores ranging from 9.4 – 9.6 
(675 – 776 reads). As shown previously the KRAS group demonstrated the largest mean 
score of 10.4 (1351 reads) followed by the cases with co-occurring NF1 and RASA1 variants, 
mean 10.2 (1176 reads) again forming a homogenous subset p = 0.936. Between our data 
set and the Pan-Lung dataset the difference between the MAPK negative group and the 
KRAS group was identical at 0.9 Log2. 
 
Figure 5.17. Pan-Lung NF1 And RASA1 positive MEK 6 gene expression signature scores.  
Groups bases on genotype with low allelic fraction samples excluded.  NF1 groups; high 
probability loss of function (H) (n = 19), unknown significance (M)(n = 30), and likely benign 
groups (L)(n = 12), MAPK PIK3CA negative (n = 387), KRAS (n = 135), NF1 RASA1 (n = 10), RASA1 
(n = 21) 
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The NF1 high probability loss of function group in the Pan-Lung dataset which included null 
variants downstream of the GAP domain and 3 homozygote deletions of NF1 showed no 
significance of the MEK 6 signature in relation to the MAPK PIK3CA negative group (p = 
0.998). This closely correlates with our data shown in section 5.9.2 (p = 0.942). 
Investigation of the 3 NF1 homozygote deletions demonstrated a signature scores ranging 
from 8.31 – 10.94 Log2 (317 – 1965 reads). This wide range suggests other factors could be 
involved in regulation of the MAPK pathway and NF1 loss alone is not enough to drive the 
this pathway in NSCLC, based on the MEK 6 signature score. The NF1 homozygote deletion 
with the lowest signature score also had a co-occurring PTEN homozygote deletion and all 
of the NF1 high probability group co-occurred with TP53 variants. The suggestion that 
other factors are required to drive the MAPK pathway in addition to NF1 null variants is 
also observed when looking at the cases with co-occurring NF1 and RASA1 variants. This 
group demonstrated a significant increase in the MEK 6 signature in relation to the MAPK 
PIK3CA negative group. However, unlike the KRAS group the NF1 and RASA1 did not show 




5.9.7 Pan-Lung Data Set: Functional Relevance of NF1 and RASA1 using a 
PI3K/AKT/mTOR Gene Expression Signiture 
Next to investigate if NF1 or RASA1 variants could have an effect in regulation of the 
PI3K/AKT/mTOR pathway we looked a related gene expression signature. The 
PI3K/AKT/mTOR (CMAP) signature was initially proposed by (Creighton et al., 2010)) 
Craighton et al. 2010, but had more recently been refined in (Zhang et al., 2016b)  Pan-
Cancer proteogenomic study of PI3K/AKT/mTOR pathway alterations. The signature has 
been shown to correlate to phosphorylation status of key members of the PI3K/AKT/mTOR 
pathway and correlates to inhibition of the same pathway. However, unlike the MEK 6 
signature, its power to predict genotypic changes has not been investigated. Normalised 
RNA seq gene expression was downloaded as described in method section 2.2.10. Cases 




Table 4.18. Oncogenic MAPK, PIC3CA,  NF1, and RASA1 variants in the Pan-Lung cohort 
of patients   
 4.18 were removed prior to analysis. 
Initial analysis of the individual genotypic groups using the 190 gene CRAS signature via a 
heatmap did demonstrate a visually observable difference in the 136 gene, up regulated 
arm, Figure 5.18. This arm demonstrated reduced expression in the MAPK positive groups, 
in relation to increased expression in the PI3K positive group. Visual analysis of the 56 gene 
down arm was less clear.  
The MAPK PI3K negative group displayed a mix of both increased and decreased 
expression in the up regulated arm of the CMAP signature as observed in Figure 5.17. Over 
half of the MAPK PI3K negative group demonstrated an increase in the expression similar 
to what is observed in the PI3K/AKT/MTOR groups, whilst the remaining demonstrated a 
decrease similar to the MAPK positive cases. When investigating the 36 gene down 
regulated arm there was less visual difference between any of the groups. The 
combination of increased and reduced expression in the MAPK PI3K negative group could 


















Figure 5.18. Pan-Lung CMAP 190 gene expression signature.  Groups based on genotype with low allelic fraction samples excluded. Blue 
represents lower expression (relative to the mean of the specific gene across all cases), yellow represents higher expression. 136 genes in the 
up regulated arm and 56 genes in the down regulated arm. Bright yellow/blue denotes change of ≥ 1 log2 from the mean. BRAF (n = 21), EGFR 
(n = 33), KRAS (n = 135), MAPK PIK3CA negative (n = 387), NF1 high probability loss of function (H) (n = 19), NF1+RASA1 (n = 10), RASA1 (n = 




To further investigate this signature we analysed the mean of all the genes in the up 
regulated arm to determine if this could distinguish between groups in a similar manner 
to the MEK and RAS signatures used previously. 
A Levene’s test showed that homogeneity of variances was not assumed (p < 0.05). The 
Welch ANOVA demonstrated significant differences between the groups (p < 0.001). A post 
hoc Games-Howell test determined significant increase in the CMAP up regulated 136 gene 
signature in the PTEN homozygote deletion group (p = 0.024) and PIK3CA amplification 
group (p < 0.001) in relation to the MAPK PI3K negative group. No significant difference 
was observed between the MAPK PI3K negative group and the PIK3CA positive group. 
Unexpectedly, the CMAP 136 up regulated signature did demonstrate a significant 
reduction in the signature score between the MAPK positive groups (BRAF p = 0.037, EGFR 
p = 0.001, and KRAS p < 0.001 ) in relation to the MAPK PI3K negative group. No significant 
difference was observed between the MAPK PI3K negative group and the NF1 H, 
NF1+RASA1, and RASA1 groups shown in Figure 5.19. 
 
Figure 5.19 Pan-Lung CMAP upregulated 156 gene expression signature scores based on 
individual groups.  Group’s bases on genotype with low allelic fraction samples excluded. The 
up regulated are of the CMAP signature (relative to the mean of the specific gene across all 
cases). NF1 groups; high probability loss of function (H) (n = 19), unknown significance (M)(n = 
30), and likely benign groups (L)(n = 12), MAPK PIK3CA negative (n = 387), KRAS (n = 135), NF1 




As the MAPK PI3K negative group could contain unknown drivers of both the MAPK and 
the PI3K/AKT/mTOR pathways, as we only excluded the main common drivers of this 
pathway described in Table 4.18, we decided to investigate the MAPK positive groups 
compared the PI3K/AKT/mTOR positive groups using the CMAP signature. Whilst there is 
still overlap between the range of the samples within the groups, the signatures resulted 
in two distinct subsets, with EGFR, KRAS, and BRAF forming one group (p = 0.999), and NF1 
H, RASA1 H, NF1+RASA1, PIK3CA amp, PIK3CA +ve, PTEN homodel, forming another group 
(p = 0.161). The MAPK positive groups were down regulated in relation to the up regulated 
PI3K/AKT/mTOR positive groups and NF1 and RASA1 groups. Surprisingly the NF1+RASA1 
group was the only one not to show a significant increase in relation to the MAPK positive 
groups. A Welch ANAOA followed by a Games-Howell test determined up regulation of all 
groups in relation to the MAPK positive groups (EGFR, KRAS, BRAF) (p < 0.021), with the 
exception of the NF1+RASA1 group, which was not significant (p > 0.259). 
Next we grouped all MAPK positive samples together (EGFR, KRAS, and BRAF) and all of 
the PI3K/AKT/mTOR positive samples together (PIK3CA +ve, PIK3CA amp PTEN homodel) 
as both formed distinct sub-groups to examine the NF1 and RASA1 groups using the up 
arm of the CMAP signature. A Levene’s test showed that homogeneity of variances was 
not assumed (p < 0.05). The Welch ANOVA demonstrated significant differences between 
the groups (p < 0.001), shown in Figure 5.20. A post hoc Games-Howell test determined 
significant increase in the CMAP up regulated 136 gene signature in relation to the MAPK 
positive group for the NF1 H (p < 0.001), and RASA1 group (p < 0.001). However, whilst the 
NF1+RASA1 group did visually display an increase in relation to the MAPK positive group, 
this was not deemed statically significant (p = 0.133). This is due to the increased range 
observed of the CMAP signature score and the overlapping 1-3 quartile range of the 
NF1+RASA1 and the MAPK positive group. One potential reason for this could be the 
relatively small number of co-occurring NF1+RASA1 cases. The Pan-Lung data only shows 




Figure 5.20. Pan-Lung CMAP 156 up regulates gene expression signature scores. Groups 
based on genotype with low allelic fraction samples excluded. Upregulated arm of the 136 
gene CMAP signature (relative to the mean of the specific gene across all cases). MAPK+ve 
group (n = 190), NF1 H (n = 19), NF1+RASA1 (n = 10), RASA1 H  (n = 18), and PI3K+ve (n = 195). 
 
The up regulated arm of the CMAP signature does demonstrate the NF1 H and RASA1 H 
groups appear to have a functional relevance in up regulation of the PI3K/AKT/mTOR 
pathway in comparison to the MAPK positive group based on this signature. The log2 
difference between the means of the MAPK positive and PI3K/AKT/mTOR groups was 0.3. 
When looking at the original counts from the RNA seq data, the CMAP signature mean 
score for the up arm was 973 reads for the MAPK positive group, compared to up the 
upregulated counts of 1195 for the PI3K/AKT/mTOR positive group, 1121 for NF1 H, 1098 
for RASA1 H and 1121 for the NF1+RASA1 group. Whist this fold change is less than what 
is observed in the MEK 6 signature there are still significant differences suggesting both 




Next we repeated the analysis shown in Figure 5.20 using the 56 gene down arm of the 
CMAP signature. A Levene’s test showed that homogeneity of variances was assumed    (p 
> 0.05). An ANOVA demonstrated significant differences between the groups (p < 0.001). 
A Tukey HSD post hoc test only demonstrated one significant difference with a slight 
increase in the PI3K/AKT/mTOR positive group in relation to the MAPK positive group, 
shown in Figure 5.21. However, the difference between the means of these groups was 
only 0.05 Log2. When looking at the original reads from the RNA seq data, the CMAP 
signature mean score for the up arm was 825 counts for the MAPK positive group, 
compared to 854 counts for the PI3K/AKT/mTOR positive group, 800 for NF1 H, 850 for 
RASA1H and 878 for the NF1+RASA1 group. This was unexpected as we should have seen 
a reduction in the PI3K/AKT/mTOR positive group in relation to the MAPK positive group, 
suggesting the down arm of the CMAP signature still requires further optimisation. 
 
Figure 5.21. Pan-Lung CMAP 56 down regulated gene expression signature scores. Groups 
based on genotype with low allelic fraction samples excluded. Up-regulated arm of the 136 
gene CMAP signature. MAPK+ve group (n = 190), NF1 H (n = 19), NF1+RASA1 (n = 10)  RASA1 H  





5.10 Gene Expression signatures and Clinical Information 
To investigate any correlations in the signature scores between subtype, gender, and stage 
we used a 3 way ANOVA. Stage 1 and 2 were grouped together and stage 3 and 4 patients 
to form stage 1-2, and stage 3-4 groups. Both the MEK 18 and MEK 6 signatures did not 
demonstrate any significant 3 way interaction (p > 0.288). However, a significant difference 
in subtype was noted using both signatures, as shown in Figure 5.22. 
The MEK 18 demonstrated the ADC group (n = 47) to have the highest mean score over 
the SQCC group (n = 29) and NOS (n = 8). A Tukey HSD post hoc test demonstrated a 
significance between ADC and SQCC (p = 0.015). No difference was observed between ADC 
vs. NOS (p = 0.068) or AQCC vs. NOS (p = 0.844).  
A Tukey HSD post-hoc test on the MEK 6 signature demonstrated a significance between 
ADC and NOS (p = 0.004) and SQCC and NOS (p = 0.023). No difference was observed 





Figure 5.22. MEK 18 and MEK 6 gene expression signature score across subtypes. 
 A) MEK 18 gene expression signature score across subtypes B) MEK 6 gene expression 





5.11 Discussion  
Here it was demonstrated that the Nanostring nCounter is a highly robust platform for 
quantitative analysis of mRNA from degraded clinical FFPET samples. The platform’s 
reproducibility with both high quality commercial standards and with highly degraded RNA 
was assessed. The Nanostring CodeSet which included over 200 genes demonstrated high 
levels of reproducibility both inter batch and intra batch. Of the 84 samples analysed, there 
were no failures or repeats required based on the internal or external QC measures. It was 
determined that the NF1 copy number changes seen at the genetic level do not influence 
NF1 mRNA expression. Furthermore, it was determined that NF1 transcript 2 was the 
predominately expressed transcript in NSCLC. Previous reports of the relevance and 
predictive power of these signatures in relation to KRAS oncogenic variants through 
activation of the MAPK pathway were confirmed (Dry et al., 2010a, Brant et al., 2017, 
Loboda et al., 2010a). In a direct comparison of the three signatures that relate to the 
MAPK activation it was shown that the MEK 6 signature has increased sensitivity and 
specificity over the MEK 18 and RAS signature in NSCLC. It was also demonstrated that the 
MEK 6 signature is predictive of EGFR oncogenic variants. Finally, this signature was used 
to demonstrate that the heterozygote loss of function NF1 variants in NSCLC do not 
directly impact MAPK regulation.  
Whilst FFPET is a challenge to work with for genetic analysis, methods of detection and 
measurement are evolving to take this into consideration. One such platform is the 
NanoString nCounter, which provides a non-enzymatic method of counting the mRNA 
transcripts in the sample using the hybridisation of fluorescent barcodes. Here it is shown 
that many of the issues, such as degradation of nucleic acids, which inhibit other methods 
such as microarray analysis and RT-qPCR are not an issue with this platform.  
The platforms reproducibility using commercially sourced RNA human reference control 
has been demonstrated. Analysing the RAW mRNA Log2 counts and comparing across 3 
independent batches demonstrated a high level of reproducibility with a R2 coefficient of 
>0.994 measuring over 200 genes. Utilising five highly degraded controls with RIN values 
≤1.4 this level of reproducibility was transferable to highly degraded FFPET derived mRNA. 
Analysis of the Log2 gene count across technical duplicates run across 3 independent 
batches resulted in R2 coefficients which ranged from 0.977 to 0.996. Use of this validation 
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set also enabled the analysis of the suitability of housekeeping genes utilising 
AstraZeneca’s in house normalisation tool. Only one housekeeping gene (G6PD) out of 21 
genes proved unsuitable due to deviations in the overall trend in relation to the other 
housekeeping genes. G6DP was flagged as unsuitable in both analyses of the validation 
samples and the actual 84 patient samples.  
Whilst this gave confidence in the CodeSet overall, it did not provide any information on 
the reproducibility of the gene expression signatures. Using the Log2 normalised read 
count, the MEK 18 and MEK6 gene expression signatures were calculated for the EGFR, 
KRAS, BRAF, NF1, and MAPK negative controls as described in section 2.1.6. The replicate 
gene expression signatures across the three batches demonstrated a high level of 
reproducibility with all 5 biological controls demonstrating ≤0.05 standard deviation (fold 
change ≤0.13) across the 6 technical replicates. This validation also demonstrated that 
MAPK oncogenic positive samples have an increased signature score in relation to NF1 
positive and MAPK negative controls. Calculating the RAS signature using the Log10 
normalised read count across all replicates produced similar results with the standard 
deviation of the five controls being 0.01. Whilst the RAS signature appeared to be selective 
for KRAS and BRAF, this was not observed with EGFR which was almost indistinguishable 
from the MAPK negative score. 
During analysis of the 84 patient samples three had below the recommended 100 ng of 
starting material as suggested by Brant and colleagues (2016). These samples ranged from 
41 ng to 86 ng. The internal QC using nSolver 4.0 highlighted two of the 84 samples to have 
low mRNA content; one of these was from NF1-223 which had 41 ng of starting material.  
NF1 expression was investigated using three probes which either target NF1 mRNA 
transcript 1 and 2 or just transcript 2. Initial investigations demonstrated significant 
differences between the probes NF1-A (exon 7-8) and NF1-B (exon 22-23) which target 
both NF1 transcripts. NF1-B demonstrated a mean increase across all the samples of 0.6 
fold in relation to NF1-A. This could potentially be the variance in the probes affinity to the 
target as it was observed consistently in all samples, shown in Figure 5.7. Whilst differences 
in probe batches have been investigated in the literature, the variability of different probes 
on the same target gene has not (Brant et al., 2017). A further possible explanation is 
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partially transcribed NF1 pseudogenes. Whilst there are no reports in the literature of 
transcription of NF1 pseudogenes, the genome browser and database Ensembl listed both 
NF1P9 and NF1P10 as having the potential to be transcribed. Our earlier work mapping 
the pseudogenes back to NF1 demonstrated that both of these pseudogenes contain 
homologs of exon 22-23 but not exon 7-8. One way to resolve this would be to compare 
multiple probes across NF1 to determine where any discrepancy lies.  
We determined NF1 transcript 2 to be predominantly expressed in all samples, including 
the four samples with no visible tumour content and positive controls. NF1 transcript 2 is 
most commonly expressed in neurons and has a higher GTPase activity than transcript 1 
(Hinman et al., 2014, Brant et al., 2017). This is due to the 21 amino acid exon 31 being 
excluded from the GAP related domain in transcript 2. The predominance of transcript 1 
has been linked to breast cancer and epithelial ovarian tumours, however this is not 
observed in out NSCLC cohort (Iyengar et al., 1999, Marrero et al., 2012). The fact this was 
observed in the four samples with no tumour contents suggest this ratio of transcript 1 
and 2 is normal for lung tissue. As transcript 2 has 10 X increased GTPase activity over 
transcript 1 it could be considered advantageous for down regulation of the MAPK 
pathway in NSCLC. Expression of these two transcripts was detected in the positive 
controls at the same ratio observed in the NSCLC samples. However, overall expression of 
NF1 was increased by 1-fold in the NSCLC samples compared to the positive controls. As 
the RNA controls originate from mixed cell lines a difference was to be expected as NF1 
expression is tissue specific. 
When investigating NF1 copy number analysis against NF1 mRNA transcription a Spearman 
correlation demonstrated a slight positive relationship (rs = 0.210), however this was not 
significant (p = 0.101). Studies investigating the relationship between copy number and 
mRNA transcription in lung cancer only report significant relationships with a correlation 
coefficient of R2 >0.7 in 1.6% of genes (Jabs et al., 2017). Jabs and colleagues work 
confirmed our reports that NF1 copy number does not correlate with mRNA expression. 
In the analysis of the 84 patient samples using the three gene expression signatures the 
cases were grouped into KRAS, EGFR, BRAF and MAPK negative groups. This analysis was 
performed in parallel, one set just with the oncogenic variants which were ubiquitously 
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expressed and the other set removing the low AF samples. For the KRAS group with the 
low AF cases excluded an increase in mean over the MAPK negative groups across all the 
signatures was observed. This was not observed with the EGFR group, as two of the sample 
with low AF variants had the greatest signature scores. The two EGFR samples which were 
excluded based on low AF (NF1-119 and NF1-205) were only just below the minus 30% of 
expected frequency cut off limit. Based on the positive response for KRAS group we 
continued with analysis using only the oncogenic variants which were ubiquitously 
expressed. 
The three signatures all demonstrated significant differences between the KRAS groups 
and the MAPK negative groups (p > 0.003). This is reflective of previous work using these 
signatures (Brant et al., 2017, Dry et al., 2010a, Loboda et al., 2010a). When we compared 
the three signatures against each other in their abilities to predict KRAS status the MEK 6 
signature displayed an increased AUC (0.855) with an increased specificity and sensitivity 
over the other two signatures. The RAS signature demonstrated the lowest with an AUC of 
0.799. This was expected as Brant and colleagues optimised this signature for NSCLC, 
whereas the MEK 18 and RAS were developed using multiple cancer cell lines (Brant et al., 
2017). Whilst the exact sensitivity and specificity was unreported in the literature for the 
MEK signatures, the RAS signature correlated exactly with Loboda and colleagues previous 
reports (Loboda et al., 2010a).  
To confirm the MEK 6 signatures ability to predict KRAS status further, we analysed 864 
cases from the Pan-Lung TGCA dataset (Campbell et al. 2016). The sensitivity and 
specificity closely correlated to the result seen in this study’s data, with the Pan-Lung 
dataset demonstrating an AUC of 0.841, compared to our 0.855 shown in Table 5.5. The 
AUC for both our study and analysis using the Pan-Lungs TGCA data demonstrated the MEK 
6 signature to provide an excellent level of discrimination at predicting KRAS oncogenic 
variants in relation to the MAPK PI3K negative group (AUC > 0.8) (Hosmer et al., 2013). This 
also validated the MEK 6 signatures predictive power using an orthogonal analytical 
platform in NSCLC, as the Pan-Lung RNA transcription analysis was generated via RNA seq 
in relation to our Nanostring analysis.  
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None of the signatures demonstrated any significant differences between the MAPK 
negative and the BRAF groups in data generated in this study. However, as previously 
mentioned the BRAF group only consisted of three cases. Analysis of the Pan-Lung TGCA 
data which had 21 BRAF positive cases did demonstrate a significant difference of the BRAF 
group in relation to the MAPK PI3K negative group (p = 0.011).The EGFR group 
demonstrated a significant difference against the MAPK negative group using the MEK 6 
signature and with the MEK 18 signature before removing the two potentially low AF 
samples. As the EGFR samples were just below the low AF cut off limit, which was 
calculated based on the pathologist subjective assessment, we decided to investigate the 
MEK 18 and MEK 6 signatures abilities to predict KRAS and EGFR driver variants. The MEK 
18 signature did see a reduction of the AUC including the EGFR variants compared to just 
KRAS of AUC = 0.809 to 0.758. Whilst this is still described as an acceptable level of 
discrimination it did see the sensitivity drop by 10%.  The MEK 6 signature also displayed a 
reduction from AUC = 0.855 to 0.820 when detecting KRAS and EGFR drivers. Even with 
the EGFR variants included this provides an excellent level of discrimination (Hosmer et al., 
2013). This was also confirmed using data from the Pan-Lung trial, in which the MEK 6 
signature demonstrated a AUC of 0.797 which is an acceptable  level of discrimination at 
predicting KRAS and EGFR oncogenic variants in relation to the MAPK PI3K negative group 
(AUC > 0.8) (Hosmer et al., 2013).  
The analysis of the NF1 loss group which included all samples with NF1 variants 
demonstrated no significant difference from the MAPK negative group, but did display a 
significant difference from the MAPK positive KRAS group. This was confirmed using both 
the MEK signatures shown in Figure 5.11 and 5.13.  This was expected, as many of the 
samples had low AF and likely benign variants as discussed in the previous chapter. This 
left two high probability NF1 loss of function samples (NF1-180 and NF1-233) and the 
unknown significance sample (NF1-225) which were ubiquitously expressed. Investigating 
the NF1 cases individually using the MEK 18 and MEK 6 signatures, NF1-180, NF1-233, and 
NF1-225 were all below the cut off limit for both signatures, defined in table 3 suggesting 
low MAPK activity. Furthermore, the 2 potential pseudogene variants, reported as 
pathogenic in neurofibromatosis patients, which were just below the -30% expected AF 
were below the cut off for both signatures. 
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Of the two null variants (NF1-233 and NF1-180) which were expressed throughout the 
region of the sample analysed, only NF1-233 was downstream of NF1s GAP domain and   
would result in heterozygote loss of function of NF1 GAP domain. The cut-off limit based 
on the MEK 6 signatures ability to predict KRAS variants was 8.82 which is equivalent to 
452 mean counts of the genes in the MEK 6 signature which demonstrated 100% sensitivity 
and 68% specificity at detecting KRAS variants. The signature score for NF1-223 was 8.18 
(290 mean counts), 162 counts below the cut-off limit. However, NF1-180 which had a null 
variant upstream of the NF1s GAP domain had a signature score of 8.7 (416 mean counts), 
whilst still below the cut-off limit the difference was only 36 counts.  
As this study only had one NF1 null variant downstream of NF1s GAP domain we repeated 
the analysis using the dataset from the Pan-Lung TGCA trial. Of the 19 NF1 cases which 
were classed as high probability of loss of NF1 function, 16 cases had null variants 
downstream of NF1s GAP domain and 3 were classed as NF1 homozygote deletions. The 
19 cases in the NF1 high probability group did not demonstrate any significate difference 
considering them as a group in relation to the MAPK PI3K negative group (p = 0.999) shown 
in Figure 5.17. However, using the cut-off limit of 9.8 (891 mean RNA reads) based on the 
MEK 6 signatures ability to predict KRAS variants in the Pan-Lung dataset, 31% (5/16) of 
the NF1 null variants cases downstream of the GAP domain were above this threshold. 
Interestingly, of the 3 homozygote NF1 deletions only 33% (1/3) was above the threshold. 
The sensitivity of the MEK 6 signature was calculated at 90%, therefore it was expected 
that 10% of cases above this threshold would be false positives. As greater than 10% of the 
NF1 cases were above this threshold, it does suggest based on the MEK 6 signature, that 
NF1 heterozygote or NF1 homozygote deletions alone is not sufficient to drive the MAPK 
pathway, and further unknown factors could be involved in the 31% of cases which were 
above the threshold. Similar findings have been observed in neurofibromatosis, where 
further mutations in addition to NF1 are involved in the transition of tumours from benign 
to malignant (Sohier et al., 2017). 
The observation based on the MEK 6 signature that NF1 loss alone is not sufficient to drive 
the MAPK pathway is also supported by the cases with co-occurring RASA1 and NF1 
variants. Of the grouped analysis, shown in Figure 5.17, the NF1+RASA1 cases are the only 
group to demonstrate a significant increase in up regulation of the MEK 6 signature in 
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relation to the MAPK PI3K negative group (p = 0.002). The analysis also highlighted the 
KRAS and NF1+RASA1 groups to form a homogenous a subset (p = 0.936). This combination 
of co-occurring variants in NSCLC has also been described in cell based models (Hayashi et 
al., 2018). Hasyashi and colleagues demonstrated the EPLC272H cell line with co mutated 
NF1 and RASA1 genes was more sensitive to MEK and PI3K inhibitors, as single agents or 
in combination, compared to cell lines only harbouring NF1 or RASA1. 
In data generated in this study a number of unexpected NF1 positive samples were 
observed with signature scores which indicate MAPK activation. Both MEK signatures 
demonstrated NF1-178 (p.Ala2532Val) to be above the cut off limits, suggesting increased 
MAPK activation. NF1-178 had a germline NF1 variant which was predicted as likely benign 
by in-silico analysis. The MEK 6 signature identified another 3 NF1 to be above the 8.82 
threshold. NF1-201 was in the likely benign group, NF1-115 and NF1-217 were from the 
unknown significance group. Of these, NF1-217 was of interest, as this was the only sample 
to display 2 NF1 null variants and therefore has the potential to cause homozygote loss of 
NF1. Unfortunately the calculated AF of these NF1-217 variants was calculated to be seen 
in only 30% of the tumour. When considering the 68% specificity the MEK 6 signature has 
demonstrated, 5 potential false positives would be predicted, which is exactly what was 
observed in the NF1 cases. 
Using the Pan-Lung TGCA dataset we investigated the effect NF1 variants have on 
regulation of the PI3K/AKT/mTOR pathway. Analysis using the 136 gene up regulated arm 
of the CMAP signature demonstrated the MAPK PI3K negative group could contain 
unknown drivers of both the MAPK and the PI3K/AKT/mTOR pathways, as shown in Figure 
5.18. Using the MAPK positive group as a PI3K/AKT/mTOR negative control we observed a 
significant increase in the CMAP mean signature score for the PI3K/AKT/mTOR positive 
group shown in Figure 5.20 (p < 0.001). The NF1 and RASA1 independent groups also 
demonstrated a significant increase in the CMAP signature score in relation to the MAPK 
positive group (p < 0.001). This does suggest cases with either a NF1 or RASA1 loss of 
function variant would function in up-regulation of the PI3K/AKT/mTOR pathway. 
Interestingly, the group with co-occurring NF1 and RASA1 variants did not show a 
significant difference in relation to the MAPK positive group, using the CMAP signature. 
However, based on the median and the quartile distribution of the NF1+RASA1 group, the 
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large range of the CMAP scores, and the small number of cases (n = 10) shown in Figure 
5.19, we strongly believe increasing the population of this group would result in a 
significant difference being observed. NF1 variants have been described to drive the 
PI3K/AKT/mTOR pathway in malignant peripheral nerve sheath tumours (MPNSTs) in 
neurofibromatosis models (Malone et al., 2014, Johannessen et al., 2005). Malone and 
colleagues demonstrated that NF1 positive MPNSTs were sensitive to mTOR1 inhibition in 
mouse models, but this only induced a cytostatic effect. However, combining an mTOR1 
inhibitor with a MEK inhibitor resulted in tumour regression.  
Our data does suggest, based on the MEK 6 and CMAP signatures that NF1 or RASA1 loss 
alone is not enough to drive the MAPK pathway, but these variants are sufficient to 
upregulate the PI3K/AKT/mTOR pathway. We postulate further genetic variations in 
addition to NF1 are required for upregulation of the MAPK pathway. This was observed in 
the Pan-Lung data analysed in this study and was demonstrated by the increase of the MEK 
6 signature score in cases with co-occurring NF1 and RASA1 variants. This combination of 
co-occurring NF1 and RASA1 variants has also been described by Hayashi et al., (2018) in 
lung cancer models and could represent a combination biomarker for PI3K and MEK 
inhibition. mTOR1 and MEK inhibitors have also been shown to reduce MPNSTs in 
neurofibromatosis mouse models (Malone et al., 2014). It is important to note 30% of NF1 
cases in the Pan-Lung dataset were above the KRAS positive threshold described in Table 
5.5, this does indicate further genetic variants could also be functioning alongside NF1 in 
upregulation of the MAPK pathway.  
This analysis investigating the different clinical and demographic groups including; 
subtype, gender, and disease stage, demonstrated a significant difference between the 
ADC and SQCC subtypes using the MEK 18 signature, and between the ADC and NOS groups 
using the MEK 6 signature. Whilst the significance was not enough to be predictive of the 
various subtypes, it does suggest the MAPK pathway is active in many SQCC cases, which 












Previous investigations into the genetic landscape of NSCLC identified a subpopulation of 
patients that harbour somatic variants in NF1 (Ding et al., 2008, Collisson et al., 2014, 
Hammerman et al., 2012). The majority of these patients only demonstrate aberrations in 
one allele. It is known from Neurofibromatosis pathogenesis that somatic variants in NF1 
leave the individual more susceptible to the development of benign and malignant 
neurofibromas (Riccardi and Lewis, 1988). In Neurofibromatosis disease development is 
subject to Knudson's two‐hit hypothesis, where bi-allelic inactivation of NF1 is required 
(Yang et al., 2008). It has been shown in lung cancer cell models that knock down of NF1 
drives cellular proliferation through activation of the MAPK pathway and causes resistance 
to TKI (de Bruin et al., 2014a). This study aimed to address whether NF1 variants in NSCLC 
are sufficient to upregulate MAPK activation in the absence of any other MAPK drivers. 
At the early stages of this study it was apparent that the variability observed in the quantity 
and quality of patients archived FFPET was going to be a limiting factor. To minimise the 
impact of this, an attempt was made to optimise and validate DNA extraction, 
quantification, and quality assessment, as detailed in Chapter 3. This included optimising 
the NGS protocol, validating the lower limits of detection, and setting up a customised 
bioinformatics pipeline. The use of ddPCR was explored in order to determine its potential 
for measuring NF1 copy number. This provided a solid foundation for the work described 
in Chapter 4. In this chapter the patients’ clinical FFPET samples were screened for somatic 
NF1 variants and known MAPK oncogenic drivers. The results of this directed the division 
of the patients based on genotype and moved forward the investigation of the gene 
expression signature as detailed in Chapter 5. The signatures were analysed to determine 
their ability to predict MAPK activation based on KRAS status. Once established, the scores 








During patient screening a great degree of variability in both the quality and quantity of 
the DNA recovered from the clinical samples was observed. Use of conventional methods 
of quantification such as the Nanodrop or Qubit would have resulted in a greater number 
of samples failing at the library preparation stage of sequencing. In line with previous 
reports the qPCR and QFI score provided a reproducible pre-sequencing QC check to 
determine the quantity and quality of starting material for NGS (Sah et al., 2013). The NF1 
pseudogene mapping, explored in Chapter 3, provided a method of flagging potential 
pseudogene variants, which should be treated with caution before reporting. This adds a 
further level of security rather than relying on the sequencing metrics alone, as previously 
described in section 3.1 (Cunha et al., 2016). 
The genomic profiling studies, which originally identified the prevalence of NF1 variants in 
NSCLC, were restricted by sequencing depth, which was dictated by the size of the whole 
genome or exome being sequenced (Ding et al., 2008, Collisson et al., 2014, Hammerman 
et al., 2012). This limited the ability to assess low level tumour content samples with 
sample with < 60% tumour content been excluded from the studies. Use of a relatively 
small targeted NGS panel enabled the sequencing of NF1 and other key MAPK genes at 
>10-fold the depth of the NSCLC Pan-Lung (Campbell et al., 2016) as described in Chapter 
3. The advantage of the current study was the ability to confidently identify variants with 
a high sensitivity at low allelic fractions, which enabled the identification of ubiquitously 
expressed variants in samples with only 6% tumour content.  
Of the 86 samples that were successfully sequenced, 25 previously reported MAPK 
oncogenic variants which are known to activate the MAPK pathway were identified. Of 
these, the 7 EGFR variants correlated with demographics and prevalence observed for ADC 
in the wider literature (Zhang et al., 2016b). In this study the prevalence of KRAS patients, 
was slightly below that seen in ADC and above that for SQCC patients (Campbell et al., 
2016, Boch et al., 2013). The two BRAF variants in ADC cases correlated with previous 
reports, but the one SQCC case was above reported prevalence (Campbell et al., 2016). 
However, based on the size of the cohort of patients this level of fluctuation in prevalence 
was to be expected. 
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Use of deep sequencing made it possible to determine whether these oncogenic variants 
were observed ubiquitously in the region of the tumour sampled, or in limited sub-
populations only. This builds on the information reported in large genomic profiling studies 
(Ding et al., 2008, Collisson et al., 2014, Hammerman et al., 2012). 72% of the 25 oncogenic 
variants were found ubiquitously throughout the region of tumour sampled, in data 
generated in this study, shown in Table 4.15. This was expected, with known oncogenic 
drivers out-competing less dominant sub-clones, these would therefore be expected to be 
found in most regions of the tumour sampled, using either multi region or single region 
analysis. This was observed in our study’s data when compared to TRACERx’s whose data 
reported 33% of KRAS cases to be sub-clonal, compared to our 21%.  
25 NF1 variants were identified in 20 patients, including the three flagged as potential 
pseudogene in origin, two of which have been reported as pathogenic (Upadhyaya et al., 
2003, Laycock-van Spyk et al., 2011), shown in Table 4.17. Of these 25 variants 15 were 
novel with no evidence of been previously reported in the literature or in databases. In-
silico analysis predicted the effect these variants could have on NF1 loss of function; 5 were 
classed as null variants, 10 defined as of unknown significance, and 10 likely benign. 
22% of patients displayed NF1 variants, close to double the 12% previously reported 
(Campbell et al., 2016). However, using the same criteria as the Pan-Lung study, which 
excluded intronic variants and those not identified using 100 X read depth, 13% of patients 
in this study displayed NF1 variants. 
Unlike the known oncogenic drivers which demonstrated similar frequencies to what was 
observed in TRACERx, after excluding germline NF1 variants, only 20% (4/20) of our cases 
expressed NF1 variants ubiquitously throughout the region of tumour analysed. It was not 
possible to correlate this with the Pan-Lung TGCA data as exact tumour content of 
individual samples was unknown. However, mining the Pan-Lung allelic frequency 
sequencing data for NF1 showed that 76% of their samples had <40% variant reads in 
relation to reference reads. Of the four patients that displayed co-expression of MAKP 
oncogenic and NF1 variants in this study, three had NF1 AF at half the level of the AF of 
the known oncogenic driver. This does demonstrate NF1 variants commonly found in 
NSCLC patients are largely sub-clonal using single region sampling. TRACERx reported NF1 
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variants to be sub-clonal in 50% of patients based on multi-region sampling; whereas our 
analysis showed only 20% of NF1 variants to be expressed throughout the region of tumour 
analysed. If a NF1 variants are sub-clonal in 50% of cases, it would be expected to see a 
greater difference between multi-region and single region analysis. 
In Chapter 5 the NanoString nCounter was shown to be tolerant to highly degraded RNA 
when quantifying gene expression. Use of this platform enabled not only the exploration 
of the gene expression signatures, but also investigation of NF1 mRNA expression.  
Analysis of NF1 transcription demonstrated that it had no correlation to NF1 copy number, 
in agreement with previously reported results (Jabs et al., 2017).  The level of expression 
of the different transcripts in lung cancer has not previously been reported but an increase 
in expression of transcript 1 has been reported in several other cancers including, breast 
cancer and epithelial ovarian tumours (Iyengar et al., 1999, Marrero et al., 2012). 
Transcript 1 has been shown to have a 10-fold reduction in its GTPase activity over 
transcript 2 leading to an increase of MAPK activation through its inhibited ability to 
deactivate KRAS. The results from this study indicate that both NF1 mRNA transcripts are 
expressed in NSCLC, with transcript 2 being predominantly expressed. As this was 
observed in the four samples with no visible tumour content, it suggests that this is a 
normal ratio for lung tissue. 
Initial work with gene expression signatures determined that these provided a viable 
means of measuring KRAS oncogenic status and therefore MAPK activation. Investigations 
of the MEK 6 signature using both data generated in this study and the Pan-Lung TGCA 
dataset confirmed the findings of previous studies with the signature being predictive of 
KRAS status (Dry et al., 2010a, Brant et al., 2017, Loboda et al., 2010a). The RAS signature 
demonstrated the lowest sensitivity and specificity but still retained an acceptable level of 
discrimination. MEK 18 and MEK 6 provided an excellent level of discrimination (AUC > 0.8) 
(Hosmer et al., 2013). In addition to the published data it was also confirmed that both the 
MEK 6 signature could be used to predict EGFR and BRAF in addition to KRAS status. This 
corroborates work in cell based models which suggests EGFR predominately drives the 
MAPK pathway (de Bruin et al., 2014a).  
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When investigating our cohort of patients only had one case with a null variant 
downstream of NF1s GAP domain. To expand on this we utilised Pan-Lung TGCA data and 
analysed 864 NSCLC cases. In addition to analysis with the MEK 6 signature we also 
investigated the CMAP signature, which is related to the PI3K/AKT/mTOR pathway. We 
observed an increased MEK 6 signature in the group with co-occurring NF1 and RASA1 
similar to the KRAS group. This could represent a combination biomarker for PI3K and MEK 
inhibition, which was original proposed by Hayashi et al. (2017) using cell based models. 
Whilst the NF1 group did not show a significant increase in the signature, as a whole, over 
30% of the individual cases were over the KRAS threshold shown in Table 5.5. We also 
demonstrated an increase in the CMAP signature for the NF1 and RASA1 groups, which 
suggests these variants, can cause upregulation of the PI3K/AKT/mTOR pathway. Malone 
et al. (2014) demonstrated NF1 can cause upregulation of the PI3K/AKT/mTOR pathway in 
pre-clinical models. Whilst the NF1 and co-occurring RASA1 group did not show a 
significant increase in the CMAP signature, we suspect this was due to the low number of 
cases in the cohort. 
In summary, the prevalence of NF1 variants in NSCLC has been confirmed. A method of 
flagging pseudogene reads by mapping back to the functional NF1 gene during realignment 
in the bioinformatics pipeline has been identified. It has been shown that NF1 transcript 2 
is predominantly expressed in NSCLC and the potential of MEK signatures for predicting 
EGFR and BRAF status has been further demonstrated. We have demonstrated co-
occurring NF1 and RASA1 variants are enough to drive the MAPK pathway based on the 
MEK 6 signature, while cases with individual NF1 or RASA1 variants can increase 
PI3K/AKT/mTOR activity. Finally, a third of all NF1 cases had an increased MEK 6 signature 
score above the KRAS calculated threshold, which warrants further investigations into co-
drivers.  
Study Limitations 
The primary limitation in this study was the variability of patient samples. 23 were rejected 
based on insufficient tissue prior to any analytical assessment. Based on this, the pre-
sample analysis establishment and validation was undertaken as described in Chapter 3, 
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to maximise the utility of the available tissue and potentially mitigate for the degree of 
variability observed.  
Time was also a constraint. There were significant challenges in in the transfer of archived 
patient material from Sheffield Teaching Hospitals Trust to Sheffield Children’s Hospital 
Trust. Many cases took in excess of 8 months from being requested to being received. This 
resulted in the majority of the samples not being accessible until March 2018, making it 
impossible to repeat any analysis. Hence it was not possible to further validate the lower 
limits of starting material required after observing the erroneous copy number results, or 
to macro-dissect samples prior to copy number analysis.  
Whilst the initial group of patients was divided adequately based on genotype, with 25 
MAPK oncogenic variants, 44 MAPK negative and 15 NF1 patients, the finding of such a 
small cohort of patients with ubiquitous NF1 variants was not expected. For further 
statistical power it would have been advantageous to have more ubiquitous NF1 patients. 
This was considered early on in the study. Using the knowledge that KRAS and NF1 are 
largely mutually exclusive, by excluding KRAS patients it would be possible to enrich the 
NF1 patients. Unfortunately, unlike EGFR, KRAS is not routinely tested therefore it could 
not be utilised for patient screening and selection.  
Future Work 
The MEK 6 and the CMAP signatures have been shown to be predictive of  key drivers of 
each both the MAPK and PI3K/AKT/mTOR pathway. These signatures can be used as 
functional tools to investigate pathway activity and help provide evidence establishing the 
functional relevance of potential new genetic biomarkers. Whilst this study has focused on 
NF1 in NSCLC, these signatures should be assessed further in different cancers to uncover 
potential unknown drivers of the MAPK and PI3K/AKT/mTOR pathways. New potential 
biomarkers should then be transferred back to preclinical models to investigate there 
therapeutic potential. Finally, the gene expression signatures need to be further 
investigated and refined in future clinical trials to develop their clinical potential. The 
signatures could add an extra dimension to current genetic biomarkers and could identify 
alternate patient groups who could respond to targeted therapeutics.  
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There is also the potential to follow up patients using their clinical data, to look at overall 
survival rates and response to treatment. This study only considered NF1’s ability as a 
GTPase activating protein and its effect on the negative regulation of KRAS and the MAPK 
pathway. However, the GAP related domain makes up less than 10% of NF1. It was briefly 
mentioned in Chapter 1 that NF1 can function as a tumour suppresser gene using MAPK 
independent mechanisms. This is an alternate route which is open to investigation and 
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Appendix 5. NGS Indexes 
 
NGS indexes for the individual samples 
Sample ID Index Sample ID Index Sample ID Index 
NA12878 ATGCCTAA NF1-159 ACATTGGC NF1-205 ATAGCGAC 
NF1-107 AACGTGAT NF1-160 CAATGGAA NF1-206 GAATCTGA 
NF1-115 AGATGTAC NF1-161 TGAAGAGA NF1-207 ATTGGCTC 
NF1-117 CATACCAA NF1-162 GCGAGTAA NF1-210 AATGTTGC 
NF1-119 CCACACGA NF1-163 ACGTATCA NF1-211 AACGCTTA 
NF1-120 ACGCTCGA NF1-164 AGATCGCA NF1-212 GTACGCAA 
NF1-122 TGGAACAA NF1-165 ACAAGCTA NF1-213 GAACAGGC 
NF1-126 TAGGATGA NF1-166 TATCAGCA NF1-214 CCGAAGTA 
NF1-130 ACTATGCA NF1-167 AGCCATGC NF1-215 CTCAATGA 
NF1-132 GGAGAACA NF1-168 CGGATTGC NF1-216 CAAGGAGC 
NF1-134 TGGCTTCA NF1-169 GATAGACA NF1-217 ACAGCAGA 
NF1-136 ACCTCCAA NF1-170 CGACACAC NF1-218 TAGAGTCG 
NF1-138 AAGAGATC NF1-171 ACACAGAA NF1-220 GTGCGACA 
NF1-139 CGACTGGA NF1-172 GCTCGGTA NF1-221 AAGACGGA 
NF1-140 AGTGGTCA NF1-173 TTCACGCA NF1-222 AACTCACC 
NF1-141 CCTAATCC NF1-174 ACACGACC NF1-223 CAAGACTA 
NF1-142 GGTGCGAA NF1-175 GTCTGTCA NF1-224 GTATCAAC 
NF1-144 CCAGTTCA NF1-176 CAGCGTTA NF1-225 CCTCCTGA 
NF1-145 CTAAGGTC NF1-177 CCATCCTC NF1-227 GAGCTGAA 
NF1-146 CATCAAGT NF1-178 ATTGAGGA NF1-231 TCTTCACA 
NF1-147 CACCTTAC NF1-179 CAACCACA NF1-232 TCGACACT 
NF1-148 CCGTGAGA NF1-180 CGAACTTA NF1-233 GATCCGCT 
NF1-150 ATCCTGTA NF1-181 AGCAGGAA NF1-234 AGGCTAAC 
NF1-151 AGTCACTA NF1-182 AAACATCG NF1-237 ATCATTCC 
NF1-152 GTCGTAGA NF1-183 ACCACTGT NF1-238 GCCACATA 
NF1-154 TGGTGGTA NF1-184 GACTAGTA NF1-239 AAGGTACA 
NF1-155 GAGTTAGC NF1-185 GTGTTCTA NF1-240 GCTAACGA 
NF1-156 CTGAGCCA NF1-201 CAGATCTG   
NF1-157 CGCATACA NF1-203 AGTACAAG   





Appendix 6. Gene Expression Signatures and Probes 
 





























































































































































































































































































































































































































































































































































































































Appendix 7. CMAP PI3K/AKT/mTOR gene expression signature 
 
CMAP upregulated 136 gene signature 
ACLY GTF2E2 POLE2 MLEC RPIA ENOPH1 
ATP1B1 HDAC2 PPIC TATDN2 RRP1B ATG3 
ATP6V0B HIF1A RFC5 MRPL19 JMJD6 ZDHHC6 
CALU HMGCR RPN1 LPGAT1 RRS1 ACD 
CASP7 HMGCS1 SPR PARP2 ARFIP2 TMEM109 
CBR1 HMOX1 DYNLT3 G3BP1 RAI14 CCDC86 
CCND3 HPRT1 TFDP1 TXNDC9 TES CHAC1 
CSK HSPA1A TPD52L2 SLC35B1 PHGDH CRELD2 
CSRP1 HSPA4 TXNRD1 HYOU1 TRAPPC3 CHMP6 
DDX10 HSPD1 UGDH DRAP1 DNTTIP2 NUP85 
DFFA DNAJB1 MAPKAPK3 EBP GMNN DHDDS 
DUSP3 ICAM3 FOSL1 WASF3 ATP6V1D GRWD1 
FDFT1 ITGAE BHLHE40 UTP14A PRKAG2 TUBB6 
FHL2 KIF5C PSMG1 BLCAP UBE2J1 MICALL1 
FKBP4 MAT2A IER3 TCERG1 GFOD1 H2AFV 
GABPB1 MCM3 DNAJA3 MLLT11 KCTD5 RPL39L 
GALE PNP USP14 CCDC85B EXOSC4  
GLI2 NRAS PRPF4 TOPBP1 DDIT4  
GLRX NUCB2 CCNE2 CORO1A YTHDF1  
GNA11 NUP88 VAPB SLC2A6 FKBP14  
GRB10 PAFAH1B1 UBE2L6 NISCH HEATR1  
MSH6 PMAIP1 ITGB1BP1 ECD ANO10  
GTF2A2 PMM2 HERPUD1 PUF60 TRIB3  
 
CMAP downregulated 56 gene signature 
CBLB LAMA3 DUSP11 HMG20B HSD17B11 TRAPPC6A 
CDKN1B MYC RNMT CRTAP EVL ARID5B 
CETN3 PIK3CA INPP4B ST6GALNAC2 TXNL4B PSRC1 
CSNK2A2 PPOX VGLL4 KIAA0907 ANKRD10 HIST1H2BK 
DDB2 KDM5A KIAA0355 WDTC1 FAM63A WIPF2 
DUSP6 RTN2 NCAPD2 KIAA1033 KDM3A SPRED2 
ERBB3 TLE1 HDAC6 KLHDC2 EAPP  
GRB7 TOP2A ARL4C CHIC2 CABC1  
ID2 TP53 TRIM13 SESN1 SCYL3  
IGF1R HIST2H2BE TRIB1 VPS28 POLD4  
 
